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Individuals with neuropsychiatric disorders (NPDs) demonstrate increased rates of 
cardiovascular disease (CVD) and metabolic syndrome (MetS). There is evidence of 
dysregulated hypothalamic pituitary adrenal (HPA) axis functioning in both NPDs and CVD 
and the HPA-axis may be a shared mechanistic pathway contributing to NPD-CVD 
comorbidity. Very few studies have, however, directly examined the association between 
NPDs, CVD risk and HPA-axis function. Hair cortisol concentrations (HCC), reflecting longer-
term systemic cortisol levels, can provide insight into the role of HPA-axis dysregulation in 
the occurrence of CVD risk, as defined by MetS, in NPDs. 
This study was a neuroendocrine ancillary study to ‘Understanding the SHARED ROOTS 
(SR) of Neuropsychiatric Disorders and Modifiable Risk Factors for Cardiovascular Disease’. 
SR was a cross-sectional matched case-control study investigating the pathways 
contributing to the comorbidity of MetS in NPDs and included three NPD cohorts 
(posttraumatic stress disorder (PTSD), schizophrenia and Parkinson’s disease). This study 
investigated the role of HPA-axis dysfunction, as measured by HCC, in the three NPDs as 
compared to controls and in relation to NPD-MetS co-occurrence. 
We demonstrated that HPA-axis function was altered in the three NPDs, with higher HCC in 
PTSD patients than trauma exposed controls, lower HCC in patients with schizophrenia than 
controls and higher hair cortisone levels, but not HCC, in Parkinson’s disease patients than 
controls. MetS was not associated with HCC in any of the individual cohorts. The lack of 
significant findings related to MetS may have been due to limited statistical power to detect 
significant associations in the individual cohorts.  
Additionally, as this is one of the first studies investigating HCC in South Africa and the 
majority of studies have been conducted in developed regions, we sought to identify basic 
determinants of HCC in a South African mixed ancestry control sample. The main 




hair product use, duration of sample storage and breastfeeding in women. We also 
demonstrated that resilience, but not self-perceived stress, was significantly inversely 
associated with HCC, underscoring the importance of identifying stress-resilience indicators 
of HCC in non-pathological samples. Finally we also found that poorer working memory 
performance was associated with higher HCC, suggesting an association between a 
neuroendocrine marker of chronic stress and working memory deficits.  
This is the first study to utilise a measure of longer-term HPA axis function to investigate the 
links between HPA-axis, NPDs and CVD risk. Considering the high burden of CVD in NPDs, 
this study provides a step towards better understanding the role played by chronic stress, as 
reflected by long-term HPA axis dysfunction, in the co-occurrence of CVD in NPDs. 
Furthermore, this study provides insights into the role of HPA-axis dysfunction in relation to 
clinical conditions and subjects of relevance to South Africa and contributes to broader 
















Individue met neuropsigiatriese versteurings (NPVs) demonstreer ‘n verhoogde voorkoms 
van kardiovaskulêre siekte (KVS) en metaboliese sindroom (MetS). Daar is bewyse dat die 
hipotalamus pituïtêre adrenale (HPA) as in beide NPVs en KVS wanfunksioneer en die HPA-
as is moontlik 'n gemeenskaplike meganistiese baan wat tot NPD-KVS komorbiditeit bydra. 
Baie min studies het egter al die verwantskap tussen NPVs, KVS risiko en HPA-as funksie 
direk ondersoek. Haar kortisol konsentrasies (HKK), wat langtermyn sistemiese 
kortisolvlakke weerspieël, kan insig aangaande die rol van HPA-as disregulasie in die 
voorkoms van KVS risiko, soos gedefinieer deur Mets, in NPVs bied.  
Hierdie studie was 'n neuro-endokriene aanvullende studie tot ‘Understanding the SHARED 
ROOTS (SR) of Neuropsychiatric Disorders and Modifiable Risk Factors for Cardiovascular 
Disease’. SR was 'n deursnit gepaarde gevallekontrolestudie wat die roetes wat tot die 
komorbiditeit van MetS in NPVs bydra in drie NPV kohorte (post-traumatiese 
stresversteuring (PTSV), skisofrenie en Parkinson se siekte) ondersoek het. Hierdie studie 
het die rol van HPA-as disfunksie, soos gemeet deur HKK, in die drie NPVs met kontroles 
vergelyk, asook in verhouding tot NPV-MetS mede-voorkoms ondersoek. 
Ons het getoon dat HPA-as funksie in die drie NPVs gewysig is, met hoër HKK in PTSV 
pasiënte as trauma blootgestelde kontroles, laer HKK in pasiënte met skisofrenie as 
kontroles en hoër hare kortisoon vlakke, maar nie HKK nie, in pasiënte met Parkinson se 
siekte as kontroles. MetS was nie geassosieer met HKK in enige van die individuele kohorte 
nie. Die gebrek aan betekenisvolle bevindinge met betrekking tot MetS is moontlik te wyte 
aan beperkte statistiese onderskeidingsvermoë om betekenisvolle assosiasies in die 
individuele kohorte te demonstreer.  
Aangesien hierdie een van die eerste studies is wat HKK in Suid-Afrika ondersoek en die 
meerderheid van die studies in ontwikkelde streke gedoen is, het ons beoog om die basiese 




identifiseer. Die belangrikste bepalingsfaktore wat met HKK verband gehou het was 
ouderdom, opvoedingsvlak, duur van blootstelling aan die son, gebruik van haarprodukte, 
duur van monster berging en borsvoeding in vroue. Ons het ook getoon dat veerkragtigheid, 
maar nie self-waargenome stres nie, aansienlik omgekeerd met HKK geassosieer was, wat 
beklmetoon hoe belangrik dit is om stres-veerkragtigheid aanwysers van HKK in nie-
patologiese steekproewe te identifiseer. Laastens het ons ook bevind dat swakker werkende 
geheue prestasie, met hoër HKK geassosieer was, wat dui op ‘n assosiasie tussen 'n neuro-
endokriene merker van chroniese stres en werkende geheue terkorte. 
Hierdie is die eerste studie wat ‘n maatstaf van langtermyn-HPA-as funksie gebruik om die 
verband tussen HPA-as, NPVs en KVS risiko te ondersoek. In ag genome die hoë las van 
KVS in NPVs, bied hierdie studie 'n tree tot ‘n beter begrip van die rol wat kroniese stres, 
soos weerspieël deur lang termyn HPA-as disfunksie, in die mede-voorkoms van KVS in 
NPVs speel. Verder bied hierdie studie insigte aangaande die rol van HPA-as disfunksie in 
kliniese toestande en onderwerpe van belang vir Suid-Afrika en lewer ‘n bydrae tot breër 
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This chapter provides a brief overview of themes and concepts and conveys the study context. As the 
chapters are written in manuscript format, additional background information is presented in each 
chapter. The study objectives and hypotheses are then described. This is followed by a brief overview 
of the parent study within which the dissertation is nested. Finally, each chapter is outlined and a 
rationale for the approach used throughout is provided. 
1 Background 
1.1 The hypothalamic pituitary adrenal axis 
The hypothalamic pituitary adrenal (HPA) axis is one of the primary pathways involved in the stress 
response. Following exposure to a stressor the HPA-axis response is initiated in the hypothalamus by 
connected neural pathways, resulting in the release of corticotrophin releasing hormone (CRH) which 
induces the anterior pituitary to secrete adrenocorticotropic hormone (ACTH) into the circulation. ACTH 
stimulates the adrenal cortex to produce and secrete cortisol which then mediates various aspects of 
the stress response primarily through binding to intracellular glucocorticoid receptors (GR) and 
influencing gene transcription (Chrousos, 2009; McEwen & Gianaros, 2010). The physiological effects 
of cortisol are related to mobilising energy stores by the breakdown of fats and proteins and increased 
gluconeogenesis, by suppressing certain inflammatory and immune responses, and by influencing 
behaviour (Chrousos, 2009). The stress response is regulated by a negative feedback loop, whereby 
cortisol binding to GR receptors in the hypothalamus and anterior pituitary halts further release of CRH 
and ACTH. Prolonged or severe stress can result in dysregulation of the HPA-axis with either blunted 
or increased cortisol release (McEwen, 2008). When the HPA-axis and related systems, such as 
immune and autonomic systems, become maladapted through prolonged or severe stress this is 
known as allostatic load (Juster, McEwen, & Lupien, 2010; McEwen, 1998). HPA-axis dysfunction and 
associated allostatic load can have significant detrimental effects on various systems, including the 





1.2 Methods used to analyse hypothalamic pituitary adrenal axis function 
Different methods have been employed to evaluate HPA-axis function, with measurement of cortisol 
levels the most frequently employed. Cortisol has traditionally been measured in blood (plasma and 
serum), saliva and urine and these include basal measurements of cortisol, repeat measures used to 
obtain diurnal secretion patterns and the cortisol-awakening response (CAR) which estimates the 
increase in cortisol following awakening from sleep (J.Yeo, Babic, Hannoush, & Weiss, 2000; Kudielka 
& Wüst, 2010). Other tests of HPA-axis function include measuring levels of other HPA-axis related 
hormones and proteins, such as ACTH, CRH, cortisol binding globulin (CBG), and 11-deoxycortisol 
(compound S) (J.Yeo et al., 2000). Further tests involve psychological and pharmacological challenge 
tests, where cortisol (and ACTH) levels are measured following exposure to either a psychological or 
pharmacological challenge. There are various pharmacological stress tests including the insulin 
tolerance test, the ACTH stimulation test, the CRH stimulation test, the metyrapone test, the naloxone 
challenge test, and the most frequently employed pharmacological stress test is the dexamethasone 
suppression test (DST) where the feedback inhibition of dexamethasone on the HPA-axis is measured 
(de Kloet et al., 2006; J.Yeo et al., 2000). Psychological stress tests involve exposure to various 
stressful paradigms, such as startling stimuli, novel situations, exposure to physically or psychologically 
painful stimuli, trauma related cues, and social performance and evaluation tasks, of which the Trier 
Social Stress Test (TSST) is the most frequently utilised (Allen et al., 2017; de Kloet et al., 2006; 
Gunnar, 2010; Zorn et al., 2017). Further measures that can be employed include utilising structural 
and functional imaging modalities of the hypothalamus, pituitary and adrenal glands (Borges, Gayer-
Anderson, & Mondelli, 2013; J.Yeo et al., 2000). Each method of assessment provides different 
insights into HPA-axis function, however none of these methods are ideally suited to ascertain longer-
term HPA-axis function and within this context measuring cortisol levels in hair samples has 
increasingly been investigated for this purpose. 
1.3 Hair cortisol concentrations 
Endogenous cortisol levels were first quantified in hair by Raul et al. in 2004 (Raul, Cirimele, Ludes, & 




of long-term cortisol release in both medical and psychiatric conditions (Gray et al., 2018; Stalder et al., 
2017; Wosu, Valdimarsdóttir, Shields, Williams, & Williams, 2013). As hair grows on average 1cm per 
month, compounds that are deposited in hair during its formation and growth come to reflect longer-
term retrospective levels (Wennig, 2000). Traditional measurements of cortisol (e.g. in blood, saliva and 
urine samples) are better suited to determine dynamic or acute circulating levels with repeated 
sampling required to obtain estimates of longer-term cortisol exposure (Stalder et al., 2017; Wosu et al., 
2013). Furthermore, these samples can be influenced by sampling and environmental factors 
impacting on acute cortisol secretion, such as diurnal fluctuations, physical activity, substance use, food 
intake and the stress associated with sampling (Gow, Thomson, Rieder, Van Uum, & Koren, 2010; 
Manenschijn, Koper, Lamberts, & Van Rossum, 2011; Stalder & Kirschbaum, 2012; Wosu et al., 
2013). Hair sampling is non-invasive and simple and samples can be stored and transported at room 
temperature thereby increasing its utility for neuroendocrine measurement (Abell et al., 2016; Stalder & 
Kirschbaum, 2012). HCC have demonstrated consistency, stable intra-individual variability and show 
good correlation with traditional measures of cortisol (Manenschijn et al., 2011; Papafotiou et al., 2017; 
Russell et al., 2015; Stalder & Kirschbaum, 2012; Stalder et al., 2017, 2012; Wosu et al., 2013; Q. 
Zhang, Chen, Chen, Xu, & Deng, 2017). HCC thus provide a useful measure of chronic stress as 
reflected by long-term HPA-axis dysfunction. 
1.4 The burden of neuropsychiatric disorders and cardiovascular disease 
Non-communicable diseases (NCDs) including neurological conditions, mental disorders and 
cardiovascular disease (CVD), are the largest contributors to disability adjusted life years (DALY’s) 
globally (Kyu et al., 2018). Of the non-communicable diseases, CVD, namely ischaemic heart disease 
and stroke, cause the greatest percentage of healthy years of life lost (Kyu et al., 2018; Whiteford et al., 
2013). Psychiatric disorders are the largest contributor to years lived with disability (YLDs) and the 
burden of psychiatric disorders, as well as CVD and neurological disease has increased over the last 
decade (Kyu et al., 2018; Patel et al., 2018; Whiteford et al., 2013). In South-Africa, NCDs as well as 
the risk factors for NCDs, are on the rise and are also the leading cause of mortality (43.4%), with 




the top ten causes of death (Mayosi et al., 2012; Pillay-van Wyk et al., 2016). Mental disorders are also 
very prevalent in South Africa and in the South African Stress and Health (SASH) study mental 
disorders were rated as more disabling than physical conditions (Herman et al., 2009; Suliman, Stein, 
Myer, Williams, & Seedat, 2010). Despite mental disorders being perceived as more disabling, South 
Africans are much less likely to receive treatment for their mental health problems (Seedat et al., 2008; 
Suliman et al., 2010).  
Individuals with neuropsychiatric disorders (NPDs) have increased rates of CVD, and risk factors for 
CVD, including metabolic syndrome (MetS), compared to the general population (Bradley & Dinan, 
2010; Penninx & Lange, 2018; Vancampfort et al., 2015). MetS denotes a cluster of risk factors for 
CVD and type 2 diabetes mellitus. Although there is some variation in diagnostic criteria proposed by 
different scientific organisations and societies (Alberti et al., 2009; Huang, 2009; Kassi, Pervanidou, 
Kaltsas, & Chrousos, 2011), risk factors for MetS include central obesity, raised blood pressure, raised 
fasting glucose, and dyslipidaemia, namely raised triglycerides and low levels of high-density 
lipoprotein (HDL) cholesterol (Alberti et al., 2009). Individuals with MetS have double the risk of 
developing CVD in the next 5-10 years and MetS contributes to disease progression in individuals with 
established CVD and diabetes (Alberti et al., 2009). MetS is considered a public health problem, due to 
a rise in its prevalence, secondary to factors, such as obesity and sedentary lifestyles. Very high rates 
of type 2 diabetes (28.8%) and MetS (62.0%) have also been demonstrated in a South African mixed-
ancestry (coloured) population from the Western Cape (Erasmus, R. T. Soita, D. J. Hassan, M. S. 
Blanco-Blanco, E. Vergotine, Z. Kengne, A. P. Matsha, 2012). In South Africa, patients with mental 
illness also demonstrate higher rates of risk factors for CVD and comorbid CVD is associated with 
greater disability in individuals with mental disorders (Saloojee, Burns, & Motala, 2016; Suliman et al., 
2010). Individuals with NPDs have increased mortality risk and lower life expectancies and this is 
mainly secondary to CVD (Correll et al., 2017; De Hert, Detraux, & Vancampfort, 2018; Penninx & 
Lange, 2018; Walker, McGee, & Drus, 2015). Despite higher rates of CVD and associated mortality, 
individuals with mental disorders have decreased access to and receipt of adequate medical care 




the pathways linking NPDs and CVD remain poorly delineated (Correll et al., 2017; De Hert et al., 
2018; Vancampfort et al., 2015) and need to expedite research investigating the factors that contribute 
to comorbidity that can inform prevention and treatment initiatives.  
1.5 Hypothalamic pituitary adrenal axis dysfunction in neuropsychiatric disorders and 
cardiovascular disease 
The HPA-axis is one of the pathways postulated to play a role in the co-occurrence of NPDs and CVD 
(Bradley & Dinan, 2010; Penninx & Lange, 2018). Altered HPA-axis function, as manifested largely by 
elevated basal cortisol levels, has been demonstrated in NPDs and in relation to CVD and MetS, 
suggesting a shared pathway contributing to NPD-CVD comorbidity (Bradley & Dinan, 2010; De Hert 
et al., 2018; Penninx & Lange, 2018). However, very few studies have directly examined the 
association between NPDs, CVD risk and HPA-axis function. HCC, a reflection of longer-term systemic 
cortisol levels, can provide insights into the role of HPA-axis dysregulation in the occurrence of MetS in 
NPDs. 
1.6 The neuropsychiatric disorders included in this study 
1.6.1 Posttraumatic stress disorder (PTSD) 
Posttraumatic stress disorder (PTSD) denotes a characteristic set of symptoms that develop 
secondary to exposure to severely stressful, or traumatic events, involving potential or actual harm to 
self or others (American Psychiatric Association [APA], 2013). In PTSD, persisting symptoms involving 
intrusion and avoidance of the traumatic event occur alongside negative changes in cognitions and 
mood and increased reactivity, causing notable distress and impairment of functioning (American 
Psychiatric Association [APA], 2013). In the World Mental Health Surveys the global prevalence of 
trauma exposure was 69.7% and of those exposed 5.6% and 2.8% had a lifetime and current PTSD 
diagnosis, respectively (Koenen et al., 2017). Although the course varies, PTSD symptoms persist for 
an average of 6 years and the burden of PTSD is estimated at 77.7 lifetime person-years/100 
respondents (Kessler et al., 2017). In the SASH study 73.8% of respondents had a history of trauma 
exposure and the lifetime prevalence of PTSD was 2.3%, with 36% of those with PTSD presenting with 




MetS, CVD and associated mortality (Ahmadi et al., 2011; Bartoli, Carra, Crocamo, Carretta, & Clerici, 
2013; Kubzansky, Koenen, & Spiro, 2007; Rosenbaum et al., 2015).  
There is evidence of a dysregulated HPA-axis in relation to trauma and PTSD, with PTSD cases 
demonstrating lower basal cortisol levels than controls, although findings have been mixed (Meewisse, 
Reitsma, de Vries, Gersons, & Olff, 2007; Morris, Compas, & Garber, 2012; Schumacher et al., 2019). 
The number of studies examining HCC in PTSD have steadily been rising and these have contributed 
to a better understanding of the effects of trauma on HPA-axis function and how that relates to PTSD 
symptomatology (Dajani, Hadfield, van Uum, Greff, & Panter-Brick, 2018; Groer, Kane, Williams, & 
Duffy, 2015; Luo et al., 2012; Steudte-Schmiedgen, Kirschbaum, Alexander, & Stalder, 2016; Steudte 
et al., 2013, 2011; Straub, Klaubert, Schmiedgen, Kirschbaum, & Goldbeck, 2017; van Zuiden et al., 
2019). There have, however, been very few studies (Blessing et al., 2017) examining the association 
between cortisol levels, PTSD and CVD risk, and none utilising HCC.  
1.6.2 Schizophrenia 
Schizophrenia is a serious psychiatric disorder where symptoms such as delusions, hallucinations, 
disorganisation of behaviour and speech, and reduced emotional expression persist and cause 
significant impairment (American Psychiatric Association [APA], 2013). The lifetime prevalence of 
schizophrenia is around 0.7% and individuals with schizophrenia have a 3 fold higher risk of dying on 
the basis of the standardized mortality ratio (McGrath, Saha, Chant, & Welham, 2008). Although 
schizophrenia is not a prevalent disorder it contributes 1.7% of years lived with disability (YLD) and the 
burden of disease is increasing, particularly in low- and middle-income countries (Charlson et al., 
2018). Individuals with schizophrenia demonstrate increased rates of MetS and CVD and amongst the 
highest mortality risk observed among psychiatric disorders (Correll et al., 2017; Mitchell et al., 2013; 
Vancampfort et al., 2013; Walker et al., 2015). There is evidence of HPA-axis dysregulation in 
schizophrenia, with patients generally demonstrating higher basal cortisol levels than controls (Borges 
et al., 2013; Bradley & Dinan, 2010; Gajsak, Gelemanovic, Kuzman, & Puljak, 2017; Girshkin, 
Matheson, Shepherd, & Green, 2014; Hubbard & Miller, 2019). There have now also been a number 




insights into long-term HPA-axis function in schizophrenia (Aas et al., 2019; Andrade et al., 2016; Streit 
et al., 2016; Touskova et al., 2018). Very few studies (Manzanares et al., 2014; Vuksan-Cúsa, Sǎgud, 
Mihaljevic-́Peleš, Jaksǐć, & Jakovljev́ic, 2014) have examined cortisol levels in relation to CVD risk in 
schizophrenia and none have utilised HCC. 
1.6.3 Parkinson’s disease 
Parkinson’s disease is a neurodegenerative disorder with the core symptoms of bradykinesia, rigidity 
and resting tremor associated with dopaminergic neuronal death in the substantia nigra (Wirdefeldt, 
Adami, Cole, Trichopoulos, & Mandel, 2011). Parkinson’s disease is the second most common 
neurodegenerative disorder and affects 1% of people older than 60 years (Tysnes & Storstein, 2017). 
The prevalence of, and mortality and DALYs secondary to, Parkinson’s disease has increased globally, 
as well as in South Africa (Ray Dorsey et al., 2018). There is mounting evidence that CVD risk factors 
and MetS can increase the risk for Parkinson’s disease and that MetS comorbidity in patients with 
Parkinson’s disease contributes to worse outcomes (Bainbridge et al., 2017; Nam et al., 2018; P. 
Zhang & Tian, 2014). Patients with Parkinson’s disease demonstrate HPA-axis dysregulation and in 
general have higher basal cortisol levels than controls (Du & Pang, 2015; Herrero, Estrada, Maatouk, & 
Vyas, 2015; Soares, Pereira, Altmann, de Almeida, & Rieder, 2019). There have been no studies 
examining HCC in Parkinson’s disease patients and no studies examining cortisol levels in relation to 
CVD in patients with Parkinson’s disease. 
HCC, reflecting long-term systemic cortisol exposure, can provide further insights into the role of HPA-
axis dysregulation in PTSD, schizophrenia, and Parkinson’s disease and the relationship with co-
occurring CVD risk.  
2 Study objectives 
Primary 
1. To evaluate the role of chronic stress, as measured by hair cortisol, in the interaction between 




2. To determine and compare the neuroendocrine signatures in these three NPDs (PTSD, SCZ 
and PD) and undertake a case-control comparison of HCC in these NPDs. 
Secondary 
1. To characterise the neuroendocrine status of individuals with schizophrenia prior to diagnosis 
and following a course of flupenthixol decanoate treatment; 
2. To determine which clinical, behavioural and biological factors influence HCC in a sample of 
mixed ancestry; 
3. To evaluate whether a neuroendocrine marker of chronic stress is associated with measures 
of self-perceived stress and resilience;  
4. To evaluate whether a neuroendocrine marker of chronic stress is associated with 
performance on cognitive testing. 
3 Hypotheses 
1. HCC will be raised in those with NPDs with MetS versus those with NPDs without MetS. 
2. HCC will be altered in patients with PTSD versus controls, with a complex interaction between 
trauma related variables (time since trauma exposure, trauma severity and load) and clinical 
features of PTSD. Considering the mixed findings demonstrated in relation to PTSD we did not 
postulate in which direction the association would be.  
3. HCC will be raised in those with Parkinson’s disease versus controls, but the effect may not be 
as significant as for PTSD and schizophrenia. 
4. HCC will be raised in those recently diagnosed with schizophrenia versus controls and HCC 
will decline following flupenthixol decanoate treatment. 
5. In a sample of South African mixed ancestry individuals HCC will demonstrate analogous 
relationships with some of the basic determinants (clinical, behavioural and biological) 
previously examined in other settings, with some dissimilarities anticipated.  
6. HCC will be associated with self-perceived stress and resilience in opposite directions, being 




7. HCC will correlate positively with cognitive impairments, particularly in domains known to be 
sensitive to the effects of cortisol, such as declarative memory, working memory, and 
executive functioning. 
4 Overview of the parent study 
This study is a neuroendocrine ancillary study to ‘Understanding the SHARED ROOTS of 
Neuropsychiatric Disorders and Modifiable Risk Factors for Cardiovascular Disease’ or SHARED 
ROOTS (SR). SR is a South African Medical Research Council (SAMRC) funded flagship project 
[Grant no. MRC-RFA-IFSP-01-2013/SHARED ROOTS]. The overarching aim of SR is the 
interrogation of genomic, neural, cellular and environmental signatures that are common to NPDs and 
CVD risk, as defined by the MetS, and that contribute to co-morbidity, symptom severity, and treatment 
outcomes. SR was designed to use a multi-omics approach combining genomic, transcriptomic, 
epigenetic, and complementary phenotypic and multimodal neuroimaging data, to disentangle 
mechanistic pathways that lead to the development of comorbidity of these disorders. This research 
question was investigated in three cohorts of NPDs of relevance to the South African context, namely 
posttraumatic stress disorder (PTSD), schizophrenia and Parkinson’s disease. SR was a cross-
sectional matched case-control study and enrolled participants over 3 years from May 2014 until June 
2017. The study aimed to sample 200 patients for each NPD cohort (100 with MetS and 100 without 
MetS). An equivalent number of non-clinical controls were also recruited for each disease cohort and 
were matched to the NPD cohort based on age, gender and MetS. There was a longitudinal 
component to the schizophrenia cohort; patients with first episode psychosis (FEP) were treated with 
open-label flupenthixol decanoate (a depot antipsychotic) and the cohort (patients and controls) 
returned for follow-up assessments 12 months later. 
The study sample was limited to individuals who self-identified as belonging to the mixed ancestry 
(coloured) ethnic group. The decision to limit SR to one ethnic group was chiefly to avoid the effects of 
population stratification on genomic analyses. The mixed ancestry group was chosen for the following 
reasons: (i) the mixed ancestry ethnic group is the predominant population group in the Western Cape, 




mixed ancestry, (ii) high rates of metabolic syndrome and related conditions (e.g. diabetes) observed in 
this ethnic group (Erasmus, R. T. Soita, D. J. Hassan, M. S. Blanco-Blanco, E. Vergotine, Z. Kengne, 
A. P. Matsha, 2012).  
In total 922 individuals were enrolled in SR (461 patients and 461 controls), of these 441 patients and 
444 controls completed participation. The PTSD cohort comprised 307 patients and 321 controls. The 
Parkinson’s disease cohort comprised 89 patients and 87 controls. The schizophrenia cohort 
comprised 62 patients and 56 controls and 31 FEP schizophrenia patients and 30 controls returned for 
month-12 longitudinal assessments.  Participants were characterised for the presence or absence of 
MetS, using international harmonised JIS criteria (Alberti et al., 2009).  
Factors that influenced the final sample size and distribution obtained included the following: (i) 
difficulties in recruiting adequate numbers of Parkinson’s disease and schizophrenia patients overall; (ii) 
PTSD patient versus trauma-exposed control (TEC) status could only be determined once diagnostic 
measures had been completed; (iii) MetS status could only be confirmed once participants had already 
been enrolled and the study investigations (such as biochemical laboratory tests) had been completed; 
(iv) the baseline prevalence of MetS is lower than 50% and thus efforts to reach the target of a 100 
PTSD patients with MetS required over-sampling; (v) we initially planned to include only FEP patients 
of mixed ancestry ethnicity in the schizophrenia cohort, but due to the difficulties recruiting FEP patients 
fulfilling the study criteria, a decision was made to remove the ethnicity criterion for that cohort, as well 
as to recruit chronic schizophrenia patients from a cohort who previously participated in an FEP study, 
called the EONKCS study (Chiliza et al., 2016).  
Participants in SR attended two to three study visits, each lasting around 2-3 hours. At the first visit, 
diagnostic and clinical measures were administered by a clinician and participant-administered 
measures were completed. The second visit occurred within 24-96 hours of the first visit and involved 
the physical procedures (e.g. fasting blood sampling, physical measurements, hair sampling), 
additional lifestyle measures, and neurocognitive testing. The subset of participants included in the 




SR was approved by the Health Research Ethics Committee at Stellenbosch University (HREC 
N13/08/115) and conducted according to the ethical guidelines and principles of the seventh revision of 
the Declaration of Helsinki (World Medical Association, 2013). 
4.1 The neuroendocrine ancillary study 
This neuroendocrine ancillary study was conceived prior to initiating recruitment on SR and thus all 
participants were eligible for inclusion. Hair samples were obtained from participants with scalp hair 
3cm or longer who provided informed consent for hair sampling. Samples were analysed with liquid 
chromatography tandem mass spectrometry (LC-MS/MS) at the laboratory of Prof Clemens 
Kirschbaum at Dresden University of Technology. The LC-MS/MS method allows for simultaneous 
identification of five steroid hormones [cortisol, cortisone, testosterone, progesterone, and 
dehydroepiandrosterone (DHEA)] in human hair. Prof Clemens Kirschbaum and Dr Tobias Stalder are 
collaborators on this study and have extensive expertise in cortisol and stress research.  
4.2 Role in the study 
I was the project manager and lead clinician on SR and was thus involved with all aspects of SR since 
study initiation. Under the guidance of my supervisor, Prof Soraya Seedat, the Principal Investigator on 
SR and recipient of the SR grant, I conceived the neuroendocrine ancillary study, formulated the 
protocol, conducted statistical analyses in consultation with Prof Carl Lombard, and first-authored all the 
manuscripts and chapters contained within this thesis.  
5 Outline of Chapters and rationale 
The central focus of this thesis is on HCC, as a measure of longer-term HPA-axis dysfunction, in 
relation to various outcomes in a case-control design. As prior HCC studies have not been conducted 
in South Africa and this was one of the first HCC studies the goal was to utilise HCC to address a 
variety of research questions applicable to the SR study as well as broader questions pertaining to the 
role of longer-term neuroendocrine dysfunction in various conditions/contexts. The primary aims of the 
thesis align with the primary aims of SR, namely to investigate HCC in relation to NPDs, and their 




to 4 these aims are addressed in each of the three NPD cohorts separately and in Chapter 5 across 
the three cohorts. The secondary aim investigating the longitudinal trajectory of HCC in patients with 
FEP schizophrenia is also addressed in Chapter 4; this chapter addresses the main aims in the 
schizophrenia cohort. The remaining aims are addressed in the control sample - these secondary aims 
investigate the role of longer-term neuroendocrine dysfunction in relation to other factors of interest, but 
that are not the primary focus of the study. Two of the secondary aims are addressed in Chapter 6, 
namely identifying the basic determinants of HCC in individuals of mixed ancestry, as well as 
investigating whether HCC are associated with measures of self-perceived stress and resilience. The 
remaining secondary aim, addressed in Chapter 7, investigates whether HCC are associated with 
performance on cognitive testing. In the manuscripts, a number additional aims that are not outlined in 
the original protocol, but that were of interest, are also addressed as outlined below in the summary of 
each of the chapters. We examined for associations between HCC and clinical severity of each of the 
NPDs as these associations can provide a quantitative measure of how HCC are related to the NPDs. 
We also included exploratory analyses of the associations between individual CVD risk factors and 
HCC as these analyses are aligned with other studies examining both total CVD risk and individual 
CVD risk factors in relation to HCC (Kuehl et al., 2015; Langerak et al., 2015; Stalder et al., 2013). 
Caution needs to be exercised in interpreting these findings as the final sample sizes were 
underpowered to detect significant associations between MetS and HCC, based on a-priori sample 
size calculations. Other aims were formulated in the process of reviewing the literature and identifying 
areas of importance as well as gaps in the knowledge. Some of these were also based on preliminary 
analyses of the data, such as including an analysis of hair cortisone levels alongside HCC in the 
Parkinson’s disease cohort. In the concluding chapter the main outcomes are summarised and the 
original contributions to the field outlined along with recommendations for future research. In Appendix 
A a published systematic review protocol directly relating to this thesis is included ‘Cortisol levels in 
different tissue samples in posttraumatic stress disorder patients versus controls: a systematic review 
and meta-analysis protocol’. In Appendix B other published manuscripts pertaining to SR where I have 




As HCC, a biomarker of longer-term HPA-axis function, form the central focus of the thesis as well as 
the core unifying theme addressed in each of the objectives, the analysis approach that was utilised 
centers on an investigation of various factors related to HCC. Thus HCC is the dependent variable in 
linear regression models constructed to address the different objectives. Although some of the 
components in each chapter may differ depending on the features of the sample and the outcomes 
addressed, an overarching and uniform approach was applied across the different chapters. Thus, for 
the most part, common data variables are included in the analysis framework for each chapter and the 
analysis strategy is also applied consistently throughout, with some modifications made as indicated. 
One of the major limitations of this study was that the majority of males did not have hair of sufficient 
length to participate in the neuroendocrine study, thus in all the chapters, excluding Chapter 4, 
analyses are limited to females. The sample sizes, as well as flow-diagrams illustrating inclusion and 
exclusion of participants in each analysis run are included in the individual chapters. 
Each of the Chapters has been written in manuscript format and the goal is to publish each of the 
manuscripts. Manuscripts were drafted in accordance with the STROBE guidelines (von Elm et al., 
2014), with the aim of increasing transparency and ensuring that the manuscripts adhere to 
international standards of reporting for observational studies. Two of the manuscripts are currently 
under review and the remaining manuscripts have been circulated for co-author contributions and 
review and will be submitted shortly to peer-reviewed journals for publication. As the chapters are in 
manuscript format there will be some repetition, particularly relating to study methodology. In Chapter 5, 
the chapter comparing HCC across the disorders and in Chapter 7, the chapter investigating cognitive 
function in relation to HCC, the methods and results have been abbreviated as these have been 
described in the preceding chapters pertaining to the same samples. 
5.1 Chapter 2 - Hair cortisol levels in posttraumatic stress disorder and metabolic syndrome: 
A case-control study in South African mixed ancestry females  
In this manuscript the main aims of this study are addressed in the PTSD cohort. Here we investigate 
whether HCC are associated with PTSD caseness, by comparing HCC in patients with PTSD and 




assess for interaction effects between PTSD and MetS on HCC. We also address the following 
additional aims: we investigate whether clinical factors related to PTSD, namely PTSD severity and 
trauma severity (as defined by a count of traumatic event exposures), as well as self-perceived stress, 
are associated with HCC and, in exploratory analyses, whether individual CVD risk factors are 
associated with HCC.  
5.2 Chapter 3 - Hair glucocorticoid levels in females with Parkinson’s disease  
In this manuscript the main aims of this study are addressed in the Parkinson’s disease cohort. Here 
we investigate whether HCC are associated with Parkinson’s disease, by comparing HCC in patients 
with Parkinson’s disease and controls. We also investigate whether MetS is associated with HCC and 
assess for the presence of a statistically significant interaction between Parkinson’s disease and MetS 
on HCC. We also address the following additional aims: we investigate whether clinical factors related 
to Parkinson’s disease (e.g., severity of motor and non-motor symptoms of Parkinson’s disease), as 
well as self-perceived stress are associated with HCC. In exploratory analyses we further investigate 
whether individual CVD risk factors are associated with HCC. In the Parkinson’s disease cohort we 
noted differential patterns between HCC and hair cortisone levels, another marker of long-term HPA-
axis function, and clinical factors. We have thus conducted analyses examining the associations 
between hair cortisone levels and relevant clinical variables, in addition to HCC. 
5.3 Chapter 4 – Hair cortisol levels in schizophrenia and metabolic syndrome 
In this manuscript the main aims of this study are addressed in the schizophrenia cohort. Here we 
investigate whether HCC are associated with schizophrenia, by comparing HCC in patients with 
schizophrenia and controls. We also investigate whether MetS is associated with HCC and examine 
interaction effects between schizophrenia diagnosis and MetS on HCC. The schizophrenia sample 
consists of two groups, a FEP psychosis group and a chronic schizophrenia group. We conduct 
analyses for the cohorts combined as well as analyses focused on the FEP cohort. The secondary aim 
investigating the longitudinal trajectory of HCC in FEP is also addressed in this chapter. We also 
address the following additional aims: we investigate whether clinical factors related to schizophrenia 




associated with HCC and in exploratory analyses whether the individual CVD risk factors are 
associated with HCC. 
5.4 Chapter 5 - Hair cortisol as a neuroendocrine biomarker to evaluate the impact of chronic 
stress on the interaction between neuropsychiatric disorders and metabolic syndrome in 
females 
In this chapter we conduct analyses across the cohorts to address components of the primary aims 
that could not be addressed in the individual cohorts. We compare HCC among the three NPDs and 
assess for shared effects of MetS across NPDs on HCC. Although there are significant limitations to 
undertaking these analyses, such as significant differences between the NPDs cohorts (e.g. average 
age) and unequal sample sizes across the cohorts, the combined analyses may provide preliminary 
insights that are not apparent in addressing the individual cohorts in each of the chapters. This chapter 
also synthesizes and integrates the key findings in accordance with the main study aims. 
5.5 Chapter 6 - Hair cortisol as a biomarker of stress and resilience in South African mixed 
ancestry females 
In this chapter we address two of the secondary aims of the thesis. We seek to determine socio-
demographic, hair related, clinical and behavioural factors that are associated with HCC in a South 
African mixed ancestry sample and assess whether self-perceived stress and resilience scores in the 
sample are associated with HCC. As this is one of the first studies investigating HCC in South Africa, 
with the majority of studies having been conducted in developed regions and in samples of primarily 
Caucasian origin, there is a need to identify the basic determinants of HCC in samples that have 
broader ethnic representation. We thus examine a wide array of factors that have the potential to 
influence HCC in non-clinical populations as exemplified by our control sample who represent fairly 
healthy individuals (common somatic conditions were permitted e.g. atopy, hypertension and diabetes) 
without any current significant psychopathology. Originally these factors were planned to be used as 
covariates across all analyses in the thesis, however this approach needed to be adjusted due to the 
varying composition and sample size of the different cohorts. In each of the NPD cohorts, we therefore 




and used these as the covariates of HCC. As cortisol is released in response to stress, various studies 
have investigated whether HCC are associated with measures of self-perceived stress and the results 
have been mixed, with largely negative findings (Stalder et al., 2017; Staufenbiel, Penninx, Spijker, 
Elzinga, & van Rossum, 2013; Wosu et al., 2013). Very few studies have investigated whether cortisol 
levels are associated with resilience or stress-coping ability (Dockray & Steptoe, 2010; García-León, 
Pérez-Mármol, Gonzalez-Pérez, García-Ríos, & Peralta-Ramírez, 2019; Milam, Slaughter, Verma, & 
McConnell, 2014; Steptoe, Dockray, & Wardle, 2009; Ullmann et al., 2016) and the precise biological 
processes underpinning resilience as compared to stress have yet to be elucidated. As such, to 
provide insights into the relationship between self-perceived stress, resilience and HPA-axis function, 
we examined whether measures of self-perceived stress and resilience were associated with HCC. 
5.6 Chapter 7 - The association between cognitive functioning and hair cortisol levels in 
South African mixed ancestry females 
In Chapter 7 we assess whether performance on neurocognitive testing is associated with HCC, as a 
biomarker of chronic stress and associated HPA-axis dysfunction. Cortisol can directly influence brain 
structure and function, particularly in regions with increased density of GR and mineralocorticoid (MR) 
receptors, such as the hippocampus and prefrontal cortices (Lupien, Maheu, Tu, Fiocco, & Schramek, 
2007; McEwen, Nasca, & Gray, 2016). There is also evidence of impairments in cognitive performance 
in domains associated with these brain regions, namely declarative memory, executive functions and 
working memory (Het, Ramlow, & Wolf, 2005; Sauro, Jorgensen, & Pedlow, 2003; Shields, Bonner, & 
Moons, 2015). We sought to examine whether performance on a battery of neurocognitive tests were 
associated with HCC in the same control sample included in Chapter 6, but with additional exclusions 
applied pertaining to factors that can influence cognitive performance (e.g. prior head injuries with loss 
of consciousness). Our aim was to investigate whether HCC were associated with cognitive domains 





5.7 Appendix A - Cortisol levels in different tissue samples in posttraumatic stress disorder 
patients versus controls: A systematic review and meta-analysis protocol 
The protocol is for a systematic review evaluating basal cortisol levels in different tissue samples (e.g. 
plasma, serum, urine, saliva, hair and nails) in PTSD patients versus controls. The systematic review 
has been placed on hold as a related systematic review evaluating basal cortisol levels in PTSD 
(Schumacher et al., 2019) was published shortly following the publication of this protocol. Work on this 
systematic review will proceed within a year or two to allow new research, including the results 
pertaining to Chapter 2, to be included in the systematic review. As the focus of the systematic review 
is on cortisol levels in different tissue samples, more studies utilising newer sample types, such as hair 
and nails, are required to be able to conduct meta-analyses and to make meaningful deductions about 
how cortisol measurements using these newer methods of tissue sampling compare with 
measurements in traditional tissue samples.  
Table 1 Overview of aims and in which chapters they are addressed 
 
Aims Chapters in which aims are addressed 
Primary  
To evaluate the role of chronic stress, as 
measured by hair cortisol, in the 
interaction between three NPDs (PTSD, 
schizophrenia and Parkinson’s disease) 
and MetS 
Chapter 2 - Hair cortisol levels in 
posttraumatic stress disorder and 
metabolic syndrome  
Chapter 3 - Hair glucocorticoid levels in 
Parkinson’s disease  
Chapter 4 – Hair cortisol levels in 
schizophrenia and metabolic syndrome 
Chapter 5 - Hair cortisol as a 
neuroendocrine biomarker to evaluate the 
impact of chronic stress on the interaction 
between neuropsychiatric disorders and 
metabolic syndrome 
To determine and compare the 
neuroendocrine signatures in these three 
NPDs (PTSD, SCZ and PD) and 
undertake a case-control comparison of 
HCC in these NPDs 
Chapter 2 - Hair cortisol levels in 
posttraumatic stress disorder and 
metabolic syndrome  
Chapter 3 - Hair glucocorticoid levels in 
Parkinson’s disease  
Chapter 4 – Hair cortisol levels in 
schizophrenia and metabolic syndrome 
Chapter 5 - Hair cortisol as a 
neuroendocrine biomarker to evaluate the 
impact of chronic stress on the interaction 






To characterise the neuroendocrine 
status of individuals with schizophrenia 
prior to diagnosis and following 
flupenthixol decanoate treatment. 
Chapter 4 - Hair cortisol levels in 
schizophrenia and metabolic syndrome 
To determine which clinical, behavioural 
and biological factors influence hair 
cortisol levels in a sample of mixed 
ancestry. 
Chapter 6: Hair cortisol as a biomarker of 
stress and resilience in females 
To evaluate whether a neuroendocrine 
marker of chronic stress is associated 
with measures of self-perceived stress 
and resilience  
Chapter 6: Hair cortisol as a biomarker of 
stress and resilience in females 
To evaluate whether a neuroendocrine 
marker of chronic stress is associated 
with performance on cognitive testing 
Chapter 7: The association between 
cognitive functioning and hair cortisol 
levels in females  
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Hair cortisol levels in posttraumatic stress disorder and metabolic 
syndrome: A case-control study in South African mixed ancestry 
females 
Abstract 
Background: Individuals with posttraumatic stress disorder (PTSD) evidence increased rates of 
metabolic syndrome (MetS) and both PTSD and MetS are associated with alterations in hypothalamic 
pituitary adrenal (HPA) axis function. Few investigations have examined the possible role of HPA-axis 
dysfunction in the co-occurrence of PTSD and MetS.  
Objectives: In a case-control study we aimed to determine whether hair cortisol concentrations (HCC) 
were associated with (i) PTSD caseness and severity and (ii) PTSD and CVD risk (as defined by the 
MetS) co-occurrence.  
Methods: We utilised the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) to determine 
PTSD diagnostic status and severity scores in 216 females of mixed ancestry aged between 20 and 79 
years (M = 43.8, SD = 13.3). Hair samples, representing a three-month retrospective window of cortisol 
levels were obtained and analysed utilizing liquid chromatography tandem mass spectrometry. We 
constructed multivariate linear regression models to evaluate whether PTSD diagnosis, PTSD severity 
and MetS comorbidity were associated with HCC (reciprocal square root transformed) controlling for 
potential confounders.  
Results: The prevalence of MetS was 30.0% in PTSD patients (n = 110) and 40.6% in trauma-
exposed controls (TEC, n = 106). HCC were significantly higher (Cohen’s d = 0.44) in PTSD patients 
than TEC (adj β = 0.09, 95% CI = 0.01; 0.18, p = 0.033). HCC were also significantly associated with 
CAPS severity scores (adj β = 0.00, 95% CI = 0.00; 0.01, p = 0.005). MetS was not associated with 




Conclusions: We demonstrate increased HCC in PTSD patients, with a directly proportional 
relationship. This study provides evidence of a chronically dysregulated neuroendocrine mediated 
stress response in PTSD. HCC do not, however, appear to have specificity for the comorbidity of 
PTSD and MetS in this sample. 






















Due to its direct relationship to severe stress or trauma, posttraumatic stress disorder (PTSD) may 
represent the disorder with the most apparent link to the biological stress response. The hypothalamic 
pituitary adrenal (HPA) axis is one of the primary pathways involved in the stress response and has 
therefore been a logical focus of investigation into pathophysiological pathways involved in PTSD. 
Although HPA axis dysfunction has been clearly linked to PTSD, findings have been mixed (Steudte-
Schmiedgen, Kirschbaum, Alexander, & Stalder, 2016). Systematic reviews and meta-analyses 
evaluating basal cortisol levels between PTSD patients and controls tend to find lower basal cortisol 
levels in PTSD patients, but also report frequent negative findings depending on the outcomes 
investigated (Meewisse, Reitsma, de Vries, Gersons, & Olff, 2007; Morris, Compas, & Garber, 2012; 
Schumacher et al., 2019). The results also appear to vary according to assay method and tissue type 
(e.g. saliva, plasma, urine), with differences possibly reflecting distinct facets of HPA-axis function 
(Steudte-Schmiedgen et al., 2016). The measurement of cortisol levels in hair, indicating more chronic 
HPA-axis function, is a fairly recent development and thus most systematic reviews have not included 
hair cortisol studies.  
A synthesis of the existing literature suggests a two-stage model of cortisol secretion following trauma 
exposure; initially trauma exposure leads to increased cortisol secretion, which results in enhanced 
HPA-axis negative feedback sensitivity and higher glucocorticoid receptor sensitivity, and over the 
longer-term to a blunted HPA-axis and lower baseline cortisol levels in PTSD (Miller, Chen, & Zhou, 
2007; Steudte-Schmiedgen et al., 2016). Context also plays an important role, with higher cortisol 
output demonstrated in PTSD patients in studies conducted in high trauma or high stress environments 
(Miller et al., 2007; Steudte-Schmiedgen et al., 2016). 
Another question pertaining to PTSD is whether the HPA-axis alterations observed are related to the 
pathophysiology of PTSD or predominantly to trauma exposure. A recent meta-analysis examining the 
association between adversity, including trauma and childhood maltreatment, and HCC demonstrated 
a small significant positive relationship (d = 0.21) between adversity and HCC (Khoury, Bosquet Enlow, 




found. Studies utilising HCC therefore tend to suggest that effects are chiefly trauma related, rather 
than specific to PTSD symptomatology (Steudte-Schmiedgen et al., 2016).  
PTSD is associated with increased risk for cardiovascular disease (CVD) and mortality (Ahmadi et al., 
2011; Kubzansky, Koenen, & Spiro, 2007). Furthermore patients with PTSD demonstrate increased 
rates (OR = 1.4; RR = 1.8) of metabolic syndrome (MetS) as compared to controls, with a pooled 
prevalence of MetS in PTSD patients of 38.7% (Bartoli, Carra, Crocamo, Carretta, & Clerici, 2013; 
Rosenbaum et al., 2015). The MetS denotes a cluster of risk factors for CVD and type 2 diabetes 
mellitus. Although there is some variation in diagnostic criteria proposed, risk factors include central 
obesity, hypertension, elevated fasting glucose, and dyslipidaemia, namely hypertriglyceridemia and 
low levels of high-density lipoprotein cholesterol (HDL-C) (Alberti et al., 2009). Longitudinal 
investigations tend to suggest that PTSD increases the risk for MetS, rather than the converse (Farr, 
Sloan, Keane, & Mantzoros, 2014; Wolf et al., 2016).  
Similar to PTSD, HPA-axis dysfunction and altered glucocorticoid levels have also been demonstrated 
in relation to MetS and CVD (Anagnostis, Athyros, Tziomalos, Karagiannis, & Mikhailidis, 2009; Stalder 
et al., 2013). Authors have thus postulated that HPA-axis dysfunction secondary to trauma and PTSD 
may be a pathway leading to MetS and CVD morbidity in PTSD (Bartoli et al., 2013; Wolf et al., 2016). 
Various pathways potentially linking PTSD, the HPA axis and CVD risk are suggested. Chronically 
elevated cortisol, secondary to trauma or PTSD, can contribute to visceral fat accumulation, insulin 
resistance, dyslipidaemia and increased food intake (Michopoulos, Vester, & Neigh, 2016). MetS can 
also increase cortisol levels, by contributing to HPA axis dysfunction, as well as by adipose tissue, 
containing 11-hydroxysteroid dehydrogenase-1 (11HSD1), converting cortisone to cortisol (Anagnostis 
et al., 2009). Inflammation, immune alterations and oxidative stress secondary to HPA-axis dysfunction 
may also contribute to increased PTSD and CVD risk (Michopoulos et al., 2016). Furthermore, both 
MetS and a dysregulated HPA-axis can potentially increase the risk for developing PTSD by directly 
influencing brain function (Farr et al., 2014; Michopoulos et al., 2016). Although HPA-axis dysfunction is 
clearly linked to both PTSD and MetS, this relationship has not been extensively examined (Bartoli et 




increased insulin resistance, found that morning plasma cortisol levels were not significantly associated 
with PTSD patient status, nor insulin resistance (Blessing et al., 2017).   
HCC, reflecting chronic cortisol release, can potentially provide additional insights into HPA-axis 
dysfunction in relation to PTSD and associated CVD risk. Our objectives, in a sample of South African 
mixed ancestry adults, were to (i) determine whether HCC were associated with PTSD and clinical 
factors related to stress (PTSD severity, trauma severity and self-perceived stress); (ii) investigate 
interactions between PTSD and MetS (as well as individual CVD risk factors) on HCC. 
2 Methods 
2.1 Study design 
This study is a neuroendocrine ancillary study to ‘Understanding the SHARED ROOTS of 
Neuropsychiatric Disorders and Modifiable Risk Factors for Cardiovascular Disease’ (SHARED 
ROOTS). The main aim of SHARED ROOTS (SR) is to determine the factors that contribute to 
comorbidity of NPDs and MetS, as a marker of CVD risk. This research question was investigated in 
three cohorts of NPDs of relevance to the South African context, namely PTSD, schizophrenia and 
Parkinson’s disease. SR was a cross-sectional matched case-control study and controls were matched 
to each NPD cohort based on age, gender, and MetS status. Here we address the original main aims 
of the neuroendocrine study in the PTSD cohort.  
2.1.1 Ethical aspects 
This study was approved by the Health Research Ethics Committee at Stellenbosch University (HREC 
N13/08/115) and conducted according to principles of the of the seventh revision of the Declaration of 
Helsinki (World Medical Association, 2013). A tiered consenting process was adhered to, allowing 
participants to opt-out of the hair sampling procedure. Participants were referred to their usual health 






Participants were enrolled over 3 years from May 2014 until June 2017 in Cape Town, Western Cape, 
South Africa. We utilised a purposive sampling approach and participants were recruited using multi-
pronged strategies. PTSD cohort participants were recruited via (i) referrals from colleagues working at 
healthcare centres and from the Mental Health Information Centre; (ii) active recruitment by a 
registered nurse visiting various community centres; (iii) existing patient databases; (iv) print, radio and 
web advertisements; and (v) word of mouth by participants already recruited.   
2.3 Participants 
The study sample was limited to individuals who self-identified as belonging to the mixed ancestry 
(coloured) ethnic group. The decision to limit the study to one ethnic group was chiefly to avoid the 
effects of population stratification on genomic analyses. All participants had to be 18 years and older, 
willing and able to provide informed consent and be able to read and write in English or Afrikaans (the 
predominant languages spoken in this population). Participants were excluded from hair sampling if 
they had hair length shorter than 3cm (see Figure 1 for a flow diagram of participants included in this 
study). 
Further exclusion criteria applied in this study were, (i) systemic or scalp steroid use, (ii) current 
pregnancy, or pregnancy within the prior three months, (iii) significant medical comorbidity (e.g. cancer, 
HIV, auto-immune disorders), (iv) current substance use disorders, as determined with the Mini 
International Neuropsychiatric Interview (MINI), and (v) lifetime or current serious psychiatric disorder (a 
psychotic or bipolar disorder) as determined based on the psychiatric history or the MINI. The 
Diagnostic and Statistical Manual of Mental Disorders (DSM–5) definition of trauma-exposure was 
employed. PTSD case status was defined as meeting the DSM-5 criteria of PTSD according to the 
diagnostic evaluation with the Clinician Administered Posttraumatic Stress Disorder Scale for DSM–5 
(CAPS-5). Trauma exposed participants in the PTSD cohort not meeting the DSM-5 criteria on the 
CAPS-5 were designated as trauma-exposed controls (TEC). We also applied a severity criterion 
excluding PTSD patients with a CAPS-5 severity score below 23 and TEC with a severity score above 




from the current analysis due to the small number recruited (n = 11). Exclusion criteria only applied to 
controls were any current psychiatric disorder, as determined based on history, the MINI or current 
psychiatric medication use, as well as a lifetime diagnosis of PTSD based on history. 
MetS status was determined based on the harmonized Joint Interim Statement (JIS) criteria (Alberti et 
al., 2009), with the presence of any three of the following five risk factors required for a diagnosis of 
MetS: (i) Raised blood pressure (BP), systolic ≥ 130 and/or diastolic ≥ 85 mmHg, or being on 
antihypertensive treatment; (ii) Elevated triglycerides (trig) > 1.70 mmol/l (150 mg/dl) or being on 
treatment for hypertriglyceridemia (fibrates or high dose omega-3 fatty acids); (iii) Reduced HDL-C, < 
1.0 mmol/l (40mg/dl) in males, and < 1.3 mmol/l (50mg/dl) in females, or being on treatment for low 
HDL-C (nicotinic acid); (iv) Elevated fasting glucose (FPG) ≥ 5.6 mmol/l (100 mg/dl) or on treatment for 
diabetes; (v) Elevated waist circumference (WC) according to population and country specific 
guidelines. We used a WC ≥ 90cm in both males and females, as a recent validation study showed this 
to be the optimal WC cut-off in mixed ancestry individuals (Matsha et al., 2013). 
2.4 Procedures 
Participants attended two to three study visits, each lasting around 3 hours. Diagnostic, clinical and 
participant-administered measures were completed at the first visit. The second visit occurred within 
24-96 hours of the first visit and involved the physical procedures and additional lifestyle measures. 
Assessments were conducted in English or Afrikaans, depending on the language preference of 
participants. Psychiatrists and physicians with experience in psychiatry conducted diagnostic and 
clinical assessments. Research nurses performed the physical procedures and personally 
administered the participant-administered measures to all participants, to aid in comprehension and to 







Figure 1 Flow diagram demonstrating inclusion and exclusion of participant 
 
a Current pregnancy or pregnancy within prior 3 months 
b Exclusion criteria only applicable to controls 
c Exclusion based on CAPS severity criterion (PT severity < 23; CT severity ≥ 23) 
CAPS, Clinician-Administered PTSD Scale; CT, control; HCC, hair cortisol concentrations; PT, PTSD 






2.4.1 Physical measurements 
Physical measurements were conducted in a consistent method in accordance with the World Health 
Organization Stepwise approach to chronic disease risk factor surveillance (WHO STEPS) instrument, 
a standardised instrument designed for non-communicable disease surveillance (World Health 
Organization, 2005). The following physical parameters were included in analysis: (i) mean systolic 
(SBP) and diastolic blood pressure (DBP, mmHg); (ii) mean heartrate (HR, bpm); (iii) body mass index 
(BMI, kg/m2); (iv) WC (cm); (v) hip circumference (HC, cm); and (vi) waist-to-hip ratio (WHR).  
2.4.2 Blood samples for metabolic parameters 
Venous blood samples were obtained following an overnight fast (at least 8 hours) and were analysed 
on the Cobas 6000 c501 Chemistry Analyser (Roche, Germany) at a commercial internationally 
accredited laboratory (Lancet laboratories) on the same day as sample collection. The following 
laboratory parameters were included in analysis: (i) FPG (mmol/l); (ii) trig (mmol/l); (iii) HDL-C (mmol/l); 
(iv) low-density lipoprotein cholesterol (LDL-C, mmol/l); (v) total cholesterol (TC, mmol/l); (vi) and 
glycated haemoglobin A1c (HbA1c, %). Values for TC > 5 mmol/l, LDL-C ≥ 3 mmol/l, and HbA1c ≥ 
6.5% were considered to be elevated (Klug et al., 2018; SEMDSA Type 2 Diabetes Guidelines Expert 
Committee., 2017). 
2.4.3 Hair sampling 
Hair samples from the posterior vertex scalp were cut with fine scissors. Samples were secured, 
placed into aluminium foil, labelled and sealed inside an envelope and stored in dark containers at 
room temperature. 
2.4.4 Hair analysis 
Hair analyses were performed at the TU Dresden laboratory (Prof. Clemens Kirschbaum). Samples 
were analysed in two batches.  A pilot sample comprising the first 21 hair samples obtained were sent 
for analysis in September 2014. The remaining samples were sent for analysis in December 2017. 
Samples were analysed using an established liquid chromatography-tandem mass spectrometry (LC-




representing cortisol secretion for the prior 3 months based on an accepted growth rate of 1cm per 
month (Wennig, 2000). 
2.5 Measures 
2.5.1 Demographic questionnaire 
Demographic variables included in this manuscript are self-identified gender (male or female), age in 
years (calculated as date of birth subtracted from date of assessment), highest level of education 
(HLOE, defined according to whether secondary education was completed), and employment status 
(defined as being employed for the greater part of the prior 12 months). 
2.5.2 Medical history questionnaires 
Variables from the medical questionnaires included in this manuscript were: (i) steroid use in the prior 6 
months (split according to whether any systemic steroids were used (oral or parenteral), topical steroids 
where used on the scalp, and any other topical steroid use (dermatologic, inhaled, nasal), (ii) hormonal 
contraceptive use in prior 6 months (including oral contraceptives and other formulations, such as 
injectable contraceptives), (iii) whether the woman was currently breastfeeding, (iv) history of previous 
PTSD, (v) current psychiatric medication use, (vi) known CVD [angina, myocardial infarct or 
cerebrovascular accident (CVA)], (vii) statin use, (viii) aspirin use, (ix) any other current medical 
conditions, and (iv) self-reported tobacco and alcohol use in the prior six months.  
2.5.3 The Clinician Administered Posttraumatic Stress Disorder Scale for DSM–5 (CAPS-5) (F 
W Weathers et al., 2013) 
The CAPS-5 was used to determine current (past month) PTSD diagnostic status and severity. The 
CAPS-5 is a structured diagnostic interview for PTSD based on DSM-5 diagnostic criteria for PTSD. 
Each DSM-5 corresponding item is rated based on the frequency and intensity of the symptoms on a 
5-point Likert score (0 = absent, 1 = mild/subthreshold, 2 = moderate/threshold, 3 = severe/markedly 
elevated, and 4 = extreme/incapacitating). A symptom is considered present if it is rated ‘2’ or higher, 
reflecting a minimum intensity of ‘clearly present’ and a minimum frequency of twice a month or 20-
30% of the time. Symptom severity scores are computed by adding the severity scores for the items 




for all 20 items (range 0 – 80). Initial psychometric evaluations of the CAPS-5 demonstrated sound 
psychometric properties for both PTSD diagnostic status and severity scores (Frank W. Weathers et 
al., 2018). Internal consistency in this sample was good (Cronbach’s α: Cluster B = 0.820, Cluster C = 
0.720, Cluster D = 0.897, Cluster E = 0.821, full scale = 0.950). 
2.5.4 The Life Events Checklist for DSM-5 (LEC-5) (Frank W Weathers et al., 2013) 
The LEC-5 was developed concurrently with the CAPS-5 to assess lifetime exposure to potentially 
traumatic events and is administered prior to the CAPS-5. The LEC-5 assesses for exposure to 16 
types of potentially traumatic events and an additional item for any other stressful events. For each 
event type, an individual indicates if they were exposed to the event in one or more ways, including if it 
happened to them personally, if they witnessed it, learned about it happening to a close family member 
or friend, or if they were exposed to it as part of their job. The worst event, or index trauma, as reported 
on the LEC-5 was used to assess for PTSD symptoms in the prior month with the CAPS-5. The LEC 
has demonstrated adequate psychometric properties in both clinical and non-clinical samples (Gray, 
Litz, Hsu, & Lombardo, 2004). Other trauma variables that are reported on include (i) the index trauma 
category/type (ii) trauma load, namely the total number of types (categories) of traumatic events 
endorsed (iii) months since the index trauma, and (iv) developmental stage when the index trauma 
occurred (≤ 18years, > 18 years). 
2.5.5 The Mini International Neuropsychiatric Interview (MINI) (Sheehan et al., 1998) 
The MINI is a short structured diagnostic interview used to diagnose psychiatric disorders based on 
DSM-IV and International Classification of Diseases (ICD-10) criteria. The MINI version 6.0 was used 
to determine the presence of any current and lifetime psychiatric disorders.  
2.5.6 Childhood Trauma Questionnaire (CTQ) (Bernstein et al., 2003) 
We used the short form of the Childhood Trauma Questionnaire (CTQ) to assess for exposure to 
maltreatment during childhood and adolescence (before the age of 18 years). The CTQ is a 28-item 
measure with 25 clinical items divided into five scales (physical, sexual and emotional abuse, and 
physical and emotional neglect), and three validity items assessing for minimisation or denial. Each 




5 = very often true). The severity scores obtained can be used as a dimensional measure of exposure 
to child abuse and neglect (scores ranging 5-25 for each subscale and 25 – 125 overall) or cut-scores 
(physical abuse ≥ 10, emotional abuse ≥ 13, sexual abuse ≥ 8, physical neglect ≥ 10 or emotional 
neglect ≥ 15) can be applied to determine the presence or absence of each type of abuse and neglect. 
In the original development and validation study, the CTQ demonstrated adequate psychometric 
properties. Internal consistency in this sample was good (Cronbach’s α: Emotional abuse = 0.858, 
physical abuse = 0.877, sexual abuse = 0.938, emotional neglect = 0.865, physical neglect = 0.696; 
total scale = 0.936). We report on the total severity score and the number of types of childhood traumas 
(none, one, two or more).  
2.5.7 The Perceived Stress Scale (PSS) (Cohen, Kamarck, & Mermelstein, 1983) 
We used the 10-item PSS (PSS-10) to measure self-perceived stress. Individuals rate to what extent 
they found their lives unpredictable, uncontrollable or overloaded in the prior month. Each item is rated 
on a 5-point Likert scale (0 = Never; 1 = Almost Never; 2 = Sometimes; 3 = Fairly often; 4 = Very often) 
with a total score ranging from 0 – 40, and higher scores indicate higher perceived stress. The PSS 
has been widely used and has demonstrated adequate psychometric properties in multiple settings 
and languages (Lee, 2012) and Cronbach’s α in this sample was 0.87.  
2.5.8 The WHO stepwise approach to chronic disease risk factor surveillance (WHO STEPS) 
(World Health Organization, 2005) 
The level of physical activity was determined with the global physical activity questionnaire (GPAQ) in 
the WHO STEPS. The GPAQ assesses average physical activity in a week occurring across three 
domains, namely work, travel and recreation. Level of physical activity (high, moderate, and low) was 
determined according to the GPAQ guidelines (World Health Organization, 2005).  
2.5.9 Hair questionnaire 
A hair questionnaire, designed for this study, assessed hair characteristics and hair care practices. Hair 
related variables reported in this manuscript include (i) whether natural hair colour is black, (ii) whether 
hair had been chemically treated in the prior three months (including colouring, relaxing and perming), 




week), (iv) whether any additional hair products had been used in the prior three months (such as hair 
styling and care products e.g. gels, oils and creams),  and (v) average hours per day that hair was 
exposed to sunlight (less than one hour, 1-2 hours, more than 2 hours). Additional hair related factors 
included the season of sampling and the duration of sample storage (less than 1 year, 1-2 years, 2-3.5 
years). 
2.6 Statistical analysis 
Sample size estimations were computed using means and standard deviations (SD) reported in other 
hair cortisol studies in PTSD and MetS samples (Stalder et al., 2013; Steudte et al., 2013), with α set at 
0.05 and power at 90%. The sample size required to distinguish between PTSD patients and controls 
was 106 (53 in each group), and 292 (146 in each group) to distinguish between those with and without 
MetS. The overall sample size was, however, limited by recruitment of the parent study as well as by 
limitations to hair sampling, such as short hair length. Due to the small number of males with hair 
cortisol data (n = 3, 1.9%), the analysis was restricted to females only. As found in other studies, HCC 
were not normally distributed and were positively skewed (Clark, Osborne, Gallagher, & Watson, 
2016). Utilising the box-cox family of power transformations (Osborne, 2010) HCC were reciprocal 
square root transformed to meet the assumption of normality. HCC were not detectable in one sample 
and we excluded one outlier with transformed HCC 3SD beyond the mean, resulting in a final sample 
of 216 participants (Figure 1). We compared the included and excluded sample with Pearson chi-
square for categorical variables, and Mann Whitney tests for continuous variables. We compared the 
PTSD patients and TEC with Pearson chi-square for categorical variables and independent sample t-
tests for continuous variables. There were very few missing data items and these were excluded from 
analysis listwise (missing items and final sample numbers reported in tables). To determine whether 
trauma severity (CTQ total score, number of types of traumas), PTSD caseness, total CAPS and 
domain severity scores, and self-perceived stress were associated with HCC we conducted 
unadjusted and adjusted linear regression models with HCC as the dependent variable. Covariates 
included in models were age, trauma related variables (CTQ total score, number of types of traumas, 




associated with HCC when we controlled for age and PTSD caseness (education, employment status, 
natural hair colour, frequency of hair washing, chemical treatment of hair, duration of storage, and 
breastfeeding). Interaction effects between MetS and PTSD caseness were assessed by regressing 
MetS on HCC in unadjusted, and then in adjusted models that included potential confounders for HCC 
alongside PTSD caseness. We also examined for any interaction effects between PTSD caseness 
and MetS. In exploratory analysis we also examined for associations between the individual CVD risk 
variables and HCC as well as for interactions with PTSD caseness. Limited sensitivity and post-hoc 
analyses were conducted to allow for additional interpretation of the data. Data were analysed with 
SPSS for windows, version 25.0, all tests were 2-tailed and the level of significance was set at .05. 
3 Results 
3.1 Participants 
Hair samples were obtained in 350 (55.7%) of the 628 participants included in the PTSD cohort and 
short hair length was the main factor limiting sampling. A further 134 participants were excluded from 
analysis, leaving a final sample of 216 participants; 110 patients and 106 TECs (see Figure 1 for 
details). The following factors differed significantly between included and excluded samples: Gender (p 
< 0.001), duration of storage (p = 0.021), tobacco use (p = 0.031), alcohol use (p < 0.001), total number 
of categories of traumas (p = 0.016), HDL-C criterion (p = 0.004), BMI (p < 0.001), WC (p = 0.003), and 
HC (p < 0.001). When we controlled for gender, these factors were no longer significantly different, 
excluding only alcohol use and the duration of storage.  
Descriptive data of the sample are presented in Table 1. Fifteen (13.6%) of the PTSD patients had a 
lifetime diagnosis of PTSD based on history and 27 (24.5%) were on current psychiatric medications. 
Of the PTSD patients, 71 (64.5%) had a current comorbid CMD MINI diagnosis, 35.5% with comorbid 
MDD and 48.2% with a comorbid anxiety or related disorder. Factors that were significantly different 
between cases and TEC included age, hair product use, duration of storage, hormonal contraceptive 
use, and tobacco use. Trauma related variables, including childhood maltreatment and trauma load, 




Table 1 Comparison of sociodemographic, hair related, behavioural, clinical, trauma and PTSD related variables between PTSD cases and trauma 
exposed controls  
 
Variables Patients TEC Test statistic p-value 
Total 110 106   
Socio-demographic     
 Age M(SD) 40.8 (11.4) 46.9 (14.4) t (199.7) = 3.45 0.001* 
 Secondary education complete n(%)   χ²(1) = 0.39 0.533 
  No 79 (71.8) 72 (67.9)   
  Yes 31 (28.2) 34 (32.1)   
 Employed n(%)   χ²(1) = 1.12 0.291 
  No 76 (69.1) 66 (62.3)   
  Yes 34 (30.9) 40 (37.7)   
Hair related     
 Natural hair colour blacka n(%)   χ²(1) = 0.00 0.970 
  No 63 (57.8) 61 (57.5)   
  Yes 46 (42.2) 45 (42.3)   
 Hair chemically treateda n(%)   χ²(1) = 0.03 0.873 
  No 34 (31.2) 32 (30.2)   
  Yes 75 (68.8) 74 (69.8)   
 Frequency of hair washinga n(%)   χ²(2) = 2.91 0.233 
  ≥ 2 times a week 30 (27.5) 31 (29.2)   
  1 time a week 49 (45.0) 56 (52.8)   
  < 1 time a week 30 (27.5) 19 (17.9)   
 Add on hair productsa n(%)   χ²(1) = 3.88 0.049* 
  No  44 (40.4) 57 (53.8)   
  Yes 65 (59.6) 49 (46.2)   
 Average hours in sunb n(%)   χ²(2) = 1.23 0.540 
  < 1 hour 46 (43.0) 44 (41.9)   
  1-2 hours 38 (35.5) 32 (30.5)   
  > 2 hours 23 (21.5) 29 (27.6)   
 Season sampled n(%)   χ²(3) = 7.78 0.051 
  Summer 29 (26.4) 25 (23.6)   
  Autumn 18 (16.4) 30 (28.3)   
  Winter 30 (27.3) 33 (31.1)   
  Spring 33 (30.0) 18 (17.0)   
 Duration of storage n(%)   χ²(2) = 11.14 0.004* 




  1 - 2 years 32 (29.1) 44 (41.5)   
  2 – 3.5 years 66 (60.0) 40 (37.7)   
Clinical      
 Hormonal contraceptive n(%)   χ²(1) = 4.17 0.041* 
  No 76 (69.1) 86 (81.1)   
  Yes 34 (30.9) 20 (18.9)   
 Currently breastfeedinga n(%)   χ²(1) = 0.65 0.420 
  No 101 (92.7) 101 (95.3)   
  Yes 8 (7.3) 5 (4.7)   
 Topical steroid use n(%)   χ²(1) = 0.62 0.430 
  No 102 (92.7) 101 (95.3)   
  Yes 8 (7.3) 5 (4.7)   
 Other medical conditions n(%)   χ²(1) = 0.61 0.434 
  No 43 (39.1) 47 (44.3)   
  Yes 67 (60.9) 59 (55.7)   
Behavioural     
 Tobacco use n(%)   χ²(1) = 5.14 0.023* 
  No 57 (51.8) 71 (67.0)   
  Yes 53 (48.2) 35 (33.0)   
 Alcohol use n(%)   χ²(1) = 0.01 0.917 
  No 62 (56.4) 59 (55.7)   
  Yes 48 (43.6) 47 (44.3)   
 Level of physical activitya n(%)   χ²(2) = 2.12 0.347 
  High 6 (5.5) 10 (9.4)   
  Moderate 33 (30.3) 38 (35.8)   
  Low 70 (64.2) 58 (54.7)   
Trauma and PTSD related     
 Childhood maltreatment     
  CTQ severity score M(SD) 61. 2 (22.0) 45.8 (17.5) t (214) = -5.69 < 0.001* 
  Number of childhood traumas n(%)   χ²(2) = 15.75 < 0.001* 
   None 20 (18.2) 43 (40.6)   
   One 23 (20.9) 24 (22.6)   
   Two or more 67 (60.9) 39 (36.8)   
 LEC trauma variables     
  Total number of trauma categories M(SD) 7.9 (3.4) 5.7 (2.9) t (214) = -5.21 < 0.001* 
   Personally experienced M(SD) 3.5 (1.7) 2.1 (1.6) t (214) = -6.36 < 0.001* 
   Witnessed M(SD) 2.0 (1.9) 1.5 (1.6) t (214) = -1.97 0.050 
   Learned about M(SD) 2.4 (1.8) 2.0 (1.5) t (214) = -1.38 0.170 




  Months since trauma M(SD) 124.8 (139.4) 143.4 (148.5) t (214) = 0.95 0.343 
  Developmental stage index trauma n(%)   χ²(1) = 2.76 0.097 
   ≤ 18 years 24 (21.8) 14 (13.2)   
   > 18 years 86 (78.2) 92 (86.8)   
  Index trauma main type n(%)   χ²(10) = 27.72 0.002* 
   Fire or explosion 1 (0.9) 2 (1.9)   
   Transportation accident 3 (2.7) 11 (10.1)   
   Other accident 1 (0.9) 0   
   Physical assault 16 (14.5) 10 (9.4)   
   Assault with a weapon 23 (20.9) 22 (20.8)   
   Sexual assault 36 (32.7) 12 (11.3)   
   Captivity 0 1 (0.9)   
   Life-threatening illness or injury 2 (1.8) 4 (3.8)   
   Sudden violent death 6 (5.5) 7 (6.6)   
   Sudden unexpected loss of someone close 21 (19.1) 29 (27.4)   
   Other event 1 (0.9) 8 (7.5)   
 CAPS severity score     
  Total severity score M(SD) 36.5 (8.4) 5.4 (5.7) t (191.1) = -31.94 < 0.001* 
   Intrusion M(SD) 8.4 (3.0) 1.7 (2.3) t (202.8) = -18.65 < 0.001* 
   Avoidance M(SD) 4.4 (1.3) 1.2 (1.7) t (192.5) = -15.78 < 0.001* 
   Negative changes M(SD) 12.9 (4.2) 1.1 (2.1) t (160.6) = -26.61 < 0.001* 
   Arousal M(SD) 10.8 (3.1) 1.4 (1.6) t (165.5) = -28.27 < 0.001* 
Perceived stress     
 PSS total score M(SD) 27.2 (6.5) 17.0 (7.4) t (214) = -10.78 <0.001* 
HCC Mdn(IQR) 7.05 (4.08; 12.33) 4.15 (2.74; 7.23) U=4228; Z=-3.49 < 0.001* 
Transformed HCC M(SD) 1.28 (0.30) 1.15 (0.28) t (214) = -3.21 0.002* 
a One missing response on this item 
b Four missing responses on this item 
* p < 0.05 
CAPS, Clinician Administered Posttraumatic Stress Disorder Scale; CTQ, Childhood Trauma Questionnaire; HCC, hair cortisol concentrations; Life Events 





Table 2 Trauma and PTSD related variables regressed on hair cortisol concentrations (HCC) 
 
Variables Simple linear regression model Multiple linear regressiona 
  B (95% CI) p-value B (95% CI) p-value 
Total number of types of traumas  0.01 (0.00; 0.02) 0.036* 0.00(-0.01; 0.01) 0.687 
CTQ total severity score 0.00 (0.00; 0.00) 0.006* 0.00 (-0.00; 0.00) 0.187 
PTSD caseness     
 TEC Ref  Ref  
 Patient 0.13 (0.05; 0.20) 0.002* 0.09 (0.01; 0.18)b 0.033* 
Total CAPS severity score 0.00 (0.00; 0.01) <0.001* 0.00 (0.00; 0.01)c 0.005* 
 Intrusion 0.02 (0.01; 0.03) <0.001* 0.02 (0.01; 0.03) 0.001* 
 Avoidance 0.03 (0.01; 0.04) 0.007* 0.02 (-0.00; 0.04) 0.060 
 Negative changes 0.01 (0.01; 0.02) <0.001* 0.01 (0.00; 0.02) 0.009* 
 Arousal  0.01 (0.00; 0.02) 0.004* 0.01 (0.00; 0.02) 0.041* 
a Controlled for age, education, employment status, natural hair colour, frequency of hair washing, chemical treatment of hair, duration of storage, 
breastfeeding, CTQ total score, number of types of traumas, months since index trauma, developmental stage of trauma, n = 214 (one participant with 
missing data for frequency of hair washing and chemical treatment of hair excluded and one participant with missing data on breastfeeding excluded) 
bModel: F (15, 198) = 4.76 (p < 0.001*), Adj R² = 0.209 
cModel: F (15, 198) = 5.05 (p < 0.001*), Adj R² = 0.222 
* p < 0.05 
CAPS, Clinician Administered Posttraumatic Stress Disorder Scale; CTQ, Childhood Trauma Questionnaire; HCC, hair cortisol concentrations; PTSD, 









3.2 PTSD, trauma and hair cortisol concentrations (Table 2) 
Trauma related variables, total number of categories of traumas and CTQ severity, were significantly 
associated with HCC in unadjusted, but not in adjusted analyses. HCC were significantly higher 
(Cohen’s d = 0.44) in PTSD cases than in TEC (Figure 2) in unadjusted and adjusted models. Total 
CAPS severity scores were significantly positively associated with HCC in unadjusted and adjusted 
analyses. PTSD symptom cluster severity scores were also significantly associated with HCC, in 
unadjusted and adjusted models, with the exception of avoidance severity that demonstrated a trend 
towards significance (p = 0.060) in the adjusted model. When symptom cluster severity scores were 
added to the model simultaneously, only intrusion severity (adj B = 0.02, 95% CI 0.00; 0.04, p = 0.033) 
remained significantly associated with HCC. 
 
Figure 2 Hair cortisol concentrations (HCC) according to PTSD diagnosis 
 
Bar chart demonstrating mean HCC according to PTSD patient status. HCC were significantly higher in 
PTSD patients than trauma exposed controls (p = 0.002) 
*p < 0.05 













3.3 Self-perceived stress, PTSD and hair cortisol concentrations  
PSS scores were significantly higher in PTSD patients than in TEC (p < 0.001) and PSS scores were 
significantly correlated with CAPS severity score (r = 0.64, p < 0.001). PSS scores were significantly 
associated with HCC in unadjusted (B = 0.01, 95% CI 0.0; 0.01, p < 0.001) and adjusted (adj B = 0.01, 
95% CI 0.01; 0.02, p = 0.029) analyses. There were no significant interaction effects between PTSD 
caseness and PSS scores on HCC.  
3.4 Cardiovascular disease risk factors, PTSD and hair cortisol concentrations  
3.4.1 Metabolic syndrome, PTSD and hair cortisol concentrations (Table 3) 
Rates of MetS were non-significantly higher (p = 0.104) in TEC than in PTSD patients. MetS was not 
significantly associated with HCC in unadjusted and adjusted analyses. Although the interaction 
between PTSD caseness and MetS was not significant, MetS was associated with higher HCC in TEC 




Table 3 PTSD and metabolic syndrome regressed on hair cortisol concentrations (HCC) 
 
  Simple linear regression Multiple linear regressiona 
    Model 1 Model 2 Model 3 
  ß (95% CI) p-value ß (95% CI) p-value ß (95% CI) p-value ß (95% CI) p-value 
PTSD caseness        0.045* 
 TEC Ref  Ref  Ref  Ref  
 Patient 0.13 (0.05; 0.20) 0.002* 0.10 (0.02; 0.18) 0.010* 0.10 (0.02; 0.18) 0.010* 0.14 (0.05; 0.24) 0.002* 
MetS        0.753 
 No Ref    Ref  Ref  
 Yes -0.01 (-0.09; 0.08) 0.850   0.08 (-0.21; 0.37) 0.557 0.08 (-0.03; 0.19) 0.169 
Patient*MetS       -0.13 (-0.28; 0.03) 0.101 
a Controlled for age, education, employment status, natural hair colour, frequency of hair washing, chemical treatment of hair, duration of storage, breastfeeding, n = 214 
(one participant with missing data for frequency of hair washing and chemical treatment of hair excluded and one participants with missing data on breastfeeding excluded) 
Model 1 – Model without MetS: F (11, 202) = 6.31 (p < 0.001*), Adj R² = 0.215; n = 214 
Model 2 – MetS added: F (12, 201) = 5.77 (p < 0.001*), Adj R² = 0.212, n = 214 
Model 3 – Interaction between case status and MetS added: F (13, 201) = 5.58 (p < 0.001*), Adj R² = 0.218; n = 214 
* p < 0.05 









Figure 3 Hair cortisol concentrations (HCC) according to PTSD patient status and metabolic 
syndrome status 
 
Bar chart demonstrating mean hair cortisol levels according to PTSD patient status and metabolic 
syndrome status (MetS). The model was significant (F (212, 3) = 4.22, p = 0.006). HCC were highest in 
PTSD patients without MetS, and were significantly higher than TEC without MetS (p = 0.003). There 
were no other significant differences between the groups based on Tukey HSD post hoc test. 
*p < 0.05 
Error bars ± 2SE 
 
3.4.2 Individual cardiovascular disease risk factors, PTSD and hair cortisol concentrations 
(Supplementary Table 1) 
CVD risk factors that differed between cases and TEC included antihypertensive medication use (p = 
0.005), FPG (p = 0.029), FPG MetS criterion (p < 0.001) and HDL-C MetS criterion (p = 0.039). When 
we controlled for age, only FPG MetS criterion remained significantly different (p = 0.031). The only 
CVD risk factors that were significantly associated with HCC in unadjusted analyses and adjusted 
analyses were HDL-C levels and HDL-C MetS criterion (Figure 4), such that lower HDL-C levels were 
associated with increased HCC. The only significant interaction between PTSD patient status and CVD 
risk variables was demonstrated for WHR (adj B = -1.08, 95% CI -1.99; -0.17, p = 0.021) where WHR 
was significantly negatively associated with HCC in patients (adj B = -0.78, 95% CI -1.45; -0.09, p = 





Figure 4 Hair cortisol concentrations (HCC) according to PTSD patient status and HDL-C 
criteria  
 
Bar chart demonstrating mean hair cortisol levels according to PTSD patient status and HDL-C criteria. 
The model was significant (F (212, 3) = 5.75, p = 0.001). HCC were highest in PTSD patients with 
HDL-C criterion, and were significantly higher than TEC without HDL-C criterion (p < 0.001), TEC with 
HDL-C criterion (p = 0.029), and demonstrated a trend towards significance against PTSD patients 
without HDL-C criterion (p = 0.068). There were no other significant differences between the groups 
based on Tukey HSD post hoc test. 
*p < 0.05 
Error bars ± 2SE 
 
3.5 Sensitivity analysis of common mental disorder comorbidity 
To assess for the influence of CMD comorbidity we repeated the final models for PTSD patient status 
and total CAPS severity scores in the larger sample (n = 253; 119 PT and 134 TEC), including controls 
with CMD comorbidity and without applying the CAPS severity criteria. When MINI CMD comorbidity 
was added to the model both PTSD caseness (adj B = 0.11, 95% CI 0.02; 0.19, p = 0.011) and CAPS 
severity scores (adj B = 0.00, 95% CI 0.00; 0.01, p = 0.009) remained significantly associated with 
HCC and CMD comorbidity was not associated with HCC. Results remained similar when MINI MDD 





We demonstrated that in South African mixed ancestry females, HCC were significantly higher in 
PTSD patients than in TEC. Furthermore, HCC were also significantly associated with PTSD severity, 
demonstrating a directly proportional relationship. The association between HCC and PTSD variables 
remained significant when potential confounders were controlled for, including trauma and CMD 
comorbidity. We did not demonstrate an association between HCC and MetS, nor an association with 
PTSD and MetS comorbidity. Individual CVD risk variables were on the whole not associated with 
HCC, with the exception of a negative association with HDL-C and HDL-C MetS criterion, and WHR, in 
PTSD cases only. 
Largely, the literature demonstrates lower baseline cortisol levels in PTSD patients than in controls 
(Meewisse et al., 2007; Morris et al., 2012; Schumacher et al., 2019). We found the converse in our 
sample, with higher HCC in PTSD patients than in TEC. Our findings can plausibly be explained by the 
context in which our study was conducted. Our sample had very high rates of trauma exposure. 
Participants were exposed to an average of seven different types of trauma and more than two thirds 
(70.8%) had experienced some form of childhood abuse or maltreatment. Our results thus align with 
the general observation that in high trauma or high stress environments, PTSD patients demonstrate 
greater baseline cortisol output (Miller et al., 2007; Steudte-Schmiedgen et al., 2016). An interpretation 
of other studies examining the association between PTSD and HCC is to some extent aligned with this 
model. Studies conducted in low stress environments in the main have demonstrated negative 
associations between PTSD parameters and HCC (Steudte et al., 2013; Straub, Klaubert, 
Schmiedgen, Kirschbaum, & Goldbeck, 2017).  In other samples with ongoing stressors, such as 
displaced populations (Dajani, Hadfield, van Uum, Greff, & Panter-Brick, 2018; Steudte et al., 2011) 
and enlisted soldiers (Groer, Kane, Williams, & Duffy, 2015) PTSD has been associated with increased 
HCC. This pattern, is however, not consistently demonstrated (Luo et al., 2012; van Zuiden et al., 2019) 
and what constitutes ongoing stress is to some degree a matter of interpretation. Other, unknown 
factors may also be contributing to the differing patterns of association observed between HCC and 




systematic review demonstrated that afternoon cortisol levels were lower in PTSD patients without, and 
higher in PTSD patients with, comorbid MDD compared with trauma unexposed controls (Morris et al., 
2012).  
Similar to a recent meta-analysis (Khoury et al., 2019) we demonstrated a small positive association 
between trauma severity indicators (both trauma load and childhood maltreatment) and HCC. 
However, these associations were no longer significant when we controlled for potential confounders. 
Furthermore, whereas previous studies have suggested that the association between HCC and PTSD 
appears to be primarily trauma related (Khoury et al., 2019; Steudte-Schmiedgen et al., 2016), our 
results demonstrated that HCC were associated with the PTSD clinical phenotype. It is, however, 
difficult to accurately define and measure trauma severity in a sample with complex and repeated 
trauma histories, such as the sample reported on here. We also included a measure of self-perceived 
stress to evaluate for associations between self-perceived stress and HCC within the context of PTSD. 
PTSD patients reported higher self-perceived stress than TEC and self-perceived stress was also 
significantly associated with CAPS severity scores. PSS scores were significantly associated with 
HCC, providing further support that the psychological stress experienced by PTSD sufferers is 
associated with higher HCC. 
We did not demonstrate a significant association between HCC and MetS, nor an association with 
PTSD and MetS comorbidity. Although not significant, MetS was associated with HCC in opposite 
directions in PTSD patients and TEC. Other studies utilising HCC tend to demonstrate higher HCC in 
relation to MetS (Kuehl et al., 2015; Stalder et al., 2013). However, a study in HIV positive individuals 
found a negative association between HCC and MetS (Langerak et al., 2015). The authors postulated 
that the contradictory findings in HIV patients could be related to cortisol hypersensitivity, where 
systemic levels of cortisol are low due to enhanced negative feedback. An analogous effect may be 
present in the PTSD patients with MetS. This similar pattern was also demonstrated for WHR in our 
sample, where WHR was significantly negatively associated with HCC in patients, but non-significantly 
positively associated with HCC in TEC. The direction of association between WHR and HCC in TEC 




factors were not associated with HCC in the same direction; meeting HDL-C and BP criteria were 
associated with higher HCC, whereas meeting FPG, Trig, and WC criteria were associated with lower 
HCC. The association between MetS and HPA-axis functioning appears to be of a smaller magnitude 
and more complex and may have been obscured by the stronger influence of trauma characteristics 
and other PTSD related factors in our sample. 
The only MetS factor significantly associated with HCC was HDL-C, both continuous HDL-C levels and 
whether levels were below the HDL-C criterion threshold. Though some studies have not found an 
association between HLD-C and cortisol (de Vries, Mocking, Assies, Schene, & Olff, 2017), other 
studies have similarly demonstrated a negative association between cortisol levels and HDL-C (Fraser 
et al., 1999; Stalder et al., 2013). Conversely, a study in a male PTSD sample demonstrated that 
plasma cortisol levels were significantly positively correlated with HDL-C in PTSD patients (Blessing et 
al., 2017). HDL-C has anti-inflammatory, antioxidant, antithrombotic and anti-apoptotic functions and is 
a known independent risk factor for CVD (März et al., 2017). Cortisol and HDL-C are potentially linked 
together in different pathways. Cortisol affects lipid metabolism and may thus influence HDL-C levels 
and HDL-C acts as a cholesterol donor for steroidogenesis in the adrenal gland (Atogo-Asse et al., 
2012; März et al., 2017). HDL-C appears to play a particular role in cortisol production in response to 
ACTH stimulation and under stressful conditions (Atogo-Asse et al., 2012). 
High rates (45.9%) of low HDL-C levels have also been demonstrated in PTSD (Rosenbaum et al., 
2015). In our sample, HDL-C levels were also significantly lower in PTSD patients than in TEC, 
although the association did not remain significant once we controlled for age. There, however, 
appeared to be a cumulative effect between PTSD caseness and HDL-C, such that HCC were highest 
in PTSD patients with low HDL-C (Figure 4). A study in baboons demonstrated a similar pattern, where 
subordinate males who experienced more social stress had significantly lower HDL-C than dominant 
males, and HDL-C and basal cortisol levels were inversely associated (Sapolskyf & Mott, 1987). 
Further evidence for unique stress related contributions to metabolic derangements were 
demonstrated in a study where diurnal stress-related cortisol release was significantly inversely 




term HPA-dysfunction alongside increased stress sensitivity (Rosmond, Dallman, & Bjorntorp, 1998). 
HDL-C may thus be one of the factors linking increased CVD risk in PTSD patients to associated HPA-
axis dysregulation. HDL-C can also be influenced by other factors such as genetic variation, smoking, 
physical activity, obesity, diet, alcohol consumption, and statin use  (März et al., 2017). When we 
controlled for statin, tobacco and alcohol use, and physical activity in our study, results were 
unchanged. 
4.1 Strengths and limitations 
Our study includes one of the largest investigations of the association between PTSD and HCC to 
date. Our sample was, however, underpowered to detect significant associations between HCC and 
MetS. This was a cross-sectional study where findings of associations are not indicative of cause-effect 
relationships. A major limitation in our study was the requirement that scalp hair length had to be 3cm 
or longer and consequently many participants, particularly males, were excluded from participation. Our 
sample was limited to a single race classification and sex (female) and these results cannot be directly 
extrapolated to other populations. For instance, gender may influence the association between cortisol 
and metabolic parameters. One study in PTSD found that LDL-C was positively associated with 
morning plasma cortisol in men, but negatively associated with cortisol in women (de Vries et al., 2017). 
They furthermore demonstrated a significant interaction between PTSD patient status and sex, such 
that triglycerides were negatively associated with cortisol in male PTSD patients, but were positively 
associated with triglycerides in female patients with PTSD, as well as in controls (de Vries et al., 2017).  
Our sample, however, is unique in representing a geographic and cultural setting where there is a 
considerable and varied trauma burden alongside notable socio-economic strain. Future studies in 
diverse populations and utilising other more viable methods of hair sampling will assist in 
contextualising these findings. We controlled for a variety of trauma related variables, including 
childhood maltreatment, trauma load, and time since index trauma, thus allowing us to partly 
distinguish PTSD related effects from trauma and adversity effects. As the pattern of cortisol 
dysregulation appears to change over time following trauma exposure (Miller et al., 2007; Steudte-




observed in relation to PTSD. We controlled for duration since the index trauma, but could not account 
for the influence of other, more recent or ongoing, trauma exposures.  Furthermore, we could not 
assess for the independent effects of trauma exposure as we did not have a sufficiently large trauma-
unexposed sample to include for comparison. We did not investigate the effects of specific trauma or 
maltreatment type on the association between PTSD and HCC and future studies examining these 
relationships in more depth are warranted. Our sample had high CMD comorbidity and PTSD patients 
with CMD comorbidity had significantly more severe illness (p < 0.001), and thus we could not 
meaningfully conduct analyses with PTSD patients without CMD comorbidity. PTSD is known to have 
high CMD comorbidity, for instance a meta-analysis reported that 52% of patients with PTSD had 
comorbid MDD (Rytwinski, Scur, Feeny, & Youngstrom, 2013). Including CMD comorbidity arguably 
reflects more real world clinical presentations of PTSD.  
4.2 Conclusions 
This study provides evidence of a chronically dysregulated neuroendocrine mediated stress response 
in PTSD. In our sample HCC appeared to be associated with the clinical phenotype, rather than with 
trauma exposure, per se. Our study is one of the few studies that have examined the association 
between PTSD, HPA-axis dysfunction and CVD risk. Similar to Blessing et al, 2017 we did not find a 
clear link between PTSD, CVD risk and cortisol levels. We did, however, demonstrate a significant 
association between HDL-C and cortisol levels, although the direction of association was opposite to 
that found in Blessing et al., 2017, which could potentially be related to gender effects. Other studies 
have suggested that potential links between PTSD, HPA-axis function, CVD risk and inflammation 
exist (Gocan, Rohr, Bachg, Schindler, & Rohr, 2012), although the exact nature of how these factors 
intersect remain to be determined. Including other markers of HPA-axis function and of inflammation 
could assist in better delineating pathways linking PTSD, HPA-axis dysregulation and CVD risk. 
Genomic analyses and longitudinal studies could also assist in identifying shared genetic risk factors 




5 Supplementary materials 
Supplementary Table 1 Cardiovascular disease risk factors in relation to PTSD caseness and hair cortisol concentrations (HCC) 
 CVD risk variables according to PTSD caseness Simple linear regression Multiple linear regressiona 
 Patients TEC ß (95% CI) p-value ß (95% CI) p-value 
Total 110 106     
MetS variables       
 MetS n(%)       
  No 77 (70.0) 63 (59.4) Ref  Ref  
  Yes 33 (30.0) 43 (40.6) -0.01 (-0.09; 0.08) 0.850 0.01 (-0.07; 0.10)b 0.723 
 Number of criteria met M(SD) 1.9 (1.3) 2.1 (1.3) 0.01 (-0.02; 0.04) 0.634 0.01 (-0.02; 0.04) 0.406 
 BP criterion n(%)       
  No 52 (47.3) 45 (42.5) Ref  Ref  
  Yes 58 (52.7) 61 (57.5) 0.05 (-0.03; 0.13) 0.247 0.02 (-0.01; 0.05) 0.306 
  On antihypertensive rx n(%)       
   No 83 (75.5) 61 (57.5) Ref  Ref  
   Yes 27 (24.5) 45 (42.5) 0.02 (-0.07; 0.10) 0.665 0.04 (-0.05; 0.14) 0.382 
  SBP (mmHg) M(SD) 126.7 (19.1) 127.5 (19.4) 0.00 (-0.00; 0.00) 0.801 0.00 (-0.00; 0.00) 0.920 
  DBP (mmHg) M(SD) 80.9 (12.2) 79.3 (10.9) 0.00 (-0.00; 0.01) 0.126 0.00 (-0.00; 0.01) 0.276 
  BP over threshold n(%)       
   No 59 (53.6) 56 (52.8) Ref  Ref  
   Yes 51 (46.4) 50 (47.2) 0.03 (-0.05; 0.11) 0.508 0.00 (-0.07; 0.08) 0.942 
 FPG criterionb n(%)       
  No 89 (80.9) 58 (54.7) Ref  Ref  
  Yes 21 (19.1) 48 (45.3) -0.04 (-0.12; 0.05) 0.389 0.01 (-0.07; 0.10) 0.762 
  On diabetes rx n(%)       
   No 103 (93.6) 95 (87.7) Ref  Ref  
   Yes 7 (6.4) 13 (12.3) 0.10 (-0.04; 0.24) 0.151 0.07 (-0.06; 0.20) 0.307 
  FPG (mmol/l) M(SD) 5.46 (2.19) 6.25 (3.06) 0.01 (-0.01; 0.02) 0.203 0.01 (-0.01; 0.02) 0.398 
 HDL-C criterionc n(%)       
  No 51 (46.4) 64 (60.4)     
  Yes 59 (53.6) 42 (39.6) 0.11 (0.03; 0.19) 0.007* 0.10 (0.02; 0.17) 0.010* 
  HDL-C (mmol/l) M(SD) 1.35 (0.40) 1.43 (0.37) -0.11 (-0.21; -0.00) 0.043* -0.11 (-0.20; -0.01) 0.030* 
 Trig criteriond n(%)       
  No 95 (86.4) 88 (83.0) Ref  Ref  
  Yes 15 (13.6) 18 (17.0) -0.05 (-0.16; 0.06) 0.374 -0.02 (-0.12; 0.09) 0.725 
  Trig (mmol/l) M(SD) 1.16 (0.49) 1.20 (0.61) -0.01 (-0.09; 0.06) 0.729 0.02 (-0.05; 0.09) 0.630 
 WC criterion n(%)       




  Yes 56 (50.9) 53 (50.0) -0.05 (-0.13; 0.03) 0.251 -0.04 (-0.11; 0.04) 0.343 
  WC (cm) M(SD) 92.2 (17.1) 93.1 (16.1) -0.00 (-0.00; 0.00) 0.155 -0.00 (-0.00; 0.00) 0.309 
Other CVD risk variables       
 Physical parameters       
  BMI (kg/m2) M(SD) 31.0 (7.8) 32.2 (8.4) -0.00 (-0.01; 0.00) 0.279 -0.00 (-0.01; 0.00) 0.737 
  HC (cm) M(SD) 108.9 (15.9) 110.4 (15.0) -0.00 (-0.00; 0.00) 0.152 0.00 (-0.00; 0.00) 0.705 
  WHR M(SD) 0.84 (0.08) 0.84 (0.08) -0.17 (-0.67; 0.32) 0.493 -0.33 (-0.78; 0.12) 0.152 
  HR (bpm) M(SD) 75.9 (11.8) 73.7 (11.1) 0.00 (-0.00; 0.01) 0.295 0.00 (-0.00; 0.00) 0.821 
 Laboratory parameters       
  TC (mmol/l) M(SD) 4.84 (1.01) 4.95 (1.02) -0.03 (-0.07; 0.07) 0.099 -0.02 (-0.06; 0.02) 0.389 
  TC > 5 mmol/l n(%)       
   No 47 (42.7) 47 (44.3) Ref  Ref  
   Yes 63 (57.3) 59 (54.1) 0.06 (-0.02; 0.14) 0.136 0.03 (-0.04; 0.11) 0.400 
  LDL-C (mmol/l) M(SD) 2.97 (0.89) 2.97 (0.93) -0.02 (-0.06; 0.02) 0.369 -0.00 (-0.04; 0.04) 0.885 
  LDL-C >= 3 mmol/l n(%)       
   No 50 (45.5) 46 (43.4) Ref  Ref  
   Yes 60 (54.5) 60 (55.6) 0.02 (-0.06; 0.10) 0.600 0.01 (-0.07; 0.08) 0.890 
  HbA1ce 5.62 (1.06) 5.97 (1.52) 0.02 (-0.01; 0.05) 0.242 0.01 (-0.02; 0.04) 0.371 
  HbA1c >= 6.5%  n(%)       
   No 100 (52.4) 91 (86.7) Ref  Ref  
   Yes 10 (9.1) 14 (13.3) -0.06 (-0.19; 0.07) 0.364 -0.03 (-0.16; 0.09) 0.578 
 CVD history variables       
  Known CVD n(%)       
   No 106 (96.4) 99 (93.4) Ref  Ref  
   Yes 4 (3.6) 7 (6.6) -0.09 (-0.27; 0.09) 0.337 -0.04 (-0.21; 0.13) 0.644 
  On statins n(%)       
   No 94 (85.5) 77 (72.6) Ref  Ref  
   Yes 16 (14.5) 29 (27.4) 0.01 (-0.10; 0.10) 0.920 0.05 (-0.06; 0.15) 0.381 
  On aspirin n(%)       
   No 101 (91.8) 86 (81.1) Ref  Ref  
   Yes 9 (8.2) 20 (18.9) -0.07 (-0.19; 0.04) 0.218 -0.06 (-0.18; 0.05) 0.288 
a Controlled for age, education, employment status, natural hair colour, frequency of hair washing, chemical treatment of hair, duration of storage, breastfeeding, PTSD 
patients status, n = 214 (one participant with missing data for frequency of hair washing and chemical treatment of hair excluded and one participants with missing data on 
breastfeeding excluded) 
b All participants who met the glucose criterion had glucose level above the threshold 
c No participants were receiving treatment to increase HDL-C 
d No participants were receiving treatment for hypertriglyceridemia  
e One missing value on this item 
* p < 0.05 
BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; DBP, diastolic blood pressure; HbA1c, Glycated haemoglobin; HC, hip circumference; HDL-C, 
high-density lipoprotein cholesterol; HR, heart rate; FPG, fasting plasma glucose; LDL-C, Low density lipoprotein cholesterol; MetS, metabolic syndrome; Ref, reference 
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Hair glucocorticoid levels in females with Parkinson’s disease  
Abstract 
Background: Parkinson’s disease (PD) and metabolic syndrome (MetS) share certain 
pathophysiological pathways, including hypothalamic pituitary adrenal (HPA) axis dysfunction. Hair 
glucocorticoid (GC) levels reflect longer-term HPA axis function and can provide additional insights into 
the role of a dysregulated HPA-axis in PD and co-occurring cardiovascular disease (CVD) risk.    
Objectives: In a case-control study of 56 females (25 PD patients and 31 controls) of mixed ancestry, 
aged between 45 and 78 years (M = 59.6, SD = 8.7) we examined the association of hair GC (cortisol 
and cortisone) levels with PD diagnosis, clinical features and PD-CVD risk (as defined by the MetS) co-
occurrence.  
Methods: Hair samples, representing a three-month retrospective window of GC levels, were collected 
and analysed utilizing liquid chromatography tandem mass spectrometry. Multivariate regression 
models were constructed with PD diagnostic status, clinical features and MetS comorbidity regressed 
on hair GC levels, adjusting for potential confounders.  
Results: The prevalence of MetS was 56.0% in PD patients and 25.8% in controls. Hair cortisone (adj 
B = 5.31, 95% CI 1.88; 8.74, p = 0.003), but not hair cortisol levels (adj B = 0.04, 95% CI -0.13; 0.21, p 
= 0.646), were significantly higher (Cohen’s d = 0.87) in PD patients than in controls. Non-motor 
symptoms of PD (e.g., mood, anhedonia and anxiety) were significantly associated with hair cortisone 
levels (adj B = 0.26, 95% CI 0.06; 0.46, p = 0.013). MetS was not associated with hair GC levels and 
there were no significant interactions between PD and MetS on hair GC levels. Hair cortisone levels 
were significantly positively associated with one of the components of MetS, waist-to-hip ratio (adj B = 
21.64, 95% CI 4.04; 39.24, p = 0.017).  
Conclusions: This study is the first study reporting on hair GC levels in PD. We found chronically 
increased cortisone, but not cortisol, levels in PD patients compared to controls. Furthermore, hair 




and anxiety. Hair GC levels were not associated with PD-MetS comorbidity in this sample. Hair 
cortisone levels may provide additional insights into HPA-axis dysfunction in PD. 























Parkinson’s disease (PD) is primarily distinguished from other neurodegenerative diseases by the 
death of dopaminergic neurons in the substantia nigra and related motor symptoms, including 
bradykinesia, resting tremor and rigidity. Symptoms of PD extend beyond classic motor symptoms and 
include sleep disturbances, autonomic dysfunction, neuropsychiatric symptoms and cognitive 
impairment (Wirdefeldt, Adami, Cole, Trichopoulos, & Mandel, 2011). Genetic, environmental and 
aging processes combine to increase the risk for PD (Herrero, Estrada, Maatouk, & Vyas, 2015). 
Several pathways play a role in the pathophysiology of PD, including accumulation of toxic proteins (α-
synuclein especially), mitochondrial dysfunction, oxidative stress, apoptosis and neuro-inflammation 
(Levy, Malagelada, & Greene, 2009).  
Stress has also been postulated to play a role in PD onset and progression (Djamshidian & Lees, 
2014; Smith, Castro, & Zigmond, 2002). PD symptoms can be triggered and exacerbated by stress in 
both animal models and clinical settings (Vyas et al., 2016). Excessive stress leading to chronically 
raised cortisol is linked to neurotoxicity and neurodegeneration of dopaminergic neurons (Djamshidian 
& Lees, 2014; Smith et al., 2002; Vyas et al., 2016). Glucocorticoids (GC) can contribute to neuronal 
loss through pathways involving excitotoxicity, mitochondrial dysfunction, synaptic dysfunction, 
apoptotic mechanisms and sensitization of neurons (Kibel & Drenjančević-Perić, 2008; Vyas et al., 
2016). Stress and GC exposure also influence epigenetic processes, such as DNA methylation, and 
this may also play a role in PD pathophysiology (Du & Pang, 2015). 
Conversely, there is also evidence suggesting that the pathology of PD influences HPA-axis function. 
Lewy bodies (LBs), eosinophilic inclusions containing α-synuclein are found not only in dopaminergic 
cells, but also in other cells throughout the body, including the adrenal glands and the hypothalamus 
(Du & Pang, 2015; Levy et al., 2009). Dopaminergic pathways regulate hypothalamic corticotrophin 
releasing factor (CRF) neurons and a study in children with growth hormone (GH) deficiency 
demonstrated that adrenocorticotropic hormone (ACTH) and cortisol levels increased after 




Papadimitriou, Kleanthous, Papadopoulou, & Papadimitriou, 2015). HPA-axis dysfunction is likely to 
occur across different levels of the HPA-axis in PD (Du & Pang, 2015). 
GC regulate inflammatory and immune processes and these are also pathways through which HPA-
axis dysfunction and the pathophysiology of PD may be linked (Herrero et al., 2015; Nolan, Sullivan, & 
Toulouse, 2013). Chronically elevated cortisol can lead to glucocorticoid receptor (GR) insensitivity and 
consequent dysregulated immune and inflammatory processes contributing to neurodegeneration in 
PD (Herrero et al., 2015; Vyas et al., 2016). Downregulated GR expression in the substantia nigra and 
increased reactive microglia have been demonstrated in PD brains and animal models of PD (Du & 
Pang, 2015; Vyas et al., 2016). Additionally, other stressors and pro-inflammatory cytokines can 
increase the release of cortisol through different mechanisms and thus contribute to chronic activation 
of the HPA-axis (Herrero et al., 2015). Although various pathways have been suggested, the cause of 
HPA-axis dysfunction and its influence on the pathophysiology of PD remains to be determined 
(Herrero et al., 2015). There is, however, clear evidence of HPA-axis dysfunction and higher cortisol 
levels in PD, although the direction of association is altered in some studies (Du & Pang, 2015; Herrero 
et al., 2015; Soares, Pereira, Altmann, de Almeida, & Rieder, 2019). The lack of studies measuring 
longer-term cortisol release has also been highlighted as a limitation to current understanding (Soares 
et al., 2019).  
Since GC were first quantified in hair, hair analyses have increasingly been utilised for measuring 
longer-term basal cortisol (Raul, Cirimele, Ludes, & Kintz, 2004). Measuring GC in hair allows for a 
retrospective calendar of cumulative glucocorticoid levels spanning months (Stalder et al., 2017). Hair 
cortisol levels (hairF) have been widely used as a marker of longer-term HPA-axis function across 
various settings and in multiple conditions (Stalder et al., 2017; Wosu, Valdimarsdóttir, Shields, 
Williams, & Williams, 2013). Measurement of hair cortisone levels (hairE) has also gained traction 
(Kuehl et al., 2015; Savas et al., 2019; Stalder et al., 2013). Cortisol is converted to cortisone by 11β-
hydroxysteroid-dehydrogenase type 2 (11β-HSD2) and 11β-hydroxysteroid-dehydrogenase type 1 
(11β-HSD1) converts cortisone to cortisol in adipose tissue and in the liver. In hair and saliva samples, 




& Trainer, 2010; Raul et al., 2004). These differences have been postulated to be due to different 
corticosteroid-binding globulin (CBG) and albumin affinities for cortisol and cortisone and the different 
locations and functions of 11β-HSD. Use of analyses of hairE may provide a more complete picture of 
HPA-axis function (Stalder et al., 2013; Staufenbiel, Penninx, de Rijke, van den Akker, & van Rossum, 
2015). Both hairF and HairE have demonstrated moderate test-retest correlations and similar 
intraindividual stability (Q. Zhang, Chen, Chen, Xu, & Deng, 2017). Hair GC have, to our knowledge, 
not been studied in PD, and there have been no published studies of cortisone levels in PD. 
Neurodegenerative disorders, such as PD, also share pathways with cardiovascular disease (CVD) 
and metabolic syndrome (MetS). MetS denotes a cluster of risk factors for CVD and type 2 diabetes 
mellitus and risk factors include central obesity, hypertension, elevated fasting glucose, 
hypertriglyceridemia and low levels of high-density lipoprotein cholesterol (HDL-C) (Alberti et al., 2009). 
PD and CVD have been conceptualised as disorders involving accelerated aging processes (Baquer 
et al., 2009). Both PD and MetS are associated with dysregulated inflammation and increased 
oxidative stress and these have been suggested as  potential pathways linking the two conditions 
(Bainbridge et al., 2017; P. Zhang & Tian, 2014). Similar to PD, HPA-axis dysfunction and altered GC 
levels have also been demonstrated in relation to MetS and CVD (Anagnostis, Athyros, Tziomalos, 
Karagiannis, & Mikhailidis, 2009; Stalder et al., 2013) and may theoretically also play a role in 
comorbidity. Although there are some pathways potentially linking PD and MetS, the relationship 
between the two disorders is not well understood. MetS has been associated with lower PD risk in 
some samples (Sääksjärvi, Knekt, Männistö, Lyytinen, & Heliövaara, 2015). However, recent studies in 
large cohorts have demonstrated that MetS and various CVD risk factors including obesity, insulin 
resistance and hyperhomocysteinemia are associated with increased risk for PD (Nam et al., 2018; P. 
Zhang & Tian, 2014). MetS has also been associated with poor outcomes in patients with PD, 
including worsened PD severity and increased risk for cognitive impairment and dementia (Bainbridge 
et al., 2017; P. Zhang & Tian, 2014). 
Hair GC levels, reflecting chronic GC release, can potentially provide additional insights into the role of 




of South African mixed ancestry adults, whether (i) hair GC levels (hairF and hairE) were associated 
with PD and clinical factors (self-perceived stress and PD symptoms); and (ii) there were interaction 
effects between PD and MetS (and individual CVD risk factors) on hair GC levels.  
2 Methods 
2.1 Study design 
This was an ancillary neuroendocrine case-control study to a project titled ‘Understanding the 
SHARED ROOTS of Neuropsychiatric Disorders and Modifiable Risk Factors for Cardiovascular 
Disease’ or SHARED ROOTS (SR). SR was a cross-sectional matched case-control study in three 
neuropsychiatric disorder cohorts (PD, posttraumatic stress disorder and schizophrenia). Controls were 
group matched to patients with PD based on age, gender, and MetS status. Here we address the 
original main aims of the neuroendocrine study in the PD cohort.  
2.1.1 Ethical aspects 
This study was approved by the Health Research Ethics Committee at Stellenbosch University (HREC 
N13/08/115) and conducted according to principles of the seventh revision of the Declaration of 
Helsinki (World Medical Association, 2013). Written informed consent was obtained from all 
participants and a tiered consenting process was adhered to, allowing participants to opt-out of the hair 
sampling procedure. Participants were referred to their usual health care service providers for any 
medical or psychiatric problems warranting further investigation and treatment.  
2.2 Setting 
Participants were enrolled over 3 years from May 2014 until June 2017 in Cape Town, South Africa. 
We utilised a purposive sampling approach. PD patients were recruited through (i) an existing 
database of patients at the Movement Disorders clinic at our facility; (ii) advertisements placed at local 
secondary and primary health care facilities; (iii) referrals of patients at district hospitals and a 
neighbouring academic centre; and (iv) print, radio and web advertisements. Control participants were 




registered nurse visiting various community centres; and (iii) word of mouth by participants already 
recruited. 
2.3 Participants 
The study sample was limited to individuals who self-identified as belonging to the mixed ancestry 
(coloured) ethnic group. The decision to limit the study to one ethnic group was chiefly to avoid the 
effects of population stratification on genomic analyses. All participants had to be 18 years and older, 
willing and able to provide informed consent and be able to read and write in English or Afrikaans (the 
predominant languages spoken within the Western Cape mixed ancestry population). Participants 
were excluded from hair sampling if they had hair length shorter than 3cm (see Figure 1 for a flow 
diagram of participants included in this study). Further exclusion criteria applied in this study were, (i) 
systemic or scalp steroid use, (ii) current pregnancy, or pregnancy within the prior three months, (iii) 
significant medical comorbidity (e.g., HIV, auto-immune disorders), (iv) current substance use 
disorders, as determined with the Mini International Neuropsychiatric Interview (MINI), (v) lifetime or 
current serious psychiatric disorder (a psychotic or bipolar disorder) as determined based on the 
psychiatric history or the MINI. Patients with PD were included if they had a UK Brain Bank clinical 
diagnosis (Hughes, Daniel, Kilford, & Lees, 1992) of idiopathic PD made by a neurologist and were 
excluded if they had a history of a significant head injury, exposure to neuroleptics, and atypical forms 
of PD. Exclusion criteria applied only to controls were current psychiatric disorder, as determined on 
history or the MINI and current psychotropic medication use.  
MetS status was determined based on the harmonized Joint Interim Statement (JIS) criteria (Alberti et 
al., 2009), with the presence of any three of the following five risk factors required for a diagnosis of 
MetS: (i) Raised blood pressure (BP), systolic ≥ 130 and/or diastolic ≥ 85 mmHg, or being on 
antihypertensive treatment; (ii) Elevated triglycerides > 1.70 mmol/l (150 mg/dl) or being on treatment 
for hypertriglyceridemia; (iii) Reduced HDL-C, < 1.0 mmol/l (40mg/dl) in males, and < 1.3 mmol/l 
(50mg/dl) in females, or being on treatment for low HDL-C; (iv) Elevated fasting glucose ≥ 5.6 mmol/l 
(100 mg/dl) or on treatment for diabetes; (v) Elevated waist circumference according to population and 




recent validation study in the Western Cape showed this to be the optimal WC cut-off in mixed ancestry 
individuals (Matsha et al., 2013). 
 
Figure 1 Flow diagram demonstrating inclusion and exclusion of participants 
 
a Exclusion criteria only applicable to controls 
CT, control; PT, patient  
 
2.4 Procedures 
Participants attended two to three study visits, each lasting around 3 hours. Diagnostic, clinical and 
participant-administered measures were completed at the first visit. The second visit occurred within 
24-96 hours of the first visit and involved the physical procedures (e.g. fasting blood sampling, physical 




Afrikaans, depending on the language preference of participants. Psychiatrists and physicians with 
experience in neuropsychiatry conducted diagnostic and clinical assessments. Research nurses 
performed the physical procedures and personally administered the participant-administered measures 
to all participants, to aid comprehension and to accommodate variation in reading level.  
2.4.1 Physical measurements 
Physical measurements were conducted in a consistent method in accordance with the WHO 
STEPwise approach to chronic disease risk factor surveillance (WHO STEPS) instrument, a 
standardised instrument designed for non-communicable disease surveillance (World Health 
Organization, 2005). The following physical parameters were included in this analysis: (i) mean systolic 
(SBP) and diastolic blood pressure (DBP, mmHg); (ii) mean heartrate (HR, bpm); (iii) body mass index 
(BMI, kg/m2); (iv) waist circumference (WC, cm); (v) hip circumference (HC, cm); and (vi) waist-to-hip 
ratio (WHR).  
2.4.2 Blood samples for metabolic parameters 
Venous blood samples were obtained following an overnight fast (at least 8 hours) and were analysed 
on the Cobas 6000 c501 Chemistry Analyser (Roche, Germany) at a commercial internationally 
accredited laboratory (Lancet laboratories) on the same day as sample collection. The following 
laboratory parameters were included in analysis: (i) fasting plasma glucose (FPG, mmol/l); (ii) 
triglycerides (trig, mmol/l); (iii) high-density lipoprotein cholesterol (HDL-C, mmol/l); (iv) low-density 
lipoprotein cholesterol (LDL-C, mmol/l); (v) total cholesterol (TC, mmol/l); (vi) and glycated haemoglobin 
A1c (HbA1c, %). Values for TC > 5 mmol/l, LDL-C ≥3 mmol/l, and HbA1c ≥ 6.5% were considered to 
be elevated (Klug et al., 2018; SEMDSA Type 2 Diabetes Guidelines Expert Committee., 2017). 
2.4.3 Hair sampling 
Hair samples from the posterior vertex scalp were cut close to the scalp with fine scissors. Samples 
were secured, placed into aluminium foil, labelled and sealed inside an envelope and were stored in 




2.4.4 Hair analysis 
Hair analyses were performed at the TU Dresden laboratory (Prof Clemens Kirschbaum). Samples 
were analysed in two batches.  A pilot sample comprising the first 21 hair samples obtained were sent 
for analysis in September 2014 and the remaining samples were sent in December 2017. Samples 
were analysed using an established liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
protocol (Gao et al., 2013). LC-MS/MS is the benchmark (gold standard) method for hair GC 
determination and different laboratories using LC-MS/MS have demonstrated almost identical results (r 
= 0.98) (Gao, Kirschbaum, Grass, & Stalder, 2016; Russell et al., 2015; Stalder et al., 2012). The 
proximal 3cm of the hair segments were used for analysis, representing cortisol secretion for the prior 3 
months based on an accepted growth rate of 1cm per month (Wennig, 2000). 
2.5 Measures 
2.5.1 Demographic questionnaire 
Demographic details were collected with a demographic questionnaire. Demographic variables 
included in this manuscript are self-identified gender (male or female), age in years, highest level of 
education (HLOE, defined according to whether secondary education was completed), and 
employment status (defined as being employed for the greater part of the prior 12 months). 
2.5.2 Medical history questionnaires 
Medical and psychiatric histories were collected with comprehensive medical questionnaires. Clinical 
items reported on in this manuscript are: (i) steroid use in the prior 6 months (split according to whether 
any systemic steroids were used (oral or parenteral), topical steroids where used on the scalp, and any 
other topical steroid use (dermatologic, inhaled, nasal), (ii) hormonal contraceptive use in prior 6 
months (including oral contraceptives and other formulations, such as implants and injectable 
contraceptives), (iii) PD disease duration, (iv) medications used for PD (v) current psychiatric 
medication use, (vi) known CVD [previous angina, myocardial infarct or cerebrovascular accident 
(CVA)], (vii) statin use, (viii) aspirin use, (ix) any other current medical conditions and (iv) self-reported 
tobacco and alcohol use in the prior six months. Details regarding medications used for PD were used 




2.5.3 The Mini International Neuropsychiatric Interview (MINI) (Sheehan et al., 1998) 
The MINI is a short structured diagnostic interview used to diagnose psychiatric disorders based on 
DSM-IV and International Classification of Diseases (ICD-10) criteria. The MINI version 6.0 was used 
to determine the presence of any current and lifetime psychiatric disorders.  
2.5.4 The Unified Parkinson’s Disease Rating Scale (UPDRS) (Fahn, Elton, & UPDRS program 
members, 1987) 
Parkinson’s disease severity was assessed with the UPDRS with patients in the ON-phase. We report 
scores for the three subscales (I – Mentation, behaviour and mood, range 1-16; II Activities of Daily 
Living, range 0 – 52; III – Motor examination, range 0 – 108) and total scores (range 1 – 176). Disease 
stage was determined with the modified Hoehn and Yahr (H&Y) scale (Goetz et al., 2004). The H&Y 
includes seven stages, with stages 1.0 - 3.0 reflecting mild to moderate disability and 4.0 - 5.0 severe 
disability.  
2.5.5 The Non-motor Symptoms Scale (NMSS) (Chaudhuri et al., 2007) 
Non-motor symptoms (NMS) of PD were assessed with the NMSS (Chaudhuri et al., 2007). The 30 
items on the NMSS are scored by multiplying severity (0 - 3) and frequency (1 - 4), with total scores 
ranging between 0 – 360. The NMSS assesses for NMS in nine domains: cardiovascular (range 0-12), 
sleep/fatigue (range 0-24), mood/cognition (range 0-72), perceptual problems (range 0-18), 
attention/memory (range 0-18), gastrointestinal tract (range 0-18), urinary (range 0-18), sexual function 
(range 0-12), and miscellaneous (range 0-14). Cronbach’s α in the PD cohort for the full scale was 0.91 
and for the subscales ranged between 0.66 – 0.92. 
2.5.6 The Perceived Stress Scale (PSS) (Cohen, Kamarck, & Mermelstein, 1983) 
We used the 10-item PSS (PSS-10) to measure self-perceived stress. Individuals rate to what extent 
they found their lives unpredictable, uncontrollable or overloaded in the prior month. Each item is rated 
on a 5-point Likert scale (0 = Never; 1 = Almost Never; 2 = Sometimes; 3 = Fairly often; 4 = Very often) 
with a total score ranging from 0 – 40, and higher scores indicate higher perceived stress. The PSS 
has been widely used and has demonstrated adequate psychometric properties in multiple settings 




2.5.7 The WHO STEPwise approach to chronic disease risk factor surveillance (WHO 
STEPS) (World Health Organization, 2005) 
The level of physical activity was determined with the global physical activity questionnaire (GPAQ) in 
the WHO STEPS. The GPAQ assesses average physical activity in a week occurring across three 
domains, namely work, travel and recreation. Level of physical activity (high, moderate, and low) was 
determined according to the GPAQ guidelines (World Health Organization, 2005).  
2.5.8 Hair questionnaire 
Participants who provided hair samples were questioned about their hair characteristics and hair care 
practices. Hair related variables reported in this manuscript include (i) whether natural hair colour is 
black, (ii) whether hair had been chemically treated in the prior three months (including colouring, 
relaxing and perming), (iii) the frequency of hair washing (two or more times a week, once a week, less 
frequent than once a week), (iv) whether any additional hair products had been used in the prior three 
months (such as hair styling and care products e.g. gels, oils and creams),  and (v) average hours per 
day that hair was exposed to sunlight (less than one hour, 1-2 hours, more than 2 hours). Additional 
hair related factors included the season sampled (based on the month the sample was obtained in), 
the duration of storage before sending the samples for analysis (less than 1 year, 1-2 years, 2-3.5 
years) and the batch analysed (pilot, final). 
2.6 Statistical analysis 
Sample size estimations for the neuroendocrine study were based on hairF studies in PTSD and MetS 
samples (Stalder et al., 2013; Steudte et al., 2012) as no hairF studies had been done in PD. Overall 
sample size was also limited by recruitment of the parent study as well as by factors influencing hair 
sampling, such as short hair length. HairE levels were normally distributed whereas HairF levels were 
positively skewed (Clark, Osborne, Gallagher, & Watson, 2016; Miller & Plessow, 2013). Utilising the 
box-cox family of power transformations (Osborne, 2010) hairF levels were reciprocal square root 
transformed to meet the assumption of normality. There were no outliers (3SD), though we excluded 




We compared the PD patients and controls with Pearson chi-square for categorical variables, and 
independent sample t-tests for continuous variables. There were only two missing responses on the 
item ‘average hours in sun’ and these were excluded from analysis listwise (missing items and final 
sample numbers reported in tables). To determine whether hair GC levels were associated with PD 
patient status, PD disease features and perceived stress we conducted linear regression models with 
hair GC levels as the dependent variable. Covariates included in the models were age, batch analysed 
and factors that remained significantly associated with HairF (duration of sun exposure) and HairE 
(employment status and chemical treatment of hair) after controlling for age and PD diagnosis. To 
assess interaction effects between MetS and PD we first regressed MetS on hair GC levels in simple 
linear regression models, and then in models controlled for covariates alongside PD diagnosis. In 
exploratory analysis we also examined for associations between the individual CVD risk variables and 
HCC as well as for interactions with PD diagnosis. Limited sensitivity and post-hoc analyses were 
conducted to allow for additional interpretation of the data. Data were analysed with SPSS for windows, 
version 25.0, all tests were 2-tailed and the level of significance was set at .05. 
3 Results 
3.1 Participants 
Of the 176 PD cohort participants, hair samples were obtained in 66 (37.5%) participants, a further 10 
participants were excluded from analysis, leaving a final sample of 56 participants; 25 PD patients and 
31 controls (see Figure 1 for details). Hair length shorter than 3cm was the main factor (82.7%) limiting 
sampling. Our analysis was limited to females as hair samples were only obtained in one (1.1%) male 
participant, a PD patient excluded due to antipsychotic use. The following factors differed significantly 
between included and excluded samples: Gender (p < 0.001), level of physical activity (p = 0.028), 
HLOE (p = 0.045), HDL-C (p < 0.001), BMI (p = 0.017), HC (p < 0.001), WHR (p < 0.001), TC (p = 
0.010), TC within range (p = 0.011), HbA1c (p = 0.040), and current psychiatric medication use (p = 
0.030). When we controlled for gender the only factor that remained significantly different between 




Descriptive data of the sample are presented in Table 1. Factors that were significantly different 
between the patients and controls included age, hair chemically treated, hair product use, duration of 
storage, and tobacco use. Clinical factors in PD patients are described in Table 2. 
Table 1 Comparison of sociodemographic, hair related, behavioural, and clinical 
characteristics between PD patients and controls  
 
Variables Patients Controls Test statistic p-value 
Total 25 31   
Socio-demographic     
 Age M(SD) 64.5 (8.4) 55.7 (6.9) t (54) = -4.35 <0.001* 
 Secondary education complete n(%)   χ²(1) = 0.10 0.623 
  No 22 (88.0) 27 (87.1)   
  Yes 3 (12.0) 4 (12.9)   
 Employed n(%)   χ²(1) = 3.90 0.052 
  No 24 (96.0) 24 (77.4)   
  Yes 1 (4.0) 7 (22.6)   
Hair related     
 Natural hair colour black n(%)   χ²(1) = 3.34 0.067 
  No 15 (60.0) 11 (35.5)   
  Yes 10 (40.0) 20 (64.5)   
 Hair chemically treated n(%)   χ²(1) = 9.81 0.002* 
  No 16 (64.0) 7 (22.6)   
  Yes 9 (36.0) 24 (77.4)   
 Frequency of hair washing n(%)   χ²(2) = 1.87 0.393 
  ≥ 2 times a week 7 (28.0) 5 (16.1)   
  1 time a week 12 (48.0) 14 (45.2)   
  < 1 time a week 6 (24.0) 12 (38.7)   
 Add on hair products n(%)   χ²(1) = 4.42 0.035* 
  No  19 (76.0) 15 (48.4)   
  Yes 6 (24.0) 16 (51.6)   
 Average hours in suna n(%)  2 χ²(2) = 3.17 0.205 
  < 1 hour 18 (72.0) 14 (48.3)   
  1-2 hours 5 (20.0) 10 (34.5)   
  > 2 hours 2 (8.0) 5 (17.2)   
 Season sampled n(%)   χ²(3) = 3.60 0.308 
  Summer 3 (12.0) 3 (9.7)   
  Autumn 11 (44.0) 9 (29.0)   
  Winter 7 (28.0) 7 (22.6)   
  Spring 4 (16.0) 12 (75.0)   
 Duration of storage n(%)   χ²(2) = 25.64 <0.001* 
  Less than 1 year 8 (32.0) 2 (6.5)   
  1 - 2 years 13 (52.0) 3 (9.7)   
  2 – 3.5 years 4 (16.0) 26 (83.9)   
 Batch analysed n(%)   χ²(1) = 2.32 0.132 
  Pilot 5 (20.0) 2 (6.5)   
  Final sample 20 (80.0) 29 (93.5)   
Clinical      
 Hormonal contraceptive n(%)   χ²(1) = 1.63 0.309 
  No 25 (100) 29 (93.5)   
  Yes 0 (0) 2 (6.5)   
 Topical steroid use n(%)   χ²(1) = 1.32 0.237 
  No 21 (84.0) 29 (93.5)   
  Yes 4 (16.0) 2 (6.5)   
 Other medical conditions n(%)   χ²(1) = 0.32 0.571 
  No 11 (44.0) 16 (51.6)   




Behavioural     
 Tobacco use n(%)   χ²(1) = 6.08 0.013* 
  No 22 (88.0) 18 (58.1)   
  Yes 3 (12.0) 13 (41.9)   
 Alcohol use n(%)   χ²(1) = 3.50 0.056 
  No 21 (84.0) 19 (61.3)   
  Yes 4 (16.0) 12 (38.7)   
 Level of physical activity n(%)   χ²(2) = 5.10 0.078 
  High 0 (0) 2 (6.1)   
  Moderate 3 (11.5) 10 (30.3)   
  Low 23 (88.5) 21 (63.6)   
Perceived stress     
 PSS total score M(SD) 15.2 (7.7) 12.3 (7.2) t (54) = -1.43 0.159 
Hair glucocorticoid levels     
 HairF Mdn(IQR) 4.5 (2.7; 7.9) 3.9 (2.4; 8.7) U=367; Z=-0.33 0.742 
 Transformed HairF M(SD) 1.14 (0.25) 1.11 (0.29) t (54) = -0.43 0.667 
 HairE M(SD) 11.33 (6.96) 6.25 (4.50) t (54) = -3.30 0.002* 
a Two missing responses on this item 
* p < 0.05 
HairE, hair cortisone levels; HairF, hair cortisol levels; PSS, perceived stress scale 
 
3.2 Parkinson’s disease and hair glucocorticoids 
HairF and hairE levels were significantly positively correlated with each other (r = 0.39, p = 0.003). 
HairF levels were not significantly different (Cohen’s d = 0.12) between PD patients and controls 
(Figure 2a; Table 3) in unadjusted (B = 0.03, 95% CI -0.12; 0.18, p = 0.667) and adjusted models (adj 
B = 0.04, 95% CI -0.13; 0.21, p = 0.646). HairE levels were significantly higher (Cohen’s d = 0.87) in 
PD patients than in controls (Figure 2b; Table 4) in unadjusted (B = 5.08, 95% CI 1.99; 8.17, p = 0.045) 
and adjusted models (adj B = 5.31, 95% CI 1.88; 8.74, p = 0.003).  
3.3 Parkinson’s disease clinical factors and hair glucocorticoids (Table 2) 
None of the PD clinical factors were significantly associated with HairF levels. NMSS domain 3 
(mood/cognition) and domain 8 (sexual function) scores were significantly positively associated with 
HairE levels. When we controlled for covariates (age, employment status and chemical treatment of 
hair) domain 8 scores (adj B = 0.59, 95% CI -4.72; 7.37, p = 0.650) were no longer significantly 
associated, but domain 3 scores (adj B = 0.26, 95% CI 0.06; 0.46, p = 0.013) remained significantly 





Table 2 Association between clinical variables and hair glucocorticoid levels in PD patients (n = 25) 
 
Variables Descriptive statistics HairF HairE 
 M (SD) ß (95% CI) ß (95% CI) 
Current CMDa n(%)    
 No 16 (64.0) Ref Ref 
 Yes 9 (36.0) -0.08 (-0.30; 0.13) 0.75 (-5.37; 6.87) 
Current psychiatric medicationb n(%)    
 No 14 (56.0) Ref Ref 
 Yes 11 (44.0) 0.08 (-0.13; 0.29) -1.46 (-7.35; 4.44) 
Duration of PD (months) 65.8 (44.4) -0.00 (-0.00; 0.00) -0.02 (-0.09; 0.04) 
LEDc 600.6 (426.5) 0.00 (0.00; 0.00) 0.004 (-0.00; 0.01) 
UPDRS total score  54.5 (19.3) -0.00 (-0.01; 0.00) 0.06 (-0.08; 0.20) 
 UPDRS I 3.9 (2.1) 0.02 (-0.03; 0.07) 0.53 (-0.73; 1.80) 
 UPDRS II  13.1 (6.2) -0.00 (-0.02; 0.02) 0.10 (-0.34; 0.54) 
 UPDRS III 37.5 (13.2) -0.00 (-0.01; 0.01) 0.09 (-0.11; 0.30) 
H&Y disability 2.9 (0.9) 0.02 (-0.11; 0.14) 0.84 (-2.35; 4.02) 
NMSS total score 53.0 (37.6) 0.00 (-0.00; 0.00) 0.05 (-0.02; 0.12) 
 Cardiovascular (range 0-12) 4.2 (5.9) 0.00 (-0.02; 0.02) -0.01 (-0.48; 0.46) 
 Sleep/fatigue (range 0-24) 10.8 (7.7) -0.00 (-0.02; 0.01) 0.07 (-0.33; 0.46) 
 Mood/cognition (range 0-72) 7.6 (10.9) 0.01 (-0.01; 0.02) 0.30 (0.08; 0.52)* 
 Perceptual problems (range 0-18) 0.9 (2.2) -0.03 (-0.08; 0.03) 0.37 (-1.08; 1.82) 
 Attention/memory (range 0-18) 5.3 (6.6) -0.01 (-0.02; 0.01) -0.23 (-0.64; 0.17) 
 Gastrointestinal tract (range 0-18)  5.2 (6.5) 0.00 (-0.01; 0.02) 0.14 (-0.28; 0.56) 
 Urinary (range 0-18) 9.4 (10.5) 0.00 (-0.01; 0.01) 0.18 (-0.12; 0.48) 
 Sexual function (range 0-12) 1.2 (2.9) 0.02 (-0.02; 0.05) 0.90 (0.05; 1.75)* 
 Miscellaneous (range 0-14) 8.4 (7.6) 0.00 (-0.01; 0.02) 0.16 (-0.20; 0.52) 
a One (4.0%) with comorbid major depressive disorder (MDD) and 8 (32.0%) with a comorbid anxiety disorder; 3 (12.0%) with agoraphobia, 2 (8.0%) with 
generalised anxiety disorder (GAD) and 5 (20.0%) with social anxiety disorder (related to PD symptoms).  
bFive (20.0%) were on benzodiazepines (BZD), 6 (24.0%) were on therapeutic antidepressants and 4 (16.0%) on low dose low dose amitriptyline.  
cTwenty-three (92.0%) of the PD patients were on levodopa, 7 (28.0%) were on dopamine agonists, 12 (48.0%) were taking other medications for PD, 
including amantadine (n = 2, 8.0%), anticholinergics (n = 10, 40.0%), and beta-blockers (n = 1, 4.0%).    
* p < 0.05 
CMD, common mental disorder; HairE, hair cortisone levels; HairF, hair cortisol levels; H&Y, Hoehn and Yahr scale; LED, levodopa equivalent daily doses; 







Table 3 Parkinson’s disease and metabolic syndrome regressed on hair cortisol levels (hairF) 
 
  Simple linear regression Multiple linear regressiona 
    Model 1 Model 2 Model 3 
  ß (95% CI) p-value ß (95% CI) p-value ß (95% CI) p-value ß (95% CI) p-value 
Case status        0.629 
 Control Ref  Ref  Ref  Ref  
 Patient 0.03 (-0.12; 0.18) 0.667 0.04 (-0.13; 0.21) 0.646 0.04 (-0.13; 0.21) 0.658 0.00 (-0.24; 0.24) 0.996 
MetS        0.946 
 No Ref    Ref  Ref  
 Yes 0.06 (-0.09; 0.21) 0.418   0.00 (-0.16; 0.16) 0.992 -0.05 (-0.31; 0.21) 0.710 
Patient*MetS       0.09 (-0.27; 0.44) 0.630 
a Multivariate adjusted model (adjusted for age, batch analysed and duration of sun exposure); n = 54; two participants with missing data for ‘average hours 
in sun’ excluded 
Model 1 – Model without MetS: F (5, 48) = 2.55 (p = 0.040*), Adj R² = 0.127; n = 54 
Model 2 – MetS added: F (6, 47) = 2.08 (p = 0.074), Adj R² = 0.109; n = 54 
Model 3 – Interaction between case status and MetS added: F (7, 47) = 1.79 (p = 0.113), Adj R² = 0.094; n = 54 
* p < 0.05 
MetS, metabolic syndrome 
 
Table 4 Parkinson’s disease and metabolic syndrome regressed on hair cortisone levels (hairE) 
 
  Simple linear regression Multiple linear regressiona 
    Model 1 Model 2 Model 3 
  ß (95% CI) p-value ß (95% CI) p-value ß (95% CI) p-value ß (95% CI) p-value 
Case status        0.010* 
 Control Ref  Ref  Ref  Ref  
 Patient 5.08 (1.99; 8.17) 0.045* 5.31 (1.88; 8.74) 0.003* 5.12 (1.60; 8.64) 0.005* 6.72 (2.36; 11.07) 0.003* 
MetS        0.464 
 No Ref    Ref  Ref  
 Yes 2.96 (-0.39; 6.31) 0.082   0.87 (-2.25; 3.98) 0.579 2.78 (-1.61; 7.17) 0.210 
Patient*MetS       -3.98 (-10.46; 2.50) 0.223 
a Multivariate adjusted model (adjusted for age, employment status and chemical treatment of hair), n = 56 
Model 1 – Model without MetS: F (5, 50) = 6.41 (p < 0.001*), Adj R² = 0.294; n = 56  
Model 2 – MetS added: F (6, 49) = 4.64 (p = 0.001*), Adj R² = 0.284; n = 56 
Model 3 – Interaction between case status and MetS added: F (7, 48) = 4.24 (p = 0.001*), Adj R² = 0.292; n = 56 
* p < 0.05 




3.4 Self-perceived stress, Parkinson’s disease and hair glucocorticoids 
In analyses controlling for age, PSS scores were significantly higher in PD patients than in controls (OR 
= 1.14; 95% CI 1.03; 1.27, p = 0.015), although this effect was not evident in unadjusted analyses (p = 
0.159). Concerning hair GCs, in unadjusted analyses PSS scores were not significantly associated 
with hairF (B = -0.00, 95% CI -0.01; 0.01, p = 0.547), and were significantly positively associated with 
hairE (B = 0.23, 95% CI 0.01; 0.45, p = 0.038). When we controlled for covariates PSS scores were not 
significantly associated with hairF (adj B = -0.01, 95% CI -0.02; 0.00, p = 0.259) nor hairE (B = 0.10, 
95% CI -0.12; 0.32, p = 0.385). There were no significant interaction effects between PD diagnosis and 
PSS scores. 
Figure 2a Hair cortisol (hairF) levels according to PD patient status 
 
Bar chart demonstrating mean hairF according to PD patient status. HairF levels were not significantly 
higher in PD patients than controls (p = 0.667) 
*p < 0.05 










Figure 2b Hair cortisone (hairE) levels according to PD patient status 
 
Bar chart demonstrating mean HairE levels according to PD patient status. HairE levels were 
significantly higher in PD patients than controls (p = 0.002) 
*p < 0.05 
Error bars ± 2SE 
 
3.5 Cardiovascular disease risk factors, Parkinson’s disease and hair glucocorticoids  
3.5.1 Metabolic syndrome, Parkinson’s disease and hair glucocorticoids 
Rates of MetS were significantly higher (p = 0.021) in PD patients (56.0%) than in controls (25.8%), but 
when we controlled for age there was only a trend towards significance (p = 0.077). MetS was not 
significantly associated with hairF in unadjusted (B = 0.06, 95% CI -0.09; 0.21, p = 0.418) and adjusted 
(adj B = 0.00, 95% CI -0.16; 0.16, p = 0.992) models and there were no significant interactions between 
PD and MetS (Figure 3a; Table 3). HairE levels were higher in those with MetS than in those without, 
showing a trend towards significance in unadjusted (B = 2.96, 95% CI -0.39; 6.31, p = 0.082) analysis, 
but were non-significant in adjusted (adj B = 0.87, 95% CI -2.25; 3.98, p = 0.579) analysis and there 
was no interaction between PD diagnosis and MetS. HairF levels remained significantly higher in 
patients without MetS than controls without MetS and there were no significant interactions between 




3.5.2 Individual cardiovascular disease risk factors, Parkinson’s disease and hair 
glucocorticoids (Supplementary table 1) 
CVD risk factors that differed significantly between patients and controls included the number of MetS 
criteria (p = 0.041), BP MetS criterion (p = 0.013), FPG MetS criterion (p = 0.038), and antihypertensive 
medication (p < 0.001), statin (p < 0.001) and aspirin use (p = 0.005). When we controlled for age, BP 
MetS criterion (p = 0.040), antihypertensive medication (p = 0.001), and aspirin use (p = 0.044) 
remained significantly different. None of the individual CVD risk factors were significantly associated 
with HairF in unadjusted or adjusted analyses. The CVD risk factors that were significantly associated 
with HairE in unadjusted analyses were the number of MetS criteria (B = 1.43, 95% CI 0.04; 2.82, p = 
0.045), antihypertensive medication use (B = 3.50, 95% CI 0.24; 6.77, p = 0.036), WHR (B = 26.74, 
95% CI 7.52; 45.95, p = 0.007), known CVD (B = 7.86, 95% CI 0.70; 15.02, p = 0.032), and aspirin use 
(B = 4.77, 95% CI 1.11; 8,43, p = 0.012) and there was a trend toward significance demonstrated for 
HDL-C (B = -3.06, 95% CI -6.67; 0.55, p = 0.095). When we controlled for covariates WHR remained 
significant (adj B = 21.64, 95% CI 4.04; 39.24, p = 0.017) and HDL-C still showed a trend towards 
significance (adj B = -2.80, 95% CI -6.09; 0.50, p = 0.095). There were no significant interactions 






Figure 3a Hair cortisol (hairF) levels according to PD patient status and metabolic syndrome 
status 
 
Bar chart demonstrating mean hairF levels according to PD patient status and metabolic syndrome 
status (MetS). The model was not significant (F(52, 3) = 0.24, p = 0.871) and there were  no significant 
differences between the groups based on Tukey HSD post hoc test. 
*p < 0.05 










Figure 3b Hair cortisone (hairE) levels according to PD patient status and metabolic syndrome 
status 
 
Bar chart demonstrating mean HairE levels according to PD patient status and metabolic syndrome 
status (MetS). The model was significant (F(52, 3) = 3.82, p = 0.015) and HairE were highest in PD 
patients with MetS, and were significantly higher than controls without MetS (p = 0.015). There were no 
other significant differences between the groups based on Tukey HSD post hoc test. 
*p < 0.05 
Error bars ± 2SE 
 
4 Discussion 
In a sample of South African mixed ancestry females we demonstrated significantly higher hairE, but 
not hairF levels, in PD patients than in controls. Furthermore increased severity of NMS of PD related 
to depression, anhedonia and anxiety were significantly positively associated with hairE levels. We did 
not demonstrate a significant association between hairF or hairE levels and MetS, nor with PD-MetS 
comorbidity. None of the individual CVD risk variables were associated with hairF levels, whereas one 
of the more robust predictors of CVD risk, WHR, was positively associated with hairE levels.  
HairE, but not hairF levels, were significantly higher in PD patients than in controls. However, similar to 
other studies, hairF and hairE levels were significantly positively correlated (Kuehl et al., 2015; Savas et 
al., 2019; Stalder et al., 2013). Generally studies demonstrate higher cortisol levels in PD patients than 




studies in PD have used an immunoassay measurement which is associated with increased cross-
reactivity with cortisone (Perogamvros et al., 2010). Furthermore, most studies have measured total 
cortisol in blood and not free cortisol, which is considered to be the biologically active form of cortisol 
(Perogamvros et al., 2010). Cortisone in different tissues may provide a better reflection of free cortisol, 
as for instance, salivary cortisone demonstrated the strongest correlation with free serum cortisol in one 
study, stronger than total serum cortisol and salivary cortisol (Perogamvros et al., 2010). HairE also 
appears to hold certain benefits to HairF. For instance, one study found diagnostic accuracy for 
Cushing’s syndrome was significantly better for HairE than HairF (Savas et al., 2019). HairF may also 
be influenced by additional factors, as evidenced by greater variability, with higher outlying values found 
with hairF than hairE (Stalder et al., 2013; Staufenbiel et al., 2015). Other studies have also found 
stronger associations with hairE than hairF and variables studied, including stress related variables 
(Davison, Singh, & McFarlane, 2019; Stalder et al., 2013), and may explain, in part, why significant 
associations were demonstrated for hairE and not hairF. Furthermore, PD patients in our sample were 
on treatment and studies have demonstrated that cortisol levels are higher in untreated PD patients, 
and conversely, that cortisol levels decrease in PD patients on treatment with dopaminergic drugs 
(Müller & Muhlack, 2007; Müller, Welnic, & Muhlack, 2007; Stypuła, Kunert-Radek, Stępień, Żylińska, 
& Pawlikowski, 1996) and in PD patients receiving sub thalamic nucleus deep brain stimulation (STN 
DBS) (Nováková et al., 2011; Růžička et al., 2015; Seifried et al., 2013). Thus in our study, treatment 
may have contributed to the non-significant results demonstrated for hairF. We, however, did not find a 
directly proportional association between LED and hairF or hairE levels. 
A measure of self-perceived stress was included to assess whether altered hair GC levels could partly 
be explained by increased stress experienced by PD patients. When we controlled for age, PD patients 
were found to have higher perceived stress scores than controls. Perceived stress was also 
significantly positively associated with hairE, but not hairF. When controlled for covariates this 
association was no longer significant and is likely explained by higher hairE levels in PD patients than in 
controls. Perceived stress has not been extensively studied in PD and there is limited evidence that 




that stress increases severity of parkinsonistic symptoms (Du & Pang, 2015).  Although not significant, 
our results suggest that PD patients experience higher levels of stress that may play a role in GC 
dysregulation. Additionally, the NMS of PD involving mood, anxiety and anhedonia were significantly 
positively associated with hairE, suggesting a dysregulated HPA-axis in PD patients may be related to 
NMS of PD. One study that demonstrated significantly higher salivary cortisol levels in PD patients than 
in controls also found that cortisol levels were significantly correlated with anxiety and depression 
severity and another found that reductions in cortisol levels were correlated with improvements in 
depression scores following STN DBS (Medeiros Costa et al., 2019; Seifried et al., 2013). Cell loss in 
PD extends beyond the substantia nigra and include the locus ceruleus, dorsal raphe nuclei, nucleus 
basalis of Meynert and postganglionic sympathetic neurons (Levy et al., 2009). HPA-axis dysfunction in 
PD may also be related to these other systems as reduced serotonergic and opioid induced cortisol 
release have been demonstrated in male PD patients (Volpi et al., 1997, 1994). 
Motor symptoms of PD and disease stage were not associated with hair GC levels. Other studies have 
similarly demonstrated no association between cortisol levels and motor symptoms or H&Y stage 
(Charlett et al., 2009; Djamshidian et al., 2011). Although findings have been mixed, with one study 
demonstrating positive correlations between cortisol and UPDRS scores (Håglin & Bäckman, 2016), 
whilst another finding an inverse association between UPDRS scores and overall cortisol release 
following levodopa intake (Müller & Muhlack, 2007). 
MetS was not significantly associated with hairF or hairE, with only a trend toward significance 
demonstrated for higher hairE levels in MetS in unadjusted analysis. There were also no significant 
interactions between PD and MetS. The small sample size of this study is a limitation considering that 
other studies in larger samples have demonstrated significantly higher hairF and hairE levels in 
individuals with MetS (Kuehl et al., 2015; Stalder et al., 2013). The lack of a significant finding may also 
be ascribed to the fact that the individual MetS factors demonstrated different directions of association 
with GCs, suggesting the association between hair GCs and MetS may be more complex. None of the 
individual CVD risk factors were associated with hairF, whereas WHR was significantly positively 




significance. These associations between hairE and WHR and HDL-C have also been demonstrated 
in one other study utilising hairE (Stalder et al., 2013), although HDL-C was not associated with hairE in 
another study (Wester et al., 2017). The direction of association between hair GCs and HDL-C and 
WHR are consistent with what has generally been observed for studies evaluating cortisol (Fraser et 
al., 1999; Stalder et al., 2013, 2017). Similar to our study other studies have also found that HairE 
demonstrated stronger associations with CVD risk markers than HairF (Stalder et al., 2013), further 
supporting the utility of including hairE as a measurement of HPA-axis function. 
4.1 Strengths and limitations 
As far as we are aware, this is the first study to examine hair GC levels in PD. Hair analyses were 
conducted with LC-MS/MS which is the gold standard method for hair GC determination (Russell et al., 
2015), whereas most studies examining basal cortisol levels in PD have used immunoassays. 
However, our sample may have been underpowered to detect significant associations, particularly 
between hair GC levels and MetS. Our sample size was greatly reduced due to the requirement that 
hair length be 3cm or longer and this resulted in the exclusion of almost all male participants. 
Restriction to a single ethnicity and sex limits the generalisability of our results. HPA axis function can 
differ according to sex with different patterns of association demonstrated. For instance, one study 
found that women, and in particular, obese women, had a higher cortisol to cortisone conversion rate 
than men (Vierhapper, Heinze, & Nowotny, 2007). It has also been shown that hairE, but not hairF, 
levels were significantly higher in Australian indigenous women than in non-indigenous women and the 
reverse was demonstrated for men (Davison et al., 2019). Due to the cross-sectional nature, cause-
effect relationships cannot be inferred. As this was an exploratory study of hair GC in PD we did not 
control for multiple comparisons. We included PD patients with CMD comorbidity, which may have 
influenced our results, however CMD comorbidity and psychiatric medication use was not associated 
with hair GC levels. 
4.2 Conclusions 
This study adds to the evidence of a dysregulated HPA-axis in PD. Though hair cortisol levels were not 




other studies, found that hair cortisone levels demonstrate stronger associations and show less 
variability than hair cortisol levels, and hair cortisone levels thus exhibit utility as an additional marker of 
HPA-axis function. Non-motor symptoms of PD related to mood and anxiety were also positively 
associated with hair cortisone levels, suggesting a role for HPA-axis dysregulation in the NMS of PD. 
Hair GC levels were not significantly associated with MetS, although hair cortisone was associated with 
WHR. Future studies, in larger samples, and representing both genders, will assist with delineating the 
role of stress and of longer-term HPA-axis dysfunction in PD patients and in the comorbidity of PD and 
MetS. As inflammatory pathways also play a role in PD and CVD and are linked to HPA-axis function, 
including markers of inflammation alongside HPA-axis function may provide additional insights into the 




5 Supplementary materials 
Supplementary Table 1 Cardiovascular disease risk factors in relation to PD patient status and hair glucocorticoid levels  
 
 CVD risk variables according to PD groups Hair F Hair E 
 PD Patients Controls ß (95% CI) ß (95% CI) 
Total 25 31   
MetS variables     
 MetS n(%)     
  No 11 (44.0) 23 (74.2) Ref Ref 
  Yes 14 (56.0) 8 (25.8) 0.06 (-0.09; 0.21) 2.96 (-0.39; 6.31) 
 Number of criteria met M(SD) 2.5 (1.2) 1.8 (1.1) 0.01 (-0.05; 0.08) 1.43 (0.04; 2.82)* 
 BP criterion n(%)     
  No 4 (16.0) 15 (48.4) Ref  
  Yes 21 (84.0) 16 (51.6) -0.09 (-0.25; 0.06) 1.26 (-2.28; 4.80) 
  On antihypertensive rx n(%)     
   No 7 (28.0) 25 (80.6) Ref Ref 
   Yes 18 (72.0) 6 (19.4) 0.03 (-0.12; 0.18) 3.50 (0.24; 6.77)* 
  SBP (mmHg) M(SD) 133.0 (25.6) 128.6 (20.5) 0.00 (-0.00; 0.00) 0.00 (-0.07; 0.08_ 
  DBP (mmHg) M(SD) 77.1 (13.9) 80.5 (14.9) 0.00 (-0.00; 0.01) 0.01 (-0.11; 0.13) 
  BP over threshold n(%)     
   No 12 (48.0) 16 (51.6) Ref Ref 
   Yes 13 (52.0) 15 (48.4) -0.09 (-0.24; 0.05) -0.63 (-3.99; 2.73) 
 FPG criterion n(%)     
  No 10 (40.0) 21 (67.7) Ref Ref 
  Yes 15 (60.0) 10 (32.3) 0.05 (-0.10; 0.20) 2.60 (-0.71; 5.91) 
  On diabetes rx n(%)     
   No 18 (72.0) 29 (93.5) Ref Ref 
   Yes 7 (28.0) 2 (6.5) 0.06 (-0.14; 0.26) 2.92 (-1.59; 7.43) 
  FPG (mmol/l) M(SD) 6.10 (1.79) 6.03 (2.76) 0.00 (-0.03; 0.04) 0.09 (-0.63; 0.81) 
  FPG ≥ 5.6 mmol/l n(%)     
   No 11 (44.0) 21 (67.7) Ref Ref 
   Yes 14 (56.0) 10 (32.3) 0.04 (-0.10; 0.19) 2.36 (-0.98; 5.69) 
 HDL-C criteriona n(%)     
  No 18 (72.0) 23 (74.2) Ref Ref 
  Yes 7 (28.0) 8 (25.8) 0.02 (-0.15; 0.19) 3.05 (-0.66; 6.76) 
  HDL-C (mmol/l) M(SD) 1.69 (0.53) 1.51 (0.39) -0.06 (-0.22; -0.10) -3.06 (-6.67; 0.55) 
 Trig criterionb n(%)     
  No 21 (84.0) 25 (80.6) Ref Ref 




  Trig (mmol/l) M(SD) 1.17 (0.45) 1.25 (0.41) -0.09 (-0.27; 0.08) 1.06 (-2.94; 5.07) 
 WC criterion n(%)     
  No 10 (40.0) 14 (45.2) Ref Ref 
  Yes 15 (60.0) 17 (54.8) 0.11 (-0.04; 0.25) 1.83 (-1.54; 5.19) 
  WC (cm) M(SD) 89.7 (13.1) 94.1 (13.9) -0.00 (-0.01; 0.01) 0.04 (-0.08; 0.17) 
Other CVD risk variables     
 Physical parameters     
  BMI (kg/m2) M(SD) 28.5 (5.0) 30.3 (6.5) -0.00 (-0.01; 0.01) -0.02 (-0.31; 0.27) 
  HC (cm) M(SD) 104.9 (10.8) 110.0 (13.2) -0.00 (-0.01; 0.01) -0.09 (-0.23; 0.05) 
  WHR M(SD) 0.85 (0.09) 0.86 (0.08) 0.02 (-0.88; 0.92) 26.74 (7.52; 45.95)* 
  HR (bpm) M(SD) 77.3 (12.5) 75.0 (8.9) 0.00 (-0.00; 0.01) 0.12 (-0.03; 0.28) 
 Laboratory parameters     
  TC (mmol/l) M(SD) 5.37 (1.03) 5.43 (1.03) -0.05 (-0.12; 0.02) -0.92 (-2.56; 0.72) 
  TC > 5 mmol/l n(%)     
   No 15 (60.0) 21 (67.7) Ref Ref 
   Yes 10 (40.0) 10 (32.3) 0.12 (-0.03; 0.27) 1.79 (-1.69; 5.26) 
  LDL-C (mmol/l) M(SD) 3.14 (0.96) 3.35 (1.03) -0.03 (-0.11; 0.04) -0.41 (-2.12; 1.29) 
  LDL-C >= 3 mmol/l n(%)     
   No 17 (68.0) 19 (61.3) Ref Ref 
   Yes 8 (32.0) 12 (38.7) -0.00 (-0.17; 0.14) -0.78 (-4.29; 2.73) 
  HbA1c 6.15 (1.12) 6.22 (1.35) -0.01 (-0.07; 0.05) -0.26 (-1.63; 1.11) 
  HbA1c >= 6.5% n(%)     
   No 18 (72.0) 25 (80.6) Ref Ref 
   Yes 7 (28.0) 6 (19.4) 0.01 (-0.16; 0.19) 0.66 (-3.32; 4.64) 
 CVD clinical variables     
  Known CVD n(%)     
   No 22 (88.0) 31 (100) Ref Ref 
   Yes 3 (12.0) 0 (0) 0.12 (-0.20; 0.45) 7.86 (0.70; 15.02)* 
  On statins n(%)     
   No 13 (52.0) 31 (100) Ref Ref 
   Yes 12 (48.0) 0 (0) -0.08 (-0.25; 0.10) 1.51 (-2.57; 5.59) 
  On aspirin n(%)     
   No 14 (56.0) 28 (90.3) Ref Ref 
   Yes 11 (44.0) 3 (9.7) 0.06 (-0.11; 0.23) 4.77 (1.11; 8.43)* 
a No participants were receiving treatment to increase HDL-C 
b No participants were receiving treatment for hypertriglyceridemia  
* p < 0.05 
BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; DBP, diastolic blood pressure; HbA1c, Glycated haemoglobin; HC, hip circumference; HDL-C, 
high-density lipoprotein cholesterol; HR, heart rate; FPG, fasting plasma glucose; LDL-C, Low density lipoprotein cholesterol; MetS, metabolic syndrome; Ref, reference 
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Hair cortisol levels in schizophrenia and metabolic syndrome  
Abstract 
Background: Individuals with schizophrenia demonstrate higher rates of metabolic syndrome (MetS) 
and cardiovascular disease (CVD) than the general population. Hypothalamic pituitary adrenal (HPA) 
axis dysfunction has been demonstrated in relation to both schizophrenia and MetS and may be 
aetiologically linked to CVD risk in schizophrenia. Few studies have, however, directly investigated 
these links. Hair cortisol concentrations (HCC) reflect longer-term HPA axis function and can provide 
additional insights into the role of the HPA-axis in schizophrenia and co-occurring CVD risk.    
Objectives: In a case-control study of 16 patients with schizophrenia (11 first episode psychosis [FEP] 
and 5 chronic) and 21 controls aged between 23 and 32 years (M = 28.0, SD = 6.5) we investigated 
whether HCC were associated with schizophrenia diagnostic status, clinical features and with CVD risk 
in schizophrenia (as defined by MetS co-occurrence). As a secondary aim we also assessed the 
longitudinal trajectory of HCC in FEP patients.  
Methods: Hair samples, representing a three-month retrospective window of cortisol, were collected 
and analysed utilizing liquid chromatography tandem mass spectrometry. Multivariate regression 
models were constructed with schizophrenia diagnostic status, clinical features and MetS comorbidity 
regressed on HCC, adjusting for potential confounders. A mixed models analysis was conducted to 
assess whether HCC changed between baseline and month-12 in FEP patients as compared to 
controls and in relation to MetS.  
Results: At baseline the prevalence of MetS was 25.0% in patients with schizophrenia and 9.5% in 
controls. At 12 months, 3 of 5 FEP patients and 3 of the 6 controls, for whom HCC were available, had 
MetS. At baseline HCC were significantly lower (Cohen’s d = 0.88) in patients with schizophrenia than 
in controls (adj B = -0.27, 95% CI -0.48; -0.06, p = 0.014) and when limited to FEP patients remained 
significantly lower (Cohen’s d = 0.97) in FEP patients than in controls (adj B = -0.28, 95% CI -0.53; -




0.73, p = 0.097) for increased HCC from baseline to month-12 in FEP patients. Domains of symptom 
severity in schizophrenia were not associated with HCC, but better patient insight (adj B = -0.07, 95% 
CI -0.13; -0.01, p = 0.037) was inversely associated with HCC. MetS was not associated with HCC at 
baseline, but HCC increased significantly from baseline to month-12 in those with MetS (adj B = 0.47, 
95% CI 0.04; 0.90, p = 0.037) and MetS was positively associated with HCC at month-12 follow-up (adj 
B = 0.41, 95% CI 0.02; 0.80, p = 0.041).  There were no significant interactions between schizophrenia 
diagnosis and MetS on HCC.  
Conclusions: Contrary to the majority of the literature we demonstrated lower HCC in schizophrenia 
patients, and in particular in FEP patients, than controls. In a subgroup of schizophrenia patients acute 
psychosis may be associated with a blunted HPA-axis with lower total cortisol output. MetS was 
associated with an increase in HCC and higher HCC at month-12 and elevated cortisol levels found in 
schizophrenia studies may be related to increased rates of MetS in schizophrenia patients.  














Schizophrenia is a severe and disabling mental disorder (Laursen, Nordentoft, & Mortensen, 2014). 
Individuals with schizophrenia have a shorter life-span and higher mortality rates than the general 
population (Hjorthøj, Stürup, McGrath, & Nordentoft, 2017; Laursen et al., 2014; Piotrowski et al., 
2017). Although unnatural causes, such as suicide, contribute to the increased mortality risk, natural 
causes, and in particular cardiovascular disease (CVD), are the leading causes of mortality in patients 
with schizophrenia (Penninx & Lange, 2018; Piotrowski et al., 2017).  
Meta-analyses have demonstrated that individuals with schizophrenia have increased rates of CVD, 
with a pooled prevalence of 11.8% (Correll et al., 2017). Furthermore, patients with schizophrenia have 
significantly higher rates of individual CVD risk factors, including abdominal obesity (OR = 4.4), low 
high-density lipoprotein cholesterol (HDL-C. OR = 2.4), hypertriglyceridemia (OR = 2.7), diabetes (OR 
– 2.0) and hypertension (OR = 1.4) (Vancampfort et al., 2013). Individuals with schizophrenia also have 
higher rates of the metabolic syndrome (MetS, OR = 2.4), with an overall prevalence of 32.5% in 
schizophrenia and 13.0% in first episode psychosis (FEP) (Mitchell et al., 2013; Vancampfort et al., 
2013). MetS denotes a cluster of risk factors for CVD and type 2 diabetes mellitus, including central 
obesity, hypertension, elevated fasting glucose, hypertriglyceridemia and low levels of HDL-C (Alberti 
et al., 2009). Although CVD risk is higher in medicated chronic schizophrenia patients there is evidence 
of increased CVD risk factors in FEP and drug free patients, as well as in at-risk groups, such as ultra-
high-risk groups and family members of patients with schizophrenia (Bradley & Dinan, 2010; Penninx & 
Lange, 2018; Petrikis et al., 2015; Spelman, Walsh, Sharifi, Collins, & Thakore, 2007). 
Various factors may contribute to increased CVD risk in patients with schizophrenia. Factors that have 
been associated with increased MetS risk in meta-analyses include antipsychotic medication use, 
duration of illness, age and body mass index (BMI) (Mitchell et al., 2013; Penninx & Lange, 2018; 
Vancampfort et al., 2015, 2013). Lifestyle factors, such as smoking, alcohol and substance use, 
physical inactivity and poor nutrition also play a role (Carney, Cotter, Bradshaw, Firth, & Yung, 2016; 
De Hert, Detraux, & Vancampfort, 2018; Penninx & Lange, 2018). Despite higher rates of CVD, 




(Laursen et al., 2014; Penninx & Lange, 2018; Walker, McGee, & Drus, 2015). The pathophysiology 
linking MetS and schizophrenia is not well understood, although there is evidence of shared pathways, 
including inflammation, mitochondrial dysfunction, oxidative stress, accelerated aging, epigenetic 
factors and shared genetic risk  (Laursen et al., 2014; Malan-Müller et al., 2016; Penninx & Lange, 
2018; Vancampfort et al., 2015).  
A dysfunctional hypothalamic pituitary adrenal (HPA) axis has also been postulated to play a role in 
CVD morbidity in schizophrenia (Bradley & Dinan, 2010; De Hert et al., 2018; Penninx & Lange, 2018). 
Systematic reviews and meta-analyses demonstrate that patients with schizophrenia exhibit a 
dysregulated HPA-axis, with higher basal cortisol levels, a blunted cortisol awakening response (CAR) 
and a blunted cortisol stress response (Berger et al., 2016; Borges, Gayer-Anderson, & Mondelli, 2013; 
Bradley & Dinan, 2010; Gajsak, Gelemanovic, Kuzman, & Puljak, 2017; Girshkin, Matheson, 
Shepherd, & Green, 2014; Hubbard & Miller, 2019; Zorn et al., 2017). Chronically elevated cortisol 
could increase CVD risk in patients with schizophrenia due to consequent effects such as central 
obesity, lipid abnormalities, and insulin resistance (Bradley & Dinan, 2010; Penninx & Lange, 2018). 
The HPA-axis also regulates inflammatory and immune function and this can be another pathway 
through which a dysfunctional HPA-axis in patients with schizophrenia can contribute to increased 
CVD risk (Bradley & Dinan, 2010; Penninx & Lange, 2018). Although a dysregulated HPA-axis has 
been postulated to play a role in CVD in patients with schizophrenia, limited studies have investigated 
the links between schizophrenia, HPA-axis function and CVD risk. A study in FEP, drug naïve, 
schizophrenia patients found that patients had significantly higher fasting plasma glucose (FPG), insulin 
and cortisol levels than controls (Spelman et al., 2007). Although the authors did not report on 
correlations between metabolic measures and cortisol levels the results suggested synergistic effects 
related to metabolic risk and cortisol levels. 
Although systematic reviews tend to demonstrate higher basal cortisol levels in schizophrenia, most 
studies have utilised measures reflecting acute or short-term cortisol release (Borges et al., 2013; 
Gajsak et al., 2017). In recent years measuring cortisol levels in hair has been established as a useful 




& Williams, 2013). Studies are also increasingly using hair cortisol concentrations (HCC) to evaluate 
HPA-axis function in patients with schizophrenia (Aas et al., 2019; Andrade et al., 2016; Streit et al., 
2016; Touskova et al., 2018). There are certain advantages to using HCC; hair sampling is non-
invasive and samples can be stored and transported at room temperature, HCC are less influenced by 
acute factors such as the stress of sampling or diurnal variations, and provide a retrospective window 
of HPA-axis function spanning months (Stalder & Kirschbaum, 2012; Stalder et al., 2017). This is 
particularly useful when studying HPA-axis function in FEP drug-naive patients as HCC reflect average 
cortisol levels for the illness period prior to antipsychotic treatment initiation. 
HCC, reflecting chronic cortisol release, can potentially provide additional insights into the role of HPA-
axis dysfunction in relation to schizophrenia and associated CVD risk. Our objectives were thus in a 
sample of South African adults (i) to determine whether schizophrenia diagnostic status (in FEP and 
chronic schizophrenia patients) and clinical factors (schizophrenia disease related and self-perceived 
stress) were associated with HCC; (ii) to investigate for any interactions between schizophrenia and 
MetS (as well as individual CVD risk factors) on HCC (iii) to assess temporal change in HCC in FEP 
schizophrenia patients.  
2 Methods 
2.1 Study design 
This is a neuroendocrine ancillary study to ‘Understanding the SHARED ROOTS of Neuropsychiatric 
Disorders and Modifiable Risk Factors for Cardiovascular Disease’ or SHARED ROOTS (SR). The SR 
study was a matched case-control study in three neuropsychiatric disease cohorts (schizophrenia, 
Parkinson’s disease and posttraumatic stress disorder). Controls were matched to the schizophrenia 
cohort based on age, gender, and MetS status. The schizophrenia cohort consisted of two arms, a 
FEP arm and a chronic schizophrenia arm. The FEP patients were newly initiated on open-label 
flupenthixol decanoate (a depot antipsychotic) and the chronic cohort included patients with 




al., 2016). There was a longitudinal component to the FEP cohort and both patients and controls 
returned for follow-up assessments 12 months post baseline.  
This study was approved by the Health Research Ethics Committee at Stellenbosch University (HREC 
N13/08/115) and conducted according to the principles of the seventh revision of the Declaration of 
Helsinki (World Medical Association, 2013). Written informed consent was obtained from all 
participants and a tiered consenting process was adhered to, allowing participants to opt-out of the hair 
sampling procedure. Participants were referred to their usual health care service providers for any 
medical or psychiatric problems that warranted further investigation and treatment.  
2.2 Setting 
Participants were enrolled over 3 years from May 2014 until June 2017 in Cape Town, South Africa.  
We utilised a purposive sampling approach and participants for all cohorts were recruited using multi-
pronged strategies. FEP schizophrenia patients were recruited from general and psychiatric hospitals 
and community health centres (CHCs) within the study catchment area following their first psychotic 
episode. Control participants were recruited through (i) print, radio and web advertisements; (ii) active 
recruitment within communities by a registered nurse; and (iii) word of mouth by participants already 
recruited. The chronic schizophrenia cohort was contacted and invited to participate in SR. 
2.3 Participants 
All participants had to be 18 years and older, willing and able to provide informed consent and able to 
read and write in English or Afrikaans. Participants were excluded from hair sampling if they had hair 
length shorter than 3cm (see Figure 1 for a flow diagram of schizophrenia cohort participants included 
in this study). Patients with a diagnosis of schizophrenia, schizophreniform, or schizoaffective disorder 
based on the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental 
Disorders, fourth edition (SCID-IV) (First, Spitzer, Gibbon, & Williams, 1997) and without intellectual 
disability were eligible for inclusion. FEP, but not chronic, schizophrenia patients were excluded if they 
had received prior antipsychotic treatment (barring the few days prior to inclusion in the study). Further 
exclusion criteria applied in this study were, (i) systemic or scalp steroid use, (ii) current pregnancy, or 




immune disorders). Exclusion criteria applied only to controls were lifetime or current serious psychiatric 
disorder (psychotic disorder or bipolar disorder) or the presence of any current psychiatric disorder as 
based on the history, the Mini International Neuropsychiatric Interview (MINI) or current psychiatric 
medication use. Patients with schizophrenia were permitted to have psychiatric comorbidity (substance 
use disorders (SUDs) and common mental disorders (CMDs) provided the primary  diagnosis, based 
on diagnostic interview with the SCID and clinician assessment, was schizophrenia, schizophreniform, 
or schizoaffective disorder and not a substance induced psychotic disorder or a mood disorder with 
psychotic features. 
MetS status was determined based on the harmonized Joint Interim Statement (JIS) criteria (Alberti et 
al., 2009), with the presence any three of the following five risk factors required for a diagnosis of MetS: 
(i) Raised blood pressure (BP), systolic ≥ 130 and/or diastolic ≥ 85 mmHg, or being on antihypertensive 
treatment; (ii) Elevated triglycerides > 1.70 mmol/l (150 mg/dl) or being on treatment for 
hypertriglyceridemia; (iii) Reduced HDL-C, < 1.0 mmol/l (40mg/dl) in males, and < 1.3 mmol/l (50mg/dl) 
in females, or being on treatment for low HDL-C; (iv) Elevated fasting glucose ≥ 5.6 mmol/l (100 mg/dl) 
or on treatment for diabetes; (v) Elevated waist circumference according to population and country 
specific guidelines. We used a waist circumference ≥ 90cm in both males and females, as a recent 
validation study in the Western Cape showed this to be the optimal WC cut-off in the source population 




Baseline   Month 12 
    
Participants included (n = 118)                Participants eligible (n = 61)          
  PT CT                  PT CT          
FE 39 44                FE 31 30          
CH 23 12                CH NA NA          
                                    
       Hair sample not obtained (n = 78)          Hair sample not obtained (n = 46) 
           FE CH              FE 
       Reason PT CT PT CT          Reason PT CT 
       Refuse 2 0 2 0          Refuse 4 6 
       Too short 24 19 14 6          Too short 14 9 
       Not attend 2 2 1 1          Not attend 6 4 
       Hairstyle 0 3 1 0          Hairstyle 0 1 
       NS 0 1 0 0          NS 0 2 
                                    
Hair samples obtained (n = 40)                Hair samples obtained (n = 15)          
  PT CT                  PT CT          
FE 11 19                FE 7 8          
CH 5 5                CH NA NA          
                                    
       Excluded from analysis (n = 3)          Excluded from analysis (n = 4) 
           FE CH              FE 
       Reason PT CT PT CT          Reason PT CT 
       Steroids 0 0 0 1          Pregnant 2 0 
       Psych disa - 2 - 0          Psych disa - 2 
                                    
                                    
Included in analysis (n = 37)                Included in analysis (n = 11)          
  PT CT                  PT CT          
FE 11 17                FE 5 6          
CH 5 4                CH NA NA          
 
Figure 1 Flow diagram demonstrating inclusion and exclusion of participants 
 
a Exclusion criteria only applicable to controls 
CH, Chronic; CT, control; FE, first episode; hairstyle, hairstyle prohibiting sampling; NA, not applicable; NS, not specified; Refuse, did not provide consent for 





Participants in SR attended two to three study visits, each lasting around 3 hours. Diagnostic, clinical 
and participant-administered measures were completed at the first visit. The second visit occurred 
within 24-96 hours of the first visit and involved physical procedures (e.g. fasting blood sampling, 
physical measurements) and additional lifestyle measures. Assessments were conducted in English or 
Afrikaans, depending on the language preference of participants. Psychiatrists conducted diagnostic 
and clinical assessments. Research nurses performed physical procedures and personally 
administered the participant-administered measures to all participants, to aid comprehension and to 
accommodate variations in reading level. All measures performed at baseline were repeated at 12-
month follow-up assessment (with the exception of measures that were not appropriate for repeated 
administration). 
2.4.1 Physical measurements 
Physical measurements were conducted consistently and methodically in accordance with the WHO 
stepwise approach to chronic disease risk factor surveillance (WHO STEPS) instrument, a 
standardised instrument designed for non-communicable disease surveillance (World Health 
Organization, 2005). The following physical parameters were included in analysis: (i) mean systolic 
(SBP) and diastolic (DBP) blood pressure (mmHg); (ii) mean heart rate (HR, bpm); (iii) body mass 
index (BMI, kg/m2); (iv) waist circumference (WC, cm); (v) hip circumference (HC, cm); and (vi) waist-
to-hip ratio (WHR).  
2.4.2 Blood samples for metabolic parameters 
Venous blood samples were obtained following an overnight fast (at least 8 hours). Samples were 
analysed on the Cobas 6000 c501 Chemistry Analyser (Roche, Germany) at a commercial 
internationally accredited laboratory (Lancet laboratories) on the same day as sample collection. The 
following laboratory parameters were included in analysis: (i) fasting plasma glucose (FPG, mmol/l); (ii) 
triglycerides (trig, mmol/l); (iii) HDL-C (mmol/l); (iv) low-density lipoprotein cholesterol (LDL-C, mmol/l); 




mmol/l, LDL-C >= 3 mmol/l, and HbA1c >= 6.5% were considered to be elevated (Klug et al., 2018; 
SEMDSA Type 2 Diabetes Guidelines Expert Committee., 2017). 
2.4.3 Hair sampling 
Hair samples from the posterior vertex scalp were cut close to the scalp with fine scissors. Samples 
were secured, placed into aluminium foil, labelled and sealed inside an envelope. All samples were 
stored in dark containers at room temperature. In both the FEP and chronic cohort hair sampling was 
done at baseline and in the FEP cohort again at 12 months follow-up. 
2.4.4 Hair analysis 
Samples were sent for analysis at the TU Dresden laboratory (Prof Clemens Kirschbaum) in 
December 2017 and were analysed using an established liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) protocol (Gao et al., 2013). LC-MS/MS is the benchmark (gold standard) 
method for hair cortisol determination and different laboratories using LC-MS/MS have demonstrated 
almost identical results (r = 0.98) (Russell et al., 2015). The proximal 3cm of the hair segments were 
used for analysis, representing cortisol secretion for the prior 3 months based on an accepted growth 
rate of 1cm per month (Wennig, 2000). 
2.5 Measures 
2.5.1 Demographic questionnaire 
Demographic details were collected with a demographic questionnaire. Demographic variables 
included in this manuscript are self-identified gender (male or female), self-identified ethnicity (mixed 
ancestry [coloured] or other), age in years, highest level of education (HLOE, defined according to 
whether secondary education was completed), and employment status (defined as being employed for 
the greater part of the prior 12 months). 
2.5.2 Medical history questionnaires 
Medical and psychiatric histories were collected with comprehensive medical questionnaires. Clinical 
items reported on in this manuscript are: (i) steroid use in the prior 6 months (split according to whether 




other topical steroid use (dermatologic, inhaled, nasal), (ii) hormonal contraceptive use in prior 6 
months (including oral contraceptives and other formulations, such as implants and injectable 
contraceptives), (iii) current breastfeeding in women, (iv) current psychiatric medication use, (v) statin 
use, (vi) aspirin use, (vii) any other current medical conditions, and (viii) self-reported tobacco, alcohol, 
and illicit substance use in the prior six months.  
2.5.3 The Mini International Neuropsychiatric Interview (MINI) (Sheehan et al., 1998) 
The MINI version 6.0 was used to determine the presence of any current and lifetime psychiatric 
disorders. The MINI is a short structured diagnostic interview used to diagnose psychiatric disorders 
based on Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) and International 
Classification of Diseases (ICD-10) criteria.  
2.5.4 Schizophrenia clinical assessments 
Symptom severity in schizophrenia patients was assessed with the Positive and Negative Syndrome 
Scale (PANSS) (Kay et al., 1987). We report on the total score (range 30 – 210, Cronbach’s α = 0.94); 
positive scale (7 – 49, Cronbach’s α = 0.86), negative scale (7 – 49, Cronbach’s α = 0.95), and general 
psychopathology scale (16 – 112, Cronbach’s α = 0.89). Putative remission status was determined 
based on established criteria (symptom severity rated mild or less on PANSS items P1-3, N1, N4, N6, 
G5 and G9) (Andreasen et al., 2005), but without the time criterion as we could not establish whether 
symptoms had been below the threshold for at least 6 months. Functional impairment was rated with 
the Social and Occupational Functioning Assessment Scale (SOFAS) (Association, 2000) and the 
Clinical Global Impression (CGI-S) scale (Guy, 1976) was applied to provide a global impression of 
mental illness severity. We assessed insight into illness with the Birchwood Insight Scale (BIS) 
(Birchwood et al., 1994). The BIS assesses for three factors related to insight; awareness of illness, 
need for treatment and attribution of symptoms. The scale contains 8 items with total scores ranging 
from 0-12, with higher scores reflecting better insight. Cronbach’s α in this sample was 0.67. We also 





2.5.5 The Perceived Stress Scale (PSS) (Cohen, Kamarck, & Mermelstein, 1983) 
We used the 10-item PSS (PSS-10) to measure self-perceived stress. Individuals rate to what extent 
they found their lives unpredictable, uncontrollable or overloaded in the prior month. Each item is rated 
on a 5-point Likert scale (0 = Never; 1 = Almost Never; 2 = Sometimes; 3 = Fairly often; 4 = Very often) 
with a total score ranging from 0 – 40, and higher scores indicate higher perceived stress. The PSS 
has been widely used and has demonstrated adequate psychometric properties in multiple settings 
and languages (Lee, 2012) and Cronbach’s α in the schizophrenia cohort was 0.87.  
2.5.6 The WHO stepwise approach to chronic disease risk factor surveillance (WHO STEPS) 
(World Health Organization, 2005) 
The level of physical activity was determined with the global physical activity questionnaire (GPAQ) in 
the WHO STEPS. The GPAQ assesses average physical activity for a week occurring across three 
domains, namely work, travel and recreation. Level of physical activity (high, moderate, and low) was 
determined according to the GPAQ guidelines (World Health Organization, 2005).  
2.5.7 Hair questionnaire 
Participants who provided hair samples were questioned about their hair characteristics and hair care 
practices. Hair related variables reported in this manuscript include (i) whether natural hair colour is 
black, (ii) whether hair had been chemically treated in the prior three months (including colouring, 
relaxing and perming), (iii) the frequency of hair washing (two or more times a week, once a week, less 
frequent than once a week), (iv) whether any additional hair products had been used in the prior three 
months (such as hair styling and care products e.g. gels, oils and creams),  and (v) average hours per 
day that hair was exposed to sunlight (less than one hour, 1-2 hours, more than 2 hours). Additional 
hair related factors included the season sampled (based on the month the sample was obtained in) 
and the duration of storage before sending the samples for analysis (less than 1 year, 1-2 years, 2-3.5 
years). 
2.6 Statistical analysis 
Sample size estimations for the neuroendocrine study were based on hair cortisol studies in PTSD and 




at the point that the study was conceptualised. The overall sample size was, however, limited by 
recruitment of the parent study as well as by factors influencing hair sampling, such as short hair length. 
HCC were not normally distributed and were positively skewed (Clark, Osborne, Gallagher, & Watson, 
2016; Miller & Plessow, 2013). Utilising the box-cox family of power transformations (Osborne, 2010) 
HCC were reciprocal square root transformed to meet the assumption of normality. There were no 
outliers 3SD beyond the mean. We compared the included and excluded sample with Pearson chi-
square for categorical variables, and Mann Whitney tests for continuous variables. We compared the 
schizophrenia patients and controls with Pearson chi-square or Fisher’s exact tests for categorical 
variables, and independent sample t-tests for continuous variables. To determine whether HCC were 
associated with a diagnosis of schizophrenia, schizophrenia symptom severity, and self-perceived 
stress we conducted simple and multiple linear regression models with HCC as the dependent 
variable. Covariates included in models were age and sex. We did not include other possible 
covariates for HCC due to the small sample size and as none of the factors remained significantly 
associated with HCC once we controlled for age, sex and case-control status. To assess whether HCC 
was associated with putative remission status we conducted an exploratory analysis by combining the 
data pertaining to HCC and remission status for the chronic patients at baseline with the FEP patients 
at month-12 follow-up. Interaction effects between MetS and schizophrenia diagnosis were assessed 
by regressing MetS on HCC in unadjusted, and then in adjusted models that included covariates 
alongside schizophrenia diagnosis. We examined for any interaction effects between schizophrenia 
diagnostic status and MetS. In exploratory analysis we also examined for associations between the 
individual CVD risk variables and HCC as well as for interactions with schizophrenia. To assess for 
change in HCC over time between FEP patients and controls and those with and without MetS we 
used a linear mixed model, with restricted maximum likelihood and an unstructured covariance matrix. 
To assess for overall change in HCC over time we first included only the events (baseline, month-12), 
we then included case status and the interaction between case status and events, finally we included 
MetS and the interaction between MetS and events as fixed effects. To account for within subject 




analysed with SPSS for windows, version 25.0, all tests were 2-tailed and the level of significance was 
set at .05. 
3 Results 
3.1 Participants 
At baseline hair samples were obtained in 40 (33.9%) of the 118 participants included in the 
schizophrenia cohort, a further 3 participants were excluded from analysis, leaving a final sample of 37 
participants; 16 patients and 21 controls (see Figure 1 for details). Hair length shorter than 3cm was the 
main factor (80.8%) limiting sampling. The following factors differed significantly between included and 
excluded samples: gender (p < 0.001), HLOE (p = 0.009), HDL-C (p = 0.033), trig (p = 0.033), and 
WHR (p = 0.019). When we controlled for gender the only factor that remained significantly different 
between included and excluded samples was HLOE (p = 0.033), such that the included sample had a 
higher percentage of individuals who had completed secondary education than the excluded sample.  
At month-12 follow-up hair samples were obtained in 15 (29.4) of the 51 FEP participants who returned 
for follow-up assessments, a further 4 participants were excluded from analysis, leaving a final sample 
of 11 participants; 5 FEP patients and 6 controls (see Figure 1 for details). The only factor that differed 
between FEP cohort participants who returned for month-12 assessments as compared to those who 
did not was that participants who returned were more likely to be female (p = 0.006).  
Descriptive data of the sample are presented in Table 1. Factors that were significantly different 
between the patients and controls, included ethnicity (p = 0.010), employment status (p = 0.039) and 
illicit substance use (p = 0.010). Schizophrenia disease related factors are presented in Table 2. At 
baseline the clinical variables that differed between FEP and chronic patients were time since 
psychosis onset (p = 0.011), time since diagnosis (p = 0.002), PANSS total (p = 0.018) and positive 
scale (p = 0.001) scores, SOFAS score (p = 0.045), CGI-S (p = 0.001) and antipsychotic treatment (p = 
0.003). PANSS total (p = 0.043) and positive scale (p = 0.043) scores changed significantly from 




Table 1 Comparison of sociodemographic, hair related, behavioural, and clinical factors between schizophrenia patients and controls  
 
Variables Patients Controls Test statistic p-value 
Total 16 21   
 Cohort n(%)   χ²(1) = 0.74 0.458 
  First episode 11 (68.8) 17 (81.0)   
  Chronic 5 (31.3) 4 (19.0)   
Socio-demographic     
 Age M(SD) 30.1 (6.9) 26.4 (5.8) t (35) = -1.77 0.085 
 Female n(%)   χ²(1) = 1.60 0.371 
  No 4 (25.0) 2 (9.5)   
  Yes 12 (75.0) 19 (90.5)   
 Mixed ancestry ethnicity n(%)   χ²(1) = 7.59 0.010* 
  No 11 (68.8) 21 (100.0)   
  Yes 5 (31.3) 0 (0.0)   
 Secondary education complete n(%)   χ²(1) = 0.12 0.729 
  No 7 (43.8) 8 (38.1)   
  Yes 9 (56.3) 13 (61.9)   
 Employed n(%)   χ²(1) = 4.26 0.039* 
  No 10 (62.5) 6 (28.6)   
  Yes 6 (37.5) 15 (71.4)   
Hair related     
 Natural hair colour black n(%)   χ²(1) = 0.19 0.705 
  No 12 (75.0) 17 (81.0)   
  Yes 4 (25.0) 4 (19.0)   
 Hair chemically treated n(%)   χ²(1) = 0.27 0.603 
  No 9 (56.3) 10 (47.6)   
  Yes 7 (43.8) 11 (52.4)   
 Frequency of hair washing n(%)   χ²(2) = 2.35 0.309 
  ≥ 2 times a week 8 (50.0) 7 (33.3)   
  1 time a week 7 (43.8) 9 (42.9)   
  < 1 time a week 1 (6.3) 5 (23.8)   
 Add on hair products n(%)   χ²(1) = 1.21 0.272 
  No  9 (56.3) 8 (38.1)   
  Yes 7 (43.8) 13 (61.9)   
 Average hours in sun n(%)   χ²(2) = 0.77 0.679 
  < 1 hour 8 (50.0) 11 (52.4)   




  > 2 hours 4 (25.0) 7 (33.3)   
 Season sampled n(%)   χ²(3) = 3.14 0.371 
  Summer 5 (31.3) 6 (28.6)   
  Autumn 1 (6.3) 6 (28.6)   
  Winter 6 (37.5) 5 (23.8)   
  Spring 4 (25.0) 4 (19.0)   
 Duration of storage n(%)   χ²(2) = 2.33 0.311 
  Less than 1 year 1 (6.3) 5 (23.8)   
  1 - 2 years 8 (50.0) 10 (47.6)   
  2 – 3.5 years 7 (43.8) 6 (28.6)   
Clinical      
 Hormonal contraceptive n(%)   χ²(1) = 3.03 0.128 
  No 10 (83.3) 10 (52.6)   
  Yes 2 (16.7) 9 (47.4)   
 Currently breastfeeding n(%)   χ²(1) = 2.10 0.265 
  No 12 (100.0) 16 (84.2)   
  Yes 0 (0.0) 3 (15.8)   
 Topical steroid use n(%)   χ²(1) = 0.04 1.000 
  No 15 (93.8) 20 (95.2)   
  Yes 1 (6.3) 1 (4.8)   
 Other medical conditions n(%)   χ²(1) = 1.27 0.315 
  No 11 (75.0) 12 (57.1)   
  Yes 4 (25.0) 9 (42.9)   
Behavioural     
 Tobacco use n(%)   χ²(1) = 3.11 0.078 
  No 6 (37.5) 14 (66.7)   
  Yes 10 (62.5) 8 (33.3)   
 Alcohol use n(%)   χ²(1) = 0.00 0.957 
  No 7 (43.8) 9 (42.9)   
  Yes 9 (56.3) 12 (57.1)   
 Illicit substance usea n(%)   χ²(1) = 7.59 0.010* 
  No 11 (68.8) 21 (100.0)   
  Yes 5 (31.3) 0 (0.0)   
 Level of physical activity n(%)   χ²(2) = 1.10 0.576 
  High 3 (18.8) 6 (28.6)   
  Moderate 8 (50.0) 6 (33.3)   
  Low 5 (31.3) 8 (38.1)   
Perceived stress     




Hair glucocorticoid levels     
 HCC Mdn(IQR) 7.0 (3.3; 18.7) 22.1 (11.0; 31.8) U=81; Z=-2.67 0.008* 
 Transformed HCC M(SD) 1.25 (0.31) 1.51 (0.28) t (35) = 2.75 0.009* 
a 2 using cannabis, 1 using methamphetamine, 1 using cannabis and methamphetamine, and 1 using cannabis and methaqualone 
* p < 0.05 
HCC, hair cortisol concentration; PSS, perceived stress scale 
 
Table 2 Association between clinical variables and hair cortisol concentrations in schizophrenia patients 
 
Variables Baseline Follow-up Baseline comparison HCC 
 FEP Chronic FEP  Test statistic p-value ß (95% CI) 
 n = 11 n = 5 n = 5    
Age at first psychosis 25.8 (4.1) 26.8 (6.7)  t (14) = -0.35 0.732 -0.01 (-0.04; 0.03) 
Months since psychosis onset Mdn (IQR) 3.8 (3.1; 37.6) 104 (80; 106)  U=71; Z=-2.55 0.011* 0.00 (-0.00; 0.00) 
Months since diagnosis  Mdn (IQR) 0.23 (0.20; 0.49) 77 (93; 102)  U=66; Z=-3.14 0.002* 0.00 (-0.00; 0.01) 
DUP (months) Mdn (IQR) 2.7 (3.6; 37.4) 4.9 (1.7; 9.0)  U=36; Z=-0.74 0.461 -0.01 (-0.01; 0.00) 
PANSS total score M (SD) 84.8 (23.2) 55.4 (9.9) 57.6 (10.1)a t (14) = 2.69 0.018* 0.00 (-0.01; 0.01) 
 Total P score M (SD) 23.8 (5.0) 12.2 (4.6) 10.2 (2.9)a t (14) = 4.42 0.001* -0.01 (-0.04; 0.01) 
 Total N score M (SD) 22.6 (8.4) 17.6 (3.9) 20.2 (5.1) t (14) = 1.24 0.234 0.01 (-0.02; 0.03) 
 Total G score M (SD) 38.5 (13.6) 25.6 (5.3) 27.2 (9.3) t (14) = 2.01 0.064 0.00 (-0.01; 0.02) 
BIS M (SD) 7.5 (2.9) 6.4 (2.1) 5.5 (2.9) t (14) = 0.72 0.483 -0.06 (-0.12; -0.01)* 
SOFAS M (SD) 44.2 (9.2) 57.8 (15.7) 53.2 (12.4) t (14) = -2.20 0.045* -0.00 (-0.02; 0.01) 
CGI-S M (SD) 4.9 (0.5)b 3.2 (1.1)c 3.0 (0.7)d t (14) = 4.27 0.001* -0.02 (-0.18; 0.14) 
Antipsychotic treatment    χ²(2) = 11.7 0.003*  
 Flupenthixol decanoate - initiated 11 (100.0) 1 (20.0)e 0 (0.0)   0.13 (-0.35; 0.61) 
 Flupenthixol decanoate - ongoing 0 (0.0) 2 (40.0) 5 (100.0)   0.53 (-0.09; 1.16) 
 Other 0 (0.0) 2 (40.0)f 0 (0.0)   Ref 
Other psychiatric medications    χ²(1) = 4.75 0.063  
 No 1 (9.1) 3 (60.0) 2 (40.0)   Ref 
 Yes 10 (90.9)g 2 (40.0)h 3 (60.0)i   -0.05 (-0.45; 0.34) 
Psychiatric comorbidity n(%)    χ²(1) = 2.42 0.245  
 No 7 (72.7) 5 (100.0) 4 (80.0)   Ref 
 Yes 4 (27.3)j 0 (0.0) 1 (20.0)k   0.09 (-0.30; 0.48) 
* p < 0.05 
a Significant change (p < 0.05) from baseline based on Wilcoxon signed rank test 
b 2 (18.2%) moderately ill, 8 (72.7%) markedly ill, 1 (9.1%) severely ill 
c 1 (20%) borderline mentally ill, 3 (60.0%) mildly ill, 1 (20.0%) markedly ill 




e flupenthixol decanoate was restarted in 1 chronic schizophrenia patient 
f 1 receiving risperidone depot and 1 receiving clozapine and amisulpiride 
g  9 (81.8%) were on short-term benzodiazepines (BZD) and 2 (18.2%) on anticholinergics 
h 2 (40.0%) were on antidepressants, 1 (20.0%) on lithium, and 1 (20.0%) on anticholinergics  
i 2 (40.0%) on antidepressants, 1 (20.0%) on lithium, 2 (40.0%) on anticholinergics. 
j  Diagnosed based on the MINI; 2 (12.5%) with a comorbid substance use disorder; 1 (16.3%) with panic disorder, agoraphobia and generalised anxiety 
disorder (GAD) and 1 (6.3%) with social anxiety disorder and a substance use disorder 
k 1 with MDD and agoraphobia 
 
BIS, Birchwood Insight Scale; CGI, Clinical Global Impression; CMD, common mental disorder; DUP, duration of untreated psychosis; FEP, first episode; 
HCC, hair cortisol concentration; MINI, the Mini International Neuropsychiatric Interview; PANSS, the Positive and Negative Syndrome Scale; SOFAS, 




Table 3 Schizophrenia and metabolic syndrome regressed on hair cortisol concentrations (HCC) 
 
  Simple linear regression Multiple linear regressiona 
    Model 1 Model 2 Model 3 
  ß (95% CI) p-value ß (95% CI) p-value ß (95% CI) p-value ß (95% CI) p-value 
Case status        0.020* 
 Control Ref  Ref  Ref  Ref  
 Patient -0.27 (-0.47; -0.07) 0.009* -0.27 (-0.48; -0.06) 0.014* -0.27 (-0.48; -0.06) 0.014* -0.24 (-0.48; -0.00) 0.048* 
MetS        0.434 
 No Ref    Ref  Ref  
 Yes 0.04 (-0.26; 0.33) 0.806   0.08 (-0.21; 0.37) 0.557 0.23 (-0.25; 0.71) 0.337 
Patient*MetS       -0.22 (-0.81; 0.36) 0.443 
a Multivariate adjusted model (adjusted for age and sex); n = 37 
Model 1 – Model without MetS: F (3, 33) = 3.21 (p = 0.036*), Adj R² = 0.156; n = 37 
Model 2 – MetS added: F (4, 32) = 2.45 (p = 0.066), Adj R² = 0.139; n = 37 
Model 3 – Interaction between case status and MetS added: F (5, 31) = 2.06 (p = 0.098), Adj R² = 0.128; n = 37 
* p < 0.05 




3.2 Schizophrenia and hair cortisol concentrations 
The HCC for cases and controls at each time-point are illustrated in Figure 2. At baseline HCC were 
significantly lower in patient than controls (Cohen’s d = 0.88) in unadjusted (B = -0.27, 95% CI -0.47; -
0.07, p = 0.009) and adjusted analyses (adj B = -0.27, 95% CI -0.48; -0.06, p = 0.014) (Table 3). When 
analysed according to cohort, patients with FEP also had significantly lower HCC than controls 
(Cohen’s d = 0.97) in unadjusted (B = -0.30, 95% CI -0.54; -0.06, p = 0.017) and adjusted analyses (adj 
B = -0.28, 95% CI -0.53; -0.03, p = 0.030) (Figure 3a). Exploratory analysis examining HCC in relation 
to putative remission status revealed that non-remitters (n = 5) had significantly lower HCC (B = -0.44, 
95% CI -0.80; -0.07, p = 0.025) than remitters (n = 5) and when compared to controls non-remitters (n 
= 5), but not remitters (n = 5), had significantly lower HCC than controls (B = -0.41, 95% CI -6.69; -0.13, 
p = 0.006) (Figure 3b). 
Overall sample   
Baseline  Month-12 
 PT CT   PT CT 
Total n = 16 n = 21  Total n = 5 n = 6 
HCC 1.25 (0.31)* 1.51 (0.28)*  HCC 1.27 (0.37) 1.27 (0.30) 
FEP n = 11 n = 17  FEP n = 5 n = 6 
HCC 1.19 (0.30)* 1.48 (0.30)*  HCC 1.27 (0.37) 1.27 (0.30) 
CHR n = 5 n = 4     
HCC 1.37 (0.31) 1.64 (0.17)     
   
HCC for baseline and month-12   
Baseline  Month-12 
 PT CT   PT CT 
FEP n = 4 n = 5  FEP n = 4 n = 5 
HCC 1.10 (0.22)* 1.51 (0.26)*  HCC 1.22 (0.41) 1.34 (0.27) 
 
Figure 2 Hair cortisol concentrations according to diagnostic groups and events 
 
Figure illustrating HCC M(SD) according to diagnostic groups and events. The only significant 
differences were between patients and controls at baseline. HCC were available for both baseline and 
month-12 in 4 FEP patients and 4 controls.  
* significant difference between patients and controls, p < 0.05 








3.2.1 Schizophrenia clinical variables and hair cortisol concentrations (Table 2) 
Although not significant HCC were inversely associated with PANSS positive symptoms scores and 
positively associated with negative, general and total symptom scores. The BIS insight score was 
significantly associated with HCC at baseline in unadjusted (B = -0.06, 95% CI -0.12; -0.01, p = 0.028) 
and adjusted (adj B = -0.07, 95% CI -0.13; -0.01, p = 0.037) analyses. 
 
Figure 3a Baseline hair cortisol concentrations (HCC) according to diagnostic status 
 
Bar chart demonstrating mean baseline HCC levels according to diagnostic status. The model was 
significant (F(34, 2) = 4.5, p = 0.018) and HCC were lowest in first episode psychosis (FEP) patients 
and were significantly lower than controls (p = 0.013). There were no other significant differences 
between the groups based on Tukey HSD post hoc test. 
*p < 0.05 






Figure 3b Hair cortisol concentrations (HCC) according to putative remission status 
 
Bar chart demonstrating mean HCC levels according to putative patient remission status and controls. 
The model was significant (F(28, 2) = 4.8, p = 0.016) and HCC were lowest in non-remitters (n = 5) and 
were significantly lower than controls (n = 22, p = 0.015) and putative remitters (n = 5, p = 0.045). There 
were no other significant differences between the groups based on Tukey HSD post hoc test. 
*p < 0.05 
Error bars ± 2SE 
 
3.3 Self-perceived stress, schizophrenia and hair cortisol concentrations 
PSS scores were significantly higher in schizophrenia patients than in controls (p < 0.001) at baseline, 
but not at follow-up (p = 0.667) in the FEP participants who provided hair samples at month-12. PSS 
scores were not significantly associated with HCC in unadjusted (B = -0.01, 95% CI -0.02; 0.01, p = 
0.449) and adjusted (adj B = 0.01, 95% CI -0.01; 0.02, p = 0.527) analyses at baseline. PSS scores 
were significantly associated with HCC at month-12 follow-up in unadjusted analysis (B = -0.02, 95% 
CI -0.04; -0.00, p = 0.022) and demonstrated a trend toward significance in adjusted analysis (adj B = -
0.02, 95% CI -0.04; 0.00, p = 0.054). There were no significant interaction effects between 




3.4 Cardiovascular disease risk factors, schizophrenia and hair cortisol concentrations  
3.4.1 Metabolic syndrome, schizophrenia and hair cortisol concentrations 
Rates of MetS were non-significantly higher in schizophrenia patients than in controls (p = 0.371), and 
two FEP and two chronic schizophrenia patients had MetS. MetS was not significantly associated with 
HCC in unadjusted (B = 0.04, 95% CI -0.26; 0.33, p = 0.806) and adjusted (adj B = 0.08, 95% CI -0.21; 
0.37, p = 0.557) analyses at baseline (Table 3). The interaction between schizophrenia and MetS was 
not significant (adj B = -0.22, 95% CI -0.81; 0.36, p = 0.443). In FEP participants who provided hair 
samples at month-12, MetS was present in 3 of the patients and 3 of the controls and HCC were 
significantly higher in those with MetS in unadjusted (B = 0.42, 95% CI 0.10; 0.75, p = 0.017) and 
adjusted (adj B = 0.41, 95% CI 0.02; 0.80, p = 0.041) analyses. The interaction between schizophrenia 
and MetS was not significant (adj B = -0.10, 95% CI -1.09; 0.89, p = 0.806) at month-12.   
3.5 Individual cardiovascular disease risk factors, schizophrenia and hair cortisol 
concentrations (Supplementary table 1) 
CVD risk factors that differed significantly between patients and controls included triglycerides (p = 
0.033), WHR (p = 0.008) and HR (p = 0.004). When we controlled for age and gender only HR (p = 
0.026) remained significantly different. None of the individual CVD risk factors were significantly 
associated with HCC in unadjusted or adjusted analyses and there were no significant interactions 
between schizophrenia and any of the CVD variables on HCC. HR demonstrated a trend toward 
significance in adjusted analyses (adj B = 0.01, 95% CI 0.00; 0.01, p = 0.054).  
At month-12 follow-up HDL-C MetS criterion was associated with HCC in unadjusted (B = 0.42, 95% 
CI 0.10; 0.75, p = 0.017) and adjusted (adj B = 0.41, 95% CI 0.02; 0.80, p = 0.041) analyses. HDL-C 
was also associated with HCC in unadjusted (B = -0.71, 95% CI -1.20; -0.23, p = 0.008) and adjusted 
(adj B = -0.70, 95% CI -1.28; -0.12, p = 0.024) analyses. Number of MetS criteria showed a trend 
towards significance in unadjusted (B = 0.13, 95% CI -0.01; 0.26, p = 0.058) analyses, but was not 






Table 4 Fixed Effects of schizophrenia diagnosis and metabolic syndrome on change in hair 
cortisol concentrations (HCC) from baseline to month-12  
 
 ß (95% CI)  S.E df t p-value 
Events     0.840 
 Baseline Ref     
 Month-12 -0.40 (-0.67; -0.12) -0.12 9.49 -3.23 0.010* 
Case status     0.257 
 Control Ref     
 Patient -0.27 (-0.52; -0.03) 0.12 25.93 -2.27 0.032* 
Month-12*patient 0.29 (-0.06; 0.63) 0.15 8.53 1.90 0.091 
MetS     0.419 
 No Ref     
 Yes -0.13 (-0.50; 0.23) 0.17 15.07 0.79 0.443 
Month-12*MetS 0.47 (0.04; 0.90) 0.19 9.92 2.41 0.037* 
-2 RLL = 21.15, n =30 
* p < 0.05 
MetS, metabolic syndrome 
 
3.6 Schizophrenia, MetS and temporal change in HCC 
HCC did not change significantly overall between baseline and month-12 (B = -0.07, 95% CI -0.27; 
0.13, p = 0.443). When case status and the interaction between case status and events were added to 
the model there were no overall effects demonstrated for events (p = 0.649) nor case status (p = 
0.389). HCC were significantly lower in patients than controls at baseline (adj B = -0.28, 95% CI -0.51; -
0.04, p = 0.022) and did not change significantly from baseline to month-12 in controls (adj B = -0.21, 
95% CI -0.48; 0.06, p = 0.116). The interaction between events and case status demonstrated a trend 
to significance (adj B = 0.33, 95% CI -0.07; 0.73, p = 0.097), such that HCC increased in patients from 
baseline to month-12. The results of the final model with MetS and the interaction between MetS and 
events are included in Table 4. The final model illustrated that in controls HCC decreased significantly 
from baseline to month-12 (p = 0.010), HCC were also significantly lower in patients than controls at 
baseline (p = 0.032), again there was a trend to significance demonstrated (p = 0.091) for HCC 
increasing in patients from baseline to month-12 (Figure 4a). HCC did not differ significantly between 
those with and without MetS at baseline (p = 0.443), but the interaction between MetS and events was 
significant, such that HCC increased significantly (p = 0.037) from baseline to month-12 in those with 
MetS (Figure 4b). Adding an interaction between case status and MetS and case status, MetS and 






Figure 4a Change in hair cortisol concentrations (HCC) between patients and controls from 
baseline to month-12 follow-up  
 
Figure illustrating the change in mean HCC between FEP patients and controls between baseline and 
month-12 follow-up. HCC increased from baseline to month-12 in FEP patients, demonstrating a trend 






Figure 4b Change in hair cortisol concentrations (HCC) in relation to metabolic syndrome 
(MetS) from baseline to month-12 follow-up  
 
Figure illustrating the change in mean HCC between those with and without MetS baseline and month-
12 follow-up. HCC increased significantly from baseline to month-12 in those with MetS (adj B = 0.47, 
95% CI 0.04 0.90, p = 0.037). 
4 Discussion 
We demonstrated that in a sample of South African adults HCC were significantly lower in patients with 
schizophrenia, and in particular FEP patients, than controls. HCC were not significantly associated with 
schizophrenia symptom severity domains, but were significantly inversely associated with patient 
insight scores. Neither MetS, nor individual CVD risk factors were associated with HCC at baseline, but 
MetS and HDL-C were associated with HCC at month-12 follow-up, with higher HCC in individuals with 
MetS and low HDL-C. HCC increased in FEP patients from baseline to month-12, demonstrating a 
trend towards significance and increased significantly from baseline to month-12 in those with MetS. 
In our sample HCC were significantly lower in schizophrenia patients, and in particular in FEP patients. 
Our results do not align with the majority of studies that have demonstrated higher basal cortisol levels 
in schizophrenia, and in FEP patients, than in controls (Borges et al., 2013; Bradley & Dinan, 2010; 




higher basal cortisol levels, or non-significant results, some have also found lower basal cortisol levels 
in schizophrenia patients than in controls. Of note, in one systematic review, the studies demonstrating 
lower cortisol levels in schizophrenia patients were largely in newly admitted drug free patients which 
resembles our FEP sample (Bradley & Dinan, 2010). Other recent studies have also demonstrated 
lower basal cortisol levels in FEP patients than in controls (Mondelli et al., 2015; Seitz et al., 2019). We 
also found that HCC were lower in non-remitted patients than in putatively remitted patients and 
controls, suggesting lower HCC were related to symptomatic status. Similarly, Mondelli et al., 2015 
found that the CAR was significantly lower in FEP treatment non-responders than in responders 
(Mondelli et al., 2015). Furthermore, a recent meta-analysis revealed that salivary cortisol levels were 
higher in individuals at ultra-high risk (UHR) for psychosis, but not in FEP patients, than controls 
(Chaumette et al., 2016). Taken together these results suggest that though basal cortisol levels may 
generally be higher in patients with schizophrenia and individuals at risk for psychosis there may be a 
subgroup of patients, and in particular FEP and symptomatic patients, who exhibit a blunted HPA-axis 
with overall lower cortisol output. 
Current meta-analyses and systematic reviews have not included cortisol measures in hair which may 
reflect a different aspect of HPA-axis functioning than acute measures. There have recently been other 
studies investigating HCC in schizophrenia samples. Contrary to our results another study in a FEP 
sample reported significantly higher HCC in FEP patients than in controls (Andrade et al., 2016). Their 
FEP sample also included patients with mood disorders with psychotic features and the inclusion of 
mood disorders may have contributed to higher HCC in the FEP patients. For instance, another study 
examining HCC in schizophrenia and bipolar disorder, found that HCC were significantly higher in 
individuals with bipolar disorder than in patients with schizophrenia and controls (Streit et al., 2016). 
They, along with another study (Aas et al., 2019) found that HCC did not differ between schizophrenia 
patients and controls. Thus results across studies have not been consistent and this could be related to 
sample characteristics, for instance two of the studies sourced controls from university/clinic staff and 
students (Andrade et al., 2016; Streit et al., 2016) and others were largely in patients with chronic 




schizophrenia patients and HCC may also still align with studies demonstrating higher short-term 
cortisol levels in patients with schizophrenia as studies have demonstrated a dissociation between 
HCC and acute measures of cortisol. For instance, one study in older adults found that higher HCC 
were associated with better cognitive performance, whereas higher diurnal salivary cortisol levels were 
associated with poorer cognitive performance, thus suggesting HCC may reflect different aspects of 
HPA-axis function as compared to acute measures (Pulopulos et al., 2014). 
Although HCC increased in FEP patients following treatment initiation this effect only demonstrated a 
trend towards significance. Another study that included acute inpatients with schizophrenia who were 
followed-up at 3 and 6 months found that HCC did not change significantly over the three time-points 
(Streit et al., 2016). We found that HCC were not associated with schizophrenia symptom severity 
domains, but were significantly lower in patients with better insight. Another study utilising HCC in 
females with FEP similarly found that HCC were not significantly associated with positive, negative or 
general psychopathology scores on the PANSS and were associated with insight, however they 
demonstrated a positive correlation between insight (self-reflection) and HCC (Touskova et al., 2018). 
Contrary to our results another study found that HCC were positively correlated with the PANSS 
general psychopathology scale (Streit et al., 2016).  
A measure of self-perceived stress was included to assess whether HCC were associated with 
increased stress experienced by patients with schizophrenia. Patients reported significantly greater 
self-perceived stress at baseline than controls, but not in those who provided hair samples at month-12 
follow-up. Self-perceived stress was not associated with HCC at baseline, but was inversely associated 
with HCC at month-12 follow-up, demonstrating a trend towards significance in adjusted analysis. The 
association between self-perceived stress and HCC is contrary to what one would expect with higher 
self-perceived stress associated with greater cortisol output, although systematic reviews and meta-
analyses generally report mixed results (Stalder et al., 2017; Wosu et al., 2013). These results may 
suggest that within this sample lower HCC may represent stress related HPA-axis dysfunction.  
MetS was not significantly associated with HCC at baseline, but was significantly associated with HCC 




of association between MetS and HCC aligns with what has been demonstrated in other HCC studies 
(Kuehl et al., 2015; Stalder et al., 2013). Although few studies have investigated cortisol levels in 
relation to metabolic risk in schizophrenia they tend to demonstrate a lack of significant associations 
between CVD risk factors and cortisol levels. A study including patients with psychotic disorders, 
individuals at high risk for psychotic disorders and controls, found that plasma and salivary cortisol 
levels were not significantly different between the groups and that cortisol levels were not associated 
with CVD risk factors, physical activity or dietary intake patterns (Manzanares et al., 2014). They only 
demonstrated a significant positive association between salivary cortisol levels and intake of saturated 
fats in the high risk group. Another study in patients with bipolar disorder and schizophrenia found that 
there was no association between morning serum cortisol levels and MetS (Vuksan-Cúsa, Sǎgud, 
Mihaljevic-́Peleš, Jaksǐć, & Jakovljev́ic, 2014). The authors postulated that the psychiatric disorders 
themselves or medication prescribed may have a larger influence on cortisol levels than MetS. A 
similar explanation may also apply to our sample where at baseline the more prominent effects 
associated with psychosis potentially obscured smaller effects related to metabolic factors. This 
explanation is supported by the stronger association demonstrated for MetS, and individual CVD risk 
factors, with HCC at month-12 than HCC at baseline and that MetS was associated with an increase in 
HCC from baseline to month-12. Many of the studies demonstrating higher HCC in patients with 
schizophrenia do not take comorbid medical disorders, and in particular MetS, into consideration 
(Gajsak et al., 2017). Considering that MetS is associated with higher basal cortisol levels and that 
schizophrenia patients, particularly those on treatment have increased rates of MetS (Mitchell et al., 
2013; Vancampfort et al., 2013) this may be an influential confounding factor in higher basal cortisol 
levels demonstrated in schizophrenia patients. HDL-C was also not significantly associated with HCC 
at baseline, but significantly inversely associated with HCC at 12-months follow-up. Though some 
studies have not demonstrated significant associations between HDL-C and HCC (Wester et al., 2017) 
others have also found significant inverse associations (Stalder et al., 2013). A study evaluating 
metformin effects on the metabolic profile of schizophrenia patients on clozapine found that in the 
placebo group there was a significant negative correlation between change in HDL-C and change in 




4.1 Strengths and limitations 
A major limitation of our study was the small sample size, this was secondary to difficulty recruiting 
schizophrenia patients that qualified for inclusion in SR and a large proportion of participants were 
excluded from hair sampling due to short hair length. Future studies in larger samples that use hair-
sampling methods that will allow for broader inclusion, such as shorter hair length, are required to 
expand on our findings. We also allowed for psychiatric comorbidity and concomitant medication in our 
schizophrenia sample which may have influenced our results, although neither were significantly 
associated with HCC. Due to the exploratory nature of our study we did not control for multiple 
comparisons. The exploratory analyses pertaining to putative remission status is limited as we could 
not establish that symptoms had been in remission for at least six months. 
Strengths include that the control participants were recruited from the same communities as our 
patients and were group matched to patients. Our FEP sample were all newly initiated on flupenthixol 
decanoate treatment and thus HCC would not be influenced by antipsychotic use at baseline and at 
follow-up the FEP patients were in receipt of the same depot antipsychotic treatment. Hair analyses 
were conducted with LC-MS/MS which is the gold standard method for hair glucocorticoid 
determination (Russell et al., 2015).  
4.2 Conclusions 
We demonstrated that HCC were significantly lower in schizophrenia patients, and in particular in FEP 
patients, than in controls. We also found that HCC were lower in non-remitted patients and that HCC 
increased following 12 months of flupenthixol decanoate treatment, demonstrating a trend towards 
significance. Although individuals at high risk for psychosis and with schizophrenia have generally been 
found to exhibit higher basal cortisol levels than controls our results suggest that the nature of HPA-axis 
dysfunction may be altered during periods of active psychosis. It may be that a generally overburdened 
HPA-axis stress system becomes decompensated during acute illness episodes, although further work 
is required to confirm this theory. Furthermore, other studies have demonstrated a dissociation 
between HCC and acute cortisol measures (Pulopulos et al., 2014) and thus further studies 




reflect a different aspect of HPA-axis function in schizophrenia. We also demonstrated that HCC 
increased from baseline to month-12 in those with MetS and that MetS was associated with increased 
HCC at follow-up and thus comorbid metabolic risk may contribute to higher cortisol levels observed in 
schizophrenia samples. Longitudinal studies in larger samples investigating the predictive utility of HCC 
as a biomarker of combined schizophrenia-CVD risk and treatment outcome (clinical response and 
adverse effects), and incorporating inflammatory markers and genetic/epigenetic markers of HPA-axis 




5 Supplementary materials 
Supplementary Table 1 Cardiovascular disease risk factors in relation to schizophrenia diagnosis and hair cortisol concentrations (HCC) 
 
Variables Descriptive data Simple linear regression Multiple linear regressiona 
 Patient Control ß (95% CI) p-value ß (95% CI) p-value 
Total n = 16 n = 21     
MetS variables       
 MetS n(%)       
  No 12 (75.0) 19 (90.5) Ref  Ref  
  Yes 4 (25.0) 2 (9.5) 0.04 (-0.26; 0.33) 0.806 0.08 (-0.21; 0.37) 0.557 
 Number of criteria met M(SD) 1.2 (1.3) 1.0 (1.1) 0.02 (-0.07; 0.12) 0.629 0.03 (-0.06; 0.12) 0.517 
 BP criterionb n(%)       
  No 9 (56.3) 12 (57.1) Ref  Ref  
  Yes 7 (43.8) 9 (42.9) 0.11 (-0.10; 0.33) 0.302 0.11 (-0.09; 0.31) 0.263 
  On antihypertensive rx n(%)       
   No 16 (100.0) 20 (95.2) #  #  
   Yes 0 (0.0) 1 (4.8)     
  SBP (mmHg) M(SD) 129.0 (17.5) 124.2 (11.6) -0.00 (-0.01; 0.01) 0.647 0.00 (-0.01; 0.01) 0.943 
  DBP (mmHg) M(SD) 81.5 (15.1) 82.6 (8.6) 0.00 (-0.01; 0.01) 0.766 -0.00 (-0.01; 0.01) 0.858 
 FPG criterionc n(%)       
  No 15 (93.8) 18 (85.7) Ref  Ref  
  Yes 1 (6.3) 3 (14.3) -0.19 (-0.53; 0.16) 0.278 -0.24 (-0.55; 0.08) 0.137 
  On diabetes Rx n(%)       
   No 16 (100.0) 20 (95.2) #  #  
   Yes 0 (0.0) 1 (4.8)     
  FPG (mmol/l) M(SD) 5.08 (0.93) 4.87 (0.64) -0.06 (-0.20; 0.08) 0.416 -0.03 (-0.17; 0.10) 0.606 
 HDL-C criteriond n(%)       
  No 11 (68.8) 17 (81.0)     
  Yes 5 (31.3) 4 (19.0) 0.17 (-0.08; 0.42) 0.167 0.19 (-0.04; 0.43) 0.104 
  HDL-C (mmol/l) M(SD) 1.45 (0.41) 1.60 (0.48) -0.09 (-0.33; 0.15) 0.434 -0.14 (-0.36; 0.09) 0.229 
 Trig criterione n(%)       
  No 15 (93.8) 20 (95.2) #  #  
  Yes 1 (6.3) 1 (4.8)     
  Trig (mmol/l) M(SD) 1.01 (0.36) 0.76 (0.32) 0.00 (-0.31; 0.31) 0.998 0.12 (-0.20; 0.45) 0.443 
 WC criterion n(%)       




  Yes 5 (31.3) 3 (14.3) -0.08 (-0.35; 0.18) 0.516 -0.04 (-0.30; 0.22) 0.744 
  WC (cm) M(SD) 85.2 (14.1) 78.3 (12.4) -0.00 (-0.01; 0.01) 0.630 0.00 (-0.01; 0.01) 0.933 
Other CVD risk variables       
 Physical parameters       
  BMI (kg/m2) M(SD) 25.6 (5.6) 25.9 (6.5) 0.00 (-0.02; 0.02) 0.915 -0.00 (-0.02; 0.02) 0.915 
  HC (cm) M(SD) 94.6 (8.9) 93.3 (11.8) 0.00 (-0.01; 0.01) 0.704 0.00 (-0.01; 0.01) 0.736 
  WHR M(SD) 0.90 (0.08) 0.84 (0.05) -1.14 (-2.70; 0.42) 0.148 -0.26 (-2.11; 1.59) 0.778 
  HR (bpm) M(SD) 93.2 (17.2) 78.4 (11.9) 0.00 (-0.01; 0.01) 0.712 0.01 (0.00; 0.01) 0.054 
 Laboratory parameters       
  TC (mmol/l) M(SD) 4.50 (0.91) 4.38 (0.82) -0.10 (-0.22; 0.03) 0.130 -0.08 (-0.20; 0.03) 0.157 
  TC > 5 mmol/l n(%)       
   No 10 (62.5) 16 (76.2) Ref  Ref  
   Yes 6 (37.5) 5 (23.8) 0.05 (-0.19; 0.29) 0.678 0.01 (-0.21; 0.23) 0.932 
  LDL-C (mmol/l) M(SD) 2.58 (0.69) 2.44 (0.65) -0.11 (-0.27; 0.05) 0.162 -0.09 (-0.24; 0.06) 0.234 
  LDL-C >= 3 mmol/l n(%)       
   No 11 (68.8) 19 (90.5) Ref  Ref  
   Yes 5 (31.3) 2 (9.5) 0.16 (-0.12; 0.43) 0.253 0.09 (-0.19; 0.37) 0.515 
  HbA1c 5.34 (0.37) 5.18 (0.62) 0.06 (-0.15; 0.26) 0.594 0.06 (-0.15; 0.27) 0.578 
  HbA1c >= 6.5%  n(%)       
   No 16 (100.0) 20 (95.2) #  #  
   Yes 0 (0.0) 1 (4.8)     
 CVD history variables       
  On statins n(%)       
   No 15 (93.8) 20 (95.2) #  #  
   Yes 1 (6.3) 1 (4.8)     
  On aspirin n(%)       
   No 16 (100.0) 20 (95.2) #  #  
   Yes 0 (0.0) 1 (4.8)     
a Controlled for age, sex, and schizophrenia diagnostic status  
b All participants who met the blood pressure criterion had blood pressure above the threshold 
c All participants who met the glucose criterion had glucose levels above the threshold 
d No participants were receiving treatment to increase HDL-C 
e No participants were receiving treatment for hypertriglyceridemia  
* p < 0.05 
# Too few observations to conduct analyses 
BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; DBP, diastolic blood pressure; HbA1c, Glycated haemoglobin; HC, hip 
circumference; HDL-C, high-density lipoprotein cholesterol; HR, heart rate; FPG, fasting plasma glucose; LDL-C, Low density lipoprotein cholesterol; MetS, 
metabolic syndrome; Ref, reference category; rx, treatment; SBP, systolic blood pressure; TC, total cholesterol; trig; serum triglyceride; WC, waist 
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Hair cortisol as a neuroendocrine biomarker to evaluate the impact 
of chronic stress on the interaction between neuropsychiatric 
disorders and metabolic syndrome in females 
Abstract 
Background: Rates of metabolic syndrome (MetS) and cardiovascular disease (CVD) are higher in 
individuals with neuropsychiatric disorders (NPDs) compared to the general population, suggesting that 
there are shared pathophysiological pathways underlying the increased CVD risk in NPDs. 
Hypothalamic pituitary adrenal (HPA) axis dysfunction has also been observed in a variety of NPDs 
and in MetS and may be one of the shared explanatory pathways for the co-occurrence. 
Objectives: In a case-control study of NPDs evaluating the factors that contribute to increased risk for 
CVD, our aims were to (i) compare HCC across three NPDs (posttraumatic stress disorder [PTSD], 
Parkinson’s disease and schizophrenia); (ii) investigate the interaction effects of NPDs and MetS on 
HCC. 
Methods: In 354 females of mixed ancestry (PTSD: 139 patients, 128 controls: Parkinson’s disease: 
25 patients, 31 controls, schizophrenia: 11 patients ,19 controls), aged between 18 – 79 years, hair 
samples, representing a three-month retrospective window of cortisol levels, were obtained and 
analysed utilizing liquid chromatography tandem mass spectrometry. We constructed multivariate 
linear regression models to evaluate whether NPDs and MetS comorbidity were associated with HCC 
(reciprocal square root transformed) controlling for potential confounders.  
Results: The overall prevalence of MetS was 33.1% with the highest prevalence in Parkinson’s 
disease patients (56.0%) and the lowest in schizophrenia controls (10.5%).  HCC were significantly 
higher in NPD patients than in controls (p = 0.027) overall. HCC did not differ significantly between the 
three NPD patient groups. Although HCC differed significantly among the three cohorts (p < 0.001) 




Parkinson’s disease cohorts. MetS was not significantly associated with HCC (p = 0.285) and there 
were no significant interactions between NPDs and MetS on HCC (p = 0.111).  
Conclusions: Overall patients had higher HCC than controls, although patterns differed within the 
individual cohorts. HCC did not differ significantly between the three patient groups, but differed across 
the three cohorts overall (patients and controls). The presence of MetS was not associated with HCC. 
Due to significant differences between the cohorts, within cohort case-control investigations may 
provide a better reflection of patterns of HPA-axis dysregulation than cross-cohort comparisons of 
HCC.  
Keywords: Neuropsychiatric disorders; post-traumatic stress disorder; Parkinson’s disease; 
















Individuals with neuropsychiatric disorders (NPDs) have elevated mortality rates and lower life 
expectancy than the general population (Penninx & Lange, 2018; Walker, McGee, & Drus, 2015). 
Although the elevated risk can partly be ascribed to unnatural causes it is largely due to natural causes 
and cardiovascular disease (CVD) in particular (Correll et al., 2017; De Hert, Detraux, & Vancampfort, 
2018; Penninx & Lange, 2018; Walker et al., 2015). Both CVD and NPDs have a major impact on 
society and in the global burden of disease study CVD and psychiatric disorders were the largest 
contributors to disability-adjusted life years (DALYs, 11.9%) and years lived with disability (YLDs, 
22.9%), respectively (Whiteford et al., 2013). Metabolic syndrome (MetS) constitutes a cluster of risk 
factors for CVD and allows for earlier identification, and possible earlier intervention, of individuals with 
increased risk for CVD (Alberti et al., 2009; Penninx & Lange, 2018). MetS has also been associated 
with poorer outcomes in psychiatric conditions, including increased chronicity and treatment resistance 
(Penninx & Lange, 2018). Increased rates of MetS and CVD are found across a number of different 
NPDs  as compared to the general population, suggesting shared mechanisms may be playing a role 
(Bradley & Dinan, 2010; Penninx & Lange, 2018; Vancampfort et al., 2015). 
Although individuals with mental disorders have higher rates of CVD and death due to CVD the 
pathophysiology linking CVD and mental disorder is not well understood (Correll et al., 2017; De Hert et 
al., 2018; Vancampfort et al., 2015). Potential pathways involved include inflammation, autonomic 
nervous system dysfunction, mitochondrial dysfunction, oxidative stress, genes with pleiotropic effects 
and epigenetic mechanisms (De Hert et al., 2018; Vancampfort et al., 2015). HPA-axis dysfunction has 
also been demonstrated both in NPDs and in CVD and may represent a shared pathway contributing 
to the increase in CVD in NPDs (Bradley & Dinan, 2010; Penninx & Lange, 2018). A dysregulated 
HPA-axis can lead to central obesity, metabolic derangements, insulin resistance and inflammation (De 
Hert et al., 2018).  
Various biological markers, including cortisol, show non-specificity for NPDs (Boksa, 2013). A meta-
analysis investigating prognostic biomarkers across disorders found that cortisol was elevated across 




disorder (MDD) (Pinto, Moulin, & Amaral, 2017). There are, however, also differences in the alterations 
of HPA-axis across NPDs, for instance one meta-analysis demonstrated a blunted cortisol stress 
response in patients with schizophrenia, but not in MDD, as compared to controls (Ciufolini, Dazzan, 
Kempton, Pariante, & Mondelli, 2014). Our understanding of the role of the HPA-axis in different NPDs, 
as well as in relation to CVD risk, is limited by the lack of studies directly comparing HPA-axis function 
between different disorders. In fact the number of studies comparing biomarkers across disorders have 
been decreasing over time (Pinto et al., 2017). There are only a few meta-analyses of studies of HPA-
axis functioning in different NPDs, and these have mostly focused on schizophrenia and mood 
disorders (Ciufolini et al., 2014; Pinto et al., 2017).  Although these meta-analyses allow for comparison 
of NPDs versus controls they have by and large not directly compared cortisol levels between 
disorders, likely due to the paucity of studies that have compared cortisol levels between disorders. The 
lack of studies performing cross-disorder investigations limits our ability to more clearly distinguish 
shared versus specific pathophysiological pathways involved in NPDs and the co-occurrence of CVD. 
In three cohorts of NPDs (posttraumatic stress disorder [PTSD], Parkinson’s disease and 
schizophrenia) we first investigated whether hair cortisol concentrations (HCC), as a marker of long-
term HPA-axis function, were associated with each of the aforementioned NPDs compared to controls 
(Chapters 2 - 4). Second, we investigated interaction effects of each NPD and MetS on HCC. For each 
of the three NPDs, there is evidence of adverse CVD related outcomes. Increased rates of MetS, CVD 
and associated increased mortality risk have been demonstrated in both PTSD and schizophrenia 
(Ahmadi et al., 2011; Bartoli, Carra, Crocamo, Carretta, & Clerici, 2013; Correll et al., 2017; Kubzansky, 
Koenen, & Spiro, 2007; Mitchell et al., 2013; Rosenbaum et al., 2015; Vancampfort et al., 2013). MetS 
is also associated with worsened outcomes in patients with Parkinson’s disease and there is some 
evidence that MetS can increase the risk of developing Parkinson’s disease (Bainbridge et al., 2017; 
Nam et al., 2018; Zhang & Tian, 2014). There is also evidence for a dysregulated HPA-axis in all three 
NPDs. Largely elevated basal cortisol levels were observed in patients with Parkinson’s disease and 
schizophrenia as compared to controls (Borges, Gayer-Anderson, & Mondelli, 2013; Bradley & Dinan, 




Shepherd, & Green, 2014; Herrero, Estrada, Maatouk, & Vyas, 2015; Hubbard & Miller, 2019; Soares, 
Pereira, Altmann, de Almeida, & Rieder, 2019), and lower cortisol levels in patients with PTSD than in 
controls (Meewisse, Reitsma, de Vries, Gersons, & Olff, 2007; Morris, Compas, & Garber, 2012; 
Schumacher et al., 2019).  
Our results in the three individual cohorts demonstrated that HCC were significantly higher in PTSD 
patients than trauma exposed controls (TEC, Chapter 2), were non-significantly higher in Parkinson’s 
disease patients than controls (Chapter 3) and were significantly lower in schizophrenia patients than 
controls (Chapter 4). We thus observed different patterns in the three NPDs. MetS was not associated 
with HCC in any of our cohorts and there were no interactions between NPDs and MetS. In this study 
we, firstly, aim to extrapolate those results by directly comparing HCC among the three NPDs. 
Secondly, we investigate whether there is an interaction effect between NPDs overall and MetS on 
HCC. Finally, we examine whether self-perceived stress, as a cross-disorder measure of psychological 
stress, is associated with HCC overall and investigate whether there are interactions between self 
perceived stress, NPD diagnosis, cohort and MetS on HCC. 
2 Methods 
2.1 Study design 
This study is a neuroendocrine ancillary study to ‘Understanding the SHARED ROOTS of 
Neuropsychiatric Disorders and Modifiable Risk Factors for Cardiovascular Disease’ or SHARED 
ROOTS (SR). SR was a cross-sectional matched case-control study investigating the factors that 
contribute to comorbidity of NPDs and MetS utilising a multi-omics approach. Participants were 
enrolled from May 2014 until June 2017 in Cape Town, South Africa and controls were matched to the 
three NPD patient groups based on age, gender, and MetS status. We utilised a purposive sampling 
approach and participants for each of the cohorts were recruited utilising multi-pronged strategies. We 
have previously reported the methods for each of the individual NPD cohorts (Chapters 2-4) and here 




This study was approved by the Health Research Ethics Committee at Stellenbosch University (HREC 
N13/08/115) and conducted according to principles of the seventh revision of the Declaration of 
Helsinki (World Medical Association, 2013). A tiered consenting process was adhered to, allowing 
participants to opt-out of the hair sampling procedure.  
2.2 Participants 
Participants were mixed ancestry (coloured) adults, aged 18 years and older, who provided hair 
samples for neuroendocrine analyses. Patients with a UK Brain Bank clinical diagnosis (Hughes, 
Daniel, Kilford, & Lees, 1992) of idiopathic Parkinson’s disease, a diagnosis of schizophrenia based on 
the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, fourth 
edition (SCID-IV) (First, Spitzer, Gibbon, & Williams, 1997), and meeting the Diagnostic and Statistical 
Manual of Mental Disorders (DSM–5) criteria of PTSD according to the diagnostic evaluation with the 
Clinician Administered Posttraumatic Stress Disorder Scale for DSM–5 (CAPS-5) were included as 
patients in the three respective cohorts. For this study patients were permitted to have common mental 
disorder (CMD) and substance use disorder (SUD) comorbidity as long as the primary diagnosis, 
based on diagnostic interview and clinician assessment, was not deemed to be a substance induced 
disorder. Patients with psychiatric comorbidity were included to optimise the sample size, particularly of 
the schizophrenia and PTSD cohorts.  Further exclusion criteria applied in this study were systemic or 
scalp steroid use, current pregnancy, or pregnancy within the prior three months, and significant 
medical comorbidity (e.g. cancer, HIV, auto-immune disorders). Exclusion criteria applied only to 
controls were lifetime or current serious psychiatric disorder (a psychotic or bipolar disorder) or the 
presence of a possible current psychiatric disorder as based on the history, the Mini International 
Neuropsychiatric Interview (MINI) or current psychotropic medication use. 
MetS was determined based on the harmonized Joint Interim Statement (JIS) criteria (Alberti et al., 
2009), with the presence of any three of the following five risk factors required for a diagnosis of MetS: 
(i) Raised blood pressure (BP), systolic ≥ 130 and/or diastolic ≥ 85 mmHg, or being on antihypertensive 
treatment; (ii) Elevated triglycerides (trig) > 1.70 mmol/l (150 mg/dl) or being on treatment for 




in males, and < 1.3 mmol/l (50mg/dl) in females, or being on treatment for low HDL-C; (iv) Elevated 
fasting glucose (FPG) ≥ 5.6 mmol/l (100 mg/dl) or on treatment for diabetes; (v) Elevated waist 
circumference (WC) according to population and country specific guidelines. We used a WC ≥ 90cm in 
both males and females, as a recent validation study showed this to be the optimal WC cut-off in mixed 
ancestry individuals (Matsha et al., 2013). 
2.3 Procedures 
Diagnostic, clinical, participant-administered assessments and physical procedures were conducted by 
psychiatrists, physicians and nurses across two study visits 24-96 hours apart. Physical measurements 
were conducted in a consistent method in accordance with the WHO stepwise approach to chronic 
disease risk factor surveillance (WHO STEPS) instrument, a standardised instrument designed for 
non-communicable disease surveillance (World Health Organization, 2005). Venous blood samples 
were obtained following an overnight fast (at least 8 hours) and were analysed on the Cobas 6000 
c501 Chemistry Analyser (Roche, Germany) at a commercial internationally accredited laboratory 
(Lancet laboratories) on the same day as sample collection. Hair samples were cut from the posterior 
vertex scalp and were secured, placed into aluminium foil, labelled and sealed inside an envelope and 
stored in dark containers at room temperature. Hair analyses using an established liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) protocol (Gao et al., 2013) were performed 
at the TU Dresden laboratory (Prof Clemens Kirschbaum). Samples were analysed in two batches; a 
pilot sample (n = 21) analysed in September 2014 and the remaining samples in December 2017. The 
proximal 3cm of the hair segments were used for analysis, representing cortisol secretion for the prior 3 
months based on an accepted growth rate of 1cm per month (Wennig, 2000). 
2.4 Measures 
2.4.1 Demographic questionnaire 
Demographic variables included in this manuscript were self-identified gender (male or female), age in 
years (calculated as date of birth subtracted from date of assessment), highest level of education 
(HLOE, defined according to whether secondary education was completed), and employment status 




2.4.2 Medical history questionnaires 
Variables from the medical questionnaires included in this manuscript were: (i) steroid use in the prior 6 
months [split according to whether any systemic steroids were used (oral or parenteral), topical steroids 
where used on the scalp, and any other topical steroid use (dermatologic, inhaled, nasal)], (ii) hormonal 
contraceptive use in prior 6 months (including oral contraceptives and other formulations, such as 
injectable contraceptives), (iii) whether the woman was currently breastfeeding, (iv) current psychiatric 
medication use, (v) any other current medical conditions, and (vi) self-reported tobacco , alcohol, and 
illicit substance use in the prior six months.  
2.4.3 The Mini International Neuropsychiatric Interview (MINI) (Sheehan et al., 1998) 
The MINI version 6.0, a short structured diagnostic interview, was used to diagnose current and lifetime 
psychiatric disorders based on DSM-IV and International Classification of Diseases (ICD-10) criteria.  
2.4.4 The Perceived Stress Scale (PSS) (Cohen, Kamarck, & Mermelstein, 1983) 
The 10-item PSS (PSS-10) was used to measure self-perceived stress with higher scores (range 0 – 
40) indicating higher perceived stress. The PSS has been widely used and has demonstrated 
adequate psychometric properties in multiple settings and languages (Lee, 2012).  
2.4.5 The WHO STEPwise approach to chronic disease risk factor surveillance (World Health 
Organization, 2005) 
The level of physical activity (high, moderate, and low) was determined with the global physical activity 
questionnaire (GPAQ) in the WHO STEPS.  
2.4.6 Hair questionnaire 
A hair questionnaire, designed for this study, assessed hair characteristics and hair care practices. Hair 
related variables reported in this manuscript include (i) whether natural hair colour is black, (ii) whether 
hair had been chemically treated in the prior three months (including colouring, relaxing and perming), 
(iii) the frequency of hair washing (two or more times a week, once a week, less frequent than once a 
week), (iv) whether any additional hair products had been used in the prior three months (such as hair 




exposed to sunlight (less than one hour, 1-2 hours, more than 2 hours). Additional hair related factors 
included the season of sampling, the duration of sample storage (less than 1 year, 1-2 years, 2-3.5 
years) and the batch analysed (pilot, final). 
2.5 Statistical analysis 
The sample size required to distinguish between those with and without MetS was 292 based on  a 
priori sample size estimations computed using means and standard deviations (SD) reported in other 
hair cortisol studies (Stalder et al., 2013; Steudte et al., 2012). Due to the small number of males (n = 6) 
with hair cortisol data, the analysis was restricted to females only. HCC were reciprocal square root 
transformed to meet the assumption of normality. We compared descriptive factors across the three 
cohorts with Pearson chi-square for categorical variables and ANOVA for continuous variables. There 
were very few missing data items and these were excluded from analysis listwise (missing items and 
final sample numbers reported in tables). We regressed NPD cohort (PTSD, Parkinson’s disease, and 
schizophrenia), NPD diagnosis (patient or control) and MetS on HCC in unadjusted and adjusted linear 
regression models. Covariates were age and factors that remained significantly associated with HCC 
when we controlled for age, NPD cohort and NPD status (HLOE, natural hair colour, frequency of hair 
washing, chemical treatment of hair, and breastfeeding). We assessed for interactions between having 
a NPD and MetS. To assess for differences between the NPD patients groups we added an interaction 
term between NPD cohort and NPD diagnosis to the model. To assess whether self-perceived stress 
is associated with HCC we regressed PSS scores on HCC in unadjusted and adjusted analyses and 
investigated for any interactions between PSS scores, NPD status, NPD cohort and MetS on HCC. To 
directly compare HCC between the three NPD patient groups we regressed NPD patient group on 
HCC, in unadjusted and adjusted regression models, that were limited to the patients only. Data were 
analysed with SPSS for windows, version 25.0, all tests were 2-tailed and the level of significance was 






Each of the cohorts have been described previously (Chapters 2 - 4), but brief descriptive data are 
presented in Table 1 for the three NPD cohorts. Numerous factors differed between the patients and 
controls across the three cohorts, including age, HLOE, employment status, natural hair colour, 
chemical treatment of hair, additional hair product use, season sampled, duration of storage, batch 
analysed, hormonal contraceptive use, MetS, tobacco use, alcohol use, illicit substance use, and level 
of physical activity. Between the three NPD patient groups the rates of current comorbid CMDs and 
psychiatric medication use also differed significantly.   
3.2 Neuropsychiatric disorders and hair cortisol concentrations (Table 2) 
HCC were significantly higher in patients than controls in both unadjusted (p = 0.023) and adjusted (p = 
0.027) analyses. NPD cohort was significantly associated with HCC in unadjusted and adjusted 
analyses (p < 0.001). HCC were significantly higher in the schizophrenia cohort than the PTSD cohort 
in unadjusted and adjusted analyses (p < 0.001) and were significantly lower in the Parkinson’s 
disease cohort than the PTSD cohort in unadjusted analysis (p = 0.043) and demonstrated a trend 
towards significance in adjusted analysis (p = 0.055). When the interaction term between NPD cohort 
and NPD status was added, NPD cohort (p < 0.001) and the interaction term (p = 0.013) were 
significantly associated with HCC, but NPD status was not significantly (p = 0.549) associated with 
HCC overall. HCC were higher in PTSD patients than Parkinson’s disease patients, demonstrating a 
trend towards significance (p = 0.057), and were not significantly different between PTSD patients and 
schizophrenia patients (p = 0.399). HCC were significantly higher in PTSD patients than PTSD controls 
(p = 0.003), there was a significant interaction between schizophrenia cohort and controls (p = 0.004), 
such that in the schizophrenia cohort controls had significantly higher HCC than patients, a significant 
interaction was not demonstrated between Parkinson’s disease cohort and controls (p = 0.409) (Figure 
1).  
When we limited analyses to the patients only NPD group demonstrated a trend to significance in 




analysis (p = 0.789) (Supplementary Table 1). HCC were significantly higher in PTSD patients than 
Parkinson’s disease patients in unadjusted (p = 0.033), but not adjusted (p = 0.543) analyses and there 
were no differences between PTSD and schizophrenia patients in unadjusted or adjusted analyses (p 
= 0.792). A post-hoc Tukey test demonstrated that HCC were higher in PTSD patients than 
Parkinson’s disease patients, demonstrating a trend towards significance (p = 0.084), but there were 
no other significant differences between the groups. When we limited the analysis to NPD patients 
without psychiatric comorbidity NPD group was not associated with HCC in unadjusted (p = 0.253) and 
adjusted (p = 0.127) analyses (Supplementary Table 2). Although HCC were not significantly lower in 
PTSD patients than in schizophrenia patients in unadjusted analysis (p = 0.261), this was significant in 
the adjusted analysis (p = 0.046). HCC were not significantly different between patients with PTSD and 
patients with Parkinson’s disease in both unadjusted (p = 0.328) and adjusted (p = 0.848) analyses. 
There were no differences between the groups based on a post-hoc Tukey test. 
 
Figure 1 Hair cortisol concentrations (HCC) according to cohort and case status  
 
Bar chart demonstrating mean HCC levels according to cohort and case status. The model was 
significant (F (348, 5) = 9.11, p < 0.001). HCC were significantly higher in schizophrenia controls than 
all other groups (p ≤ 0.001), excluding schizophrenia patients (p = 0.187). PTSD patients had 
significantly higher HCC than PTSD controls (p = 0.004). There were no other significant differences 
between the groups based on Tukey HSD post hoc test. 
*p < 0.05 




Table 1 Description and comparison of sociodemographic, hair related, behavioural, and clinical factors between patients and controls across the 
three cohorts 
 
Variables Total PTSD Parkinson’s disease Schizophrenia Test statistic p-value 
  Patients Controls Patients Controls Patients Controls   
Total 354 139 129 25 31 11 19   
Socio-demographic          
 Age M(SD) 44.5 (14.7) 40.7 (11.6) 45.9 (14.8) 64.5 (8.4) 55.7 (6.9) 28.3 (7.1) 26.8 (5.8) F(5, 348) = 34.0 <0.001* 
 
Secondary education complete 
n(%) 
       χ²(5) = 19.8 0.001* 
  No 246 (69.5) 100 (71.9) 84 (65.1) 22 (88.0) 27 (87.1) 5 (45.5) 8 (42.1)   
  Yes 108 (30.5) 39 (28.1) 45 (34.9) 3 (12.0) 4 (12.9) 6 (54.5) 11 (57.9)   
 Employed n(%)        χ²(5) = 27.0 <0.001* 
  No 245 (69.2) 97 (69.8) 86 (66.7) 24 (96.0) 24 (77.4) 9 (81.8) 5 (26.3)   
  Yes 109 (30.8) 42 (30.2) 43 (33.3) 1 (4.0) 7 (22.6) 2 (18.2) 14 (73.7)   
Hair related          
 Natural hair colour blacka n(%)        χ²(5) = 12.46 0.029* 
  No 203 (57.5) 79 (57.2) 74 (57.4) 15 (60.0) 11 (35.5) 9 (81.8) 15 (78.9)   
  Yes 150 (42.5) 59 (42.8) 55 (42.6) 10 (40.0) 20 (64.5) 2 (18.2) 4 (21.1)   
 Hair chemically treateda n(%)        χ²(5) = 15.65 0.008* 
  No 111 (31.4) 39 (28.3) 37 (28.7) 16 (64.0) 7 (22.6) 4 (36.4) 8 (42.1)   
  Yes 242 (68.6) 99 (71.7) 92 (71.3) 9 (36.0) 24 (77.4) 7 (63.6) 11 (57.9)   
 Frequency of hair washinga n(%)        χ²(10) = 9.58 0.478 
  ≥ 2 times a week 93 (26.3) 36 (26.1) 36 (27.9) 7 (28.0) 5 (16.1) 4 (36.4) 5 (26.3)   
  1 time a week 169 (47.9) 60 (43.5) 68 (52.7) 12 (48.0) 14 (45.2) 6 (54.5) 9 (47.4)   
  < 1 time a week 91 (25.8) 42 (30.4) 25 (19.4) 6 (24.0) 12 (38.7) 1 (9.1) 5 (26.3)   
 Add on hair productsa n(%)        χ²(5) = 11.83 0.037* 
  No  178 (50.4) 60 (43.5) 71 (55.0) 19 (76.0) 15 (48.4) 6 (54.5) 7 (36.8)   
  Yes 175 (49.6) 78 (56.5) 58 (45.0) 6 (24.0) 16 (51.6) 5 (45.5) 12 (63.2)   
 Average hours in sunb n(%)        χ²(10) = 12.92 0.228 
  < 1 hour 162 (46.6) 59 (43.4) 54 (42.2) 18 (72.0) 14 (48.3) 7 (63.6) 10 (52.6)   
  1-2 hours 106 (30.5) 46 (33.8) 40 (31.3) 5 (20.0) 10 (34.5) 2 (18.2) 3 (15.8)   
  > 2 hours 80 (23.0) 31 (22.8) 34 (26.6) 2 (8.0) 5 (17.2) 2 (18.2) 6 (31.6)   
 Season sampled n(%)        χ²(15) = 28.92 0.016* 
  Summer 76 (21.5) 34 (24.5) 27 (20.9) 3 (12.0) 3 (9.7) 3 (27.3) 6 (31.6)   
  Autumn 85 (24.0) 22 (15.8) 38 (29.5) 11 (44.0) 9 (29.0) 1 (9.1) 4 (21.1)   
  Winter 102 (28.8) 36 (25.9) 43 (33.3) 7 (28.0) 7 (22.6) 4 (36.4) 5 (26.3)   
  Spring 91 (25.7) 47 (33.8) 21 (16.3) 4 (16.0) 12 (75.0) 3 (27.3) 4 (21.1)   
 Duration of storage n(%)        χ²(10) = 48.7 <0.001* 
  Less than 1 year 66 (18.6) 17 (12.2) 34 (26.4) 8 (32.0) 2 (6.5) 1 (9.1) 4 (21.1)   
  1 - 2 years 116 (32.8) 38 (27.3) 46 (35.7) 13 (52.0) 3 (9.7) 6 (54.5) 10 (52.6)   




 Batch analysed n(%)        χ²(5) = 21.07 0.001* 
  Pilot 16 (4.5) 1 (0.7) 8 (6.2) 5 (20.0) 2 (6.5) 0 (0.0) 0 (0.0)   
  Final sample 338 (95.5) 138 (99.3) 121 (93.8) 20 (80.0) 29 (93.5) 11 (100.0) 19 (100.0)   
Clinical           
 Hormonal contraceptive n(%)        χ²(5) = 24.33 <0.001* 
  No 270 (76.3) 95 (68.3) 102 (79.1) 25 (100) 29 (93.5) 9 (81.8) 10 (52.6)   
  Yes 84 (23.7) 44 (31.7) 27 (20.9) 0 (0) 2 (6.5) 2 (18.2) 9 (47.4)   
 Currently breastfeedinga n(%)        χ²(5) = 9.80 0.081 
  No 335 (94.9) 128 (92.8) 124 (96.1) 25 (100.0) 31 (100.0) 11 (100.0) 16 (84.2)   
  Yes 18 (5.1) 10 (7.2) 5 (3.9) 0 (0.0) 0 (0.0) 0 (0.0) 3 (15.8)   
 Topical steroid use n(%)        χ²(5) = 5.46 0.363 
  No 331 (93.5) 129 (92.8) 124 (96.1) 21 (84.0) 29 (93.5) 10 (90.9) 18 (94.7)   
  Yes 23 (6.5) 10 (7.2) 5 (3.9) 4 (16.0) 2 (6.5) 1 (9.1) 1 (5.3)   
 Metabolic syndrome n(%)        χ²(5) = 13.42 0.020* 
  No 237 (66.9) 98 (70.5) 80 (62.0) 11 (44.0) 23 (74.2) 8 (72.7) 17 (89.5)   
  Yes 117 (33.1) 41 (29.5) 49 (38.0) 14 (56.0) 8 (25.8) 3 (27.3) 2 (10.5)   
 Other medical conditions n(%)        χ²(5) = 10.00 0.075 
  No 160 (45.2) 54 (38.8) 59 (45.7) 11 (44.0) 16 (51.6) 9 (81.8) 11 (57.9)   
  Yes 194 (54.8) 85 (61.2) 70 (54.3) 14 (56.0) 15 (48.4) 2 (18.2) 8 (42.1)   
Behavioural          
 Tobacco use n(%)        χ²(5) = 20.94 0.001* 
  No 212 (59.9) 66 (47.5) 87 (67.4) 22 (88.0) 18 (58.1) 6 (54.5) 13 (68.4)   
  Yes 142 (40.1) 73 (52.5) 42 (32.6) 3 (12.0) 13 (41.9) 5 (45.5) 6 (31.6)   
 Alcohol use n(%)        χ²(5) = 12.73 0.026* 
  No 192 (54.2) 70 (50.4) 69 (53.5) 21 (84.0) 19 (61.3) 6 (54.5) 7 (36.8)   
  Yes 162 (45.8) 69 (49.6) 60 (46.5) 4 (16.0) 12 (38.7) 5 (45.5) 12 (63.2)   
 Illicit substance usec n(%)        χ²(5) = 29.42 <0.001* 
  No 337 (95.2) 130 (93.5) 125 (96.9) 25 (100.0) 31 (100.0) 7 (63.6) 19 (100.0)   
  Yes 17 (4.8) 9 (6.5) 4 (3.1) 0 (0.0) 0 (0.0) 4 (36.4) 0 (0.0)   
 Level of physical activitya n(%)        χ²(5) = 25.97 0.004* 
  High 26 (7.4) 8 (5.8) 11 (8.5) 0 (0) 2 (6.1) 1 (9.1) 5 (26.3)   
  Moderate 109 (30.9) 41 (29.7) 44 (34.1) 3 (11.5) 10 (30.3) 6 (54.5) 6 (31.6)   
  Low 218 (61.8) 89 (64.5) 74 (57.4) 23 (88.5) 21 (63.6) 4 (36.4) 8 (42.1)   
Perceived stress scores M(SD) 20.5 (8.9) 27.0 (6.4) 16.9 (7.4) 15.2 (7.7) 12.3 (7.2) 24.8 (9.4) 15.6 (6.0) F(5, 348) = 44.8 <0.001* 
Psychiatric comorbidity          
 Common mental disorderd n(%)        χ²(2) = 14.7 0.001* 
  No 74 (42.3) 49 (35.3) NA 16 (64.0) NA 9 (81.8) NA   
  Yes 101 (57.7) 90 (64.7)  9 (36.0)  2 (18.2)    
 Substance use disorderd n(%)        χ²(2) = 4.17 0.124 
  No 154 (88.0) 120 (86.3) NA 
25 (100.0) 
(64.0) 
NA 9 (81.8) NA   





Current psychiatric medication 
n(%) 
       χ²(2) = 29.6 <0.001 
  No 120 (68.6) 106 (76.3) NA 14 (56.0) NA 0 (0.0) NA   
  Yes 55 (31.4) 33 (23.7)  11 (44.0)  11 (100.0)    
Transformed hair cortisol levels 
M(SD) 
1.22 (0.31) 1.27 (0.30) 1.14 (0.31) 1.14 (0.25) 1.11 (0.29) 1.30 (0.25) 1.56 (0.24) F(5, 348) = 9.11 <0.001* 
a One missing response on this item 
b Six missing responses on this item 
c 14 using cannabis, 8 using methamphetamine and 2 using methaqualone 
d Determined based on the Mini International Neuropsychiatric Interview (MINI) 
* p < 0.05 
 
Table 2 Cohort, case status and metabolic syndrome regressed on hair cortisol concentrations (HCC) 
 
  Simple linear regression Multiple linear regressiona 
    Model 1 Model 2 Model 3 
  ß (95% CI) p-value ß (95% CI) p-value ß (95% CI) p-value ß (95% CI) p-value 
Cohort  <0.001*  <0.001*  <0.001*  <0.001* 
 PTSD Ref  Ref  Ref  Ref  
 SCZ 0.25 (0.14; 0.36) <0.001* 0.28 (0.16; 0.39) <0.001* 0.08 (-0.10; 0.26) 0.399 -0.28 (-0.40; -0.17) <0.001* 
 PD -0.09 (-0.18; -0.00) 0.043* -0.09 (-0.18; 0.00) 0.055 -0.13 (-0.27; 0.00) 0.057 -0.36 (-0.51; -0.21) <0.001* 
NPD status      0.549  0.114 
 Control -0.08 (-0.14; -0.01) 0.023* -0.07 (-0.13; -0.01) 0.027* -0.11 (-0.18; -0.04) 0.003* -0.10 (-0.18; -0.03) 0.006* 
 Patient Ref  Ref  Ref  Ref  
MetS        0.272 
 No Ref  Ref  Ref  Ref  
 Yes -0.01 (-0.08; 0.06) 0.761 0.04 (-0.03; 0.10) 0.285 0.04 (-0.02; 0.11) 0.210 -0.02 (-0.11; 0.08) 0.756 
Cohort*NPD status      0.013*   
 SCZ*Control     0.33 (0.11; 0.56) 0.004*   
 PD*Control     0.07 (-0.10; 0.25) 0.409   
Control*MetS       0.10 (-0.02; 0.23) 0.111 
a Multivariate adjusted model (adjusted for age, education, natural hair colour, frequency of hair washing, chemical treatment of hair, and breastfeeding), n = 352; (one 
participant with missing data related to hair care practices and one participant with missing data on breastfeeding excluded) 
Model 1 – Model without interaction terms: F (11, 340) = 7.10 (p < 0.001*), Adj R² = 0.160 
Model 2 – Interaction between cohort and case status added: F (13, 338) = 6.80 (p < 0.001*), Adj R² = 0.177 
Model 3 – Interaction between case status and MetS added: F (12, 339) = 6.75 (p < 0.001*), Adj R² = 0.164 





3.3 Metabolic syndrome, neuropsychiatric disorder status and hair cortisol concentrations 
(Table 2) 
Rates of MetS differed significantly across the groups and were highest in the Parkinson’s disease 
patients and lowest in the schizophrenia controls. HCC were not significantly associated with MetS in 
unadjusted (p = 0.761) and adjusted (p = 0.285) analyses. When the interaction between NPDs and 
MetS was added to the model neither NPDs (p = 0.114) nor MetS (p = 0.272) were significantly 
associated with HCC overall. Patients without MetS demonstrated significantly higher HCC than 
controls without MetS (p = 0.006), HCC did not differ significantly between patients with and without 
MetS (p = 0.756), and the interaction between NPDs and MetS was not significant (p = 0.111) (Figure 
2). 
 
Figure 2 Hair cortisol concentrations (HCC) according to case status and metabolic syndrome  
 
Bar chart demonstrating mean HCC levels according to NPD case status and metabolic syndrome 
(MetS). The model demonstrated a trend towards significance (F (353, 3) = 2.31, p = 0.076) and HCC 
were significantly higher in patients without MetS than controls without MetS (p = 0.048). There were 
no other significant differences between the groups based on Tukey HSD post hoc test. 
*p < 0.05 






Figure 3 Perceived stress scale (PSS) scores according to cohort and case status  
 
Bar chart demonstrating mean PSS scores according to cohort and case status. The model was 
significant (F (348, 5) = 44.79, p < 0.001) and a post-hoc Tukey test revealed that PSS scores were 
highest in PTSD patients and were significantly higher (p < 0.001) than all the other groups, excluding 
schizophrenia patients. Schizophrenia patients also demonstrated significantly higher PSS scores (p < 
0.001) than all the other groups and PTSD controls had significantly higher PSS scores than 
Parkinson’s disease controls (p = 0.017). 
*p < 0.05 
Error bars ± 2SE 
 
3.4 Self-perceived stress, neuropsychiatric disorder status and hair cortisol concentrations  
PSS scores differed significantly between the six groups (Table 1; Figure 3) and a post-hoc Tukey test 
revealed that PSS scores were highest in PTSD patients and were significantly higher (p < 0.001) than 
all the other groups, excluding schizophrenia patients. Schizophrenia patients also demonstrated 
significantly higher PSS scores (p < 0.001) than all the other groups and PTSD controls had 
significantly higher PSS scores than Parkinson’s disease controls (p = 0.017). PSS scores were 
significantly positively associated with HCC in unadjusted analysis (B = 0.01, 95% CI 0.00; 0.01, p = 
0.002), but not in adjusted analysis (adj B = 0.00, 95% CI -0.00; 0.01, p = 0.210). There were no 
significant interactions between PSS scores and case status on HCC (p = 0.986). There was a trend 
towards significance demonstrated for the interaction between cohort and PSS scores (p = 0.079), 




0.01, 95% CI 0.00; 0.01, p = 0.037), and were inversely associated with HCC in the Parkinson’s 
disease (adj B = -0.01, 95% CI -0.02; 0.00, p = 0.132) and schizophrenia (adj B = -0.01, 95% CI -0.03; 
0.00, p = 0.066) cohorts, demonstrating a trend towards significance in the latter cohort. There were no 
significant interactions between PSS scores and MetS on HCC (p = 0.490) and no other interaction 
terms added were significant. 
4 Discussion 
Our objectives, in a sample of South African mixed ancestry females were to compare HCC between 
three NPDs and investigate interactions between NPDs and MetS on HCC. HCC were significantly 
higher in NPD patients than controls overall. We also found that HCC differed significantly across the 
three cohorts overall, with highest HCC in the schizophrenia cohort, followed by the PTSD and 
Parkinson’s disease cohorts. With respect to differences between the three NPD patient groups, when 
mental disorder comorbidity was included HCC were significantly higher in PTSD than Parkinson’s 
disease patients, but only in unadjusted analysis. When we excluded patients with mental disorder 
comorbidity HCC were significantly higher in schizophrenia patients than PTSD patients in the adjusted 
model. MetS was not significantly associated with HCC and there were no interactions between NPDs 
and MetS. 
HCC were significantly higher in patients with NPDs than controls overall, suggesting HPA-axis 
dysfunction occurs across NPDs. These results are, however, likely influenced by the larger sample 
size of the PTSD cohort. When the interaction between cohort and NPD diagnosis was included HCC 
remained significantly higher in PTSD patients than PTSD controls and the direction of association was 
reversed for the schizophrenia cohort, with higher HCC in the controls than the patients. These results 
align with those demonstrated in the individual cohorts (Chapters 2 - 4). Thus although we 
demonstrated opposite directions of association for PTSD and schizophrenia as compared to controls 
to what has generally been observed (Gajsak et al., 2017; Girshkin et al., 2014; Hubbard & Miller, 
2019; Meewisse et al., 2007; Morris et al., 2012; Schumacher et al., 2019) the consistency in outcomes 




PTSD patients demonstrated the highest self-perceived stress scores, followed by schizophrenia 
patients and scores for both these groups were significantly higher than all the other groups. Perceived 
stress scores were significantly positively associated with HCC in the PTSD cohort and were inversely 
associated with HCC in the schizophrenia cohort, demonstrating a trend towards significance. These 
results further suggest that the relationship between the psychological experience of stress and HCC is 
reversed in these two cohorts, and that in the context of PTSD stress may be associated with 
increased cortisol output and in schizophrenia with a blunted HPA-axis. 
The differences observed in HCC among the three NPD cohorts may not be surprising as the groups 
also differed according to various factors. HCC decreased in the cohorts according to the average age 
of the groups, which aligns with the inverse association demonstrated between age and HCC in our 
control sample (Chapter 6). The pattern observed in the three patient groups mirrored that of the 
cohorts overall, with highest HCC in the schizophrenia patients, followed by the PTSD patients and 
lowest HCC in the Parkinson’s disease patients. In the analysis where the total sample was included 
HCC were higher in PTSD patients than Parkinson’s disease patients, demonstrating a trend towards 
significance. When analyses were limited to the patient groups and psychiatric comorbidity was 
permitted HCC were significantly lower in Parkinson’s disease patients than PTSD patients, but only in 
unadjusted analysis. When patients with psychiatric comorbidity were excluded, HCC were significantly 
higher in schizophrenia patients than PTSD patients in the adjusted model. The sample size was, 
however, significantly reduced once patients with psychiatric comorbidity were excluded. There thus 
appear to be some weak differences between the patient groups. Considering that HCC differed 
significantly among the three cohorts overall and the cohorts differed significantly in various respects 
direct comparisons between the patient groups may not accurately reflect how HCC differ across the 
three NPDs. For instance, although HCC were higher in the schizophrenia patients than the PTSD 
patients, the direction of association between their respective control groups was reversed. Thus higher 
HCC in schizophrenia patients than PTSD patients, and in PTSD patients than Parkinson’s disease 
patients may, for instance, reflect higher HCC in younger cohorts than older cohorts, rather than true 




differences between the three NPD cohorts that case-control comparisons within the NPD cohorts 
likely provide more valid estimates than comparisons across the NPD patient groups.  
Similar to the analyses according to the individual cohorts, HCC were not significantly associated with 
MetS, nor with NPD and MetS comorbidity. The association patterns followed those demonstrated for 
the PTSD cohort (Chapter 2), which again may be ascribed to the larger sample size of the PTSD 
cohort, with non-significantly lower HCC in patients with MetS than those without. Based on analyses of 
the individual cohorts we found that MetS was non-significantly associated with higher HCC across all 
the groups, excluding only the PTSD patients. If we excluded PTSD patients from the total sample we 
demonstrated a trend towards significance (p = 0.072) for higher HCC in individuals with MetS. 
Although our total sample was sufficiently powered to examine associations between MetS and HCC 
once we excluded PTSD patients our power to demonstrate significant associations was reduced and 
may explain why we only found a trend towards significance. Thus for all the groups, excluding PTSD 
patients, our results align with what is generally demonstrated in terms of higher HCC in the context of 
MetS (Kuehl et al., 2015; Stalder et al., 2013). The altered pattern demonstrated in our PTSD cases 
may possibly be due to enhanced HPA-axis negative feedback sensitivity secondary to a dual burden 
of PTSD and MetS (Langerak et al., 2015). Our results also highlight the importance of adjusting for 
metabolic factors in studies assessing for associations between NPDs and cortisol levels. Considering 
the high comorbidity of MetS in NPDs (Bradley & Dinan, 2010; Penninx & Lange, 2018; Vancampfort 
et al., 2015), some of the cortisol related effects observed may be secondary to MetS rather than be 
specific to the NPDs studied. However, we generally observed that the effects related to NPD 
phenotype were larger, particularly for PTSD and schizophrenia, than the effects related to MetS. 
Furthermore, in our Parkinson’s disease patients we observed significant associations between non-
motor symptoms pertaining to depression and anhedonia and HCC (Chapter 3). Our results suggest 
that clinical features related to mental disorder are associated with chronic stress as reflected by long-





4.1 Strengths and limitations 
There are limitations pertaining to the study, such as the cross-sectional nature of the study, the hair 
length requirement resulting in exclusion of many participants and the study being limited to a single 
ethnicity and gender that have been discussed in the individual cohort manuscripts. Here we focus the 
discussion on strengths and limitations particular to the combined analysis conducted here. Although 
the aim of the study was to obtain equivalent sample sizes for the three cohorts, there were various 
factors influencing recruitment of patients with Parkinson’s disease and schizophrenia and thus the 
samples included across the three cohorts differed in size. The three cohorts also differed in various 
other respects, and of particular importance according to age. This can partly be ascribed to the 
epidemiology of the three NPDs, schizophrenia usually has its onset in late-adolescence and early 
adulthood, PTSD can occur at any age, but is observed particularly in younger adults and Parkinson’s 
disease is usually observed in older adults and increases in prevalence with age (American Psychiatric 
Association [APA], 2013; Pringsheim, Jette, Frolkis, & Steeves, 2014). The differences in age 
occurrence make it difficult to disentangle age related effects from those specific to the different NPDs.  
Although our study design allowed estimations within the individual NPDs, there were aspects of the 
study design that limit these investigations across NPD diagnoses. Some of these factors, such as the 
differing epidemiology of the disorders, may not be possible to fully control for. However, certain study 
design features can be adapted to allow for better equivalence across groups. Future studies, aiming to 
compare factors across disorders, should consider methods to increase comparability across groups, 
such as considerations pertaining to age, stage of illness and treatment received. However, even 
considering the limitations to cross-disorder comparisons in this study, the analyses across cohorts still 
provided additional insights to those limited to the individual NPD cohorts and thus emphasize the utility 
of conducting studies across disorders. Furthermore, although the cohorts differed in certain respects 
the participants in the different cohorts completed the same measures and assessments were 





There are few studies directly comparing cortisol levels (HPA-axis function) between different NPDs. 
HCC were significantly higher in patients with NPDs than controls overall, although this varied between 
the cohorts. When the NPD patient groups were directly compared, there were some significant 
findings, that differed depending on whether psychiatric comorbidity was included. We also found that 
HCC differed significantly between the three cohorts overall and that various factors differed among the 
groups, thus suggesting the cohorts were not directly comparable. Our results suggest that evaluating 
case-control effects within the individual cohorts likely provide better estimates of patterns of HPA-axis 
dysregulation present in each of the NPDs than direct cross-disorder comparisons. We also observed 
that overall, excluding PTSD patients demonstrating an inverse pattern, HCC were higher in individuals 
with MetS, demonstrating a trend towards significance. The altered pattern demonstrated for PTSD 
patients suggests that associations between HPA-axis dysfunction and MetS within NPDs may not be 
universal and warrants further investigation. Although our study had several limitations influencing 
cross-cohort comparisons, our results still highlight the benefit of including different NPDs within the 
same study. To accurately determine shared versus unique pathways involved in the pathophysiology 
of NPDs and associated CVD risk more studies are required that directly compare effects across 
NPDs. To better estimate the association between NPDs, HPA-axis dysfunction and CVD risk 
longitudinal studies are required that can evaluate how these systems interact over time and thus 









5 Supplementary materials 
Supplementary Table 1 NPD patient groups regressed on hair cortisol concentrations (HCC), 
psychiatric comorbidity included 
 
  Simple linear regression Multiple linear regressiona 
  ß (95% CI) p-value ß (95% CI) p-value 
Cohort  0.091  0.789 
 PTSD Ref  Ref  
 SCZ 0.02 (-0.15; 0.20) 0.792 0.03 (-0.15; 0.22) 0.792 
 PD -0.13 (-0.36; -0.01) 0.033* -0.05 (-0.21; 0.11) 0.543 
a Multivariate adjusted model (adjusted for age, education, natural hair colour, frequency of hair 
washing, chemical treatment of hair, breastfeeding, and MetS), n = 174; (one participant with 
missing data on breastfeeding excluded) 
Simple linear regression model: F (2, 172) = 2.43 (p = 0.091), Adj R² = 0.016 
Multiple linear regression model: F (10, 162) = 2.80 (p = 0.003*), Adj R² = 0.095 
HCC, hair cortisol concentrations; MetS, metabolic syndrome; PD, Parkinson’s disease; PTSD, 
posttraumatic stress disorder; NPD, neuropsychiatric disorder; SCZ, schizophrenia 
 
Supplementary Table 2 NPD patient groups regressed on hair cortisol concentrations (HCC), 
psychiatric comorbidity excluded 
 
  Simple linear regression Multiple linear regressiona 
  ß (95% CI) p-value ß (95% CI) p-value 
Cohort  0.253  0.127 
 PTSD Ref  Ref  
 SCZ 0.13 (-0.10; 0.35) 0.261 0.23 (0.00; 0.46) 0.046* 
 PD -0.08 (-0.26; 0.09) 0.328 0.22 (-0.21; 0.25) 0.848 
a Multivariate adjusted model (adjusted for age, education, natural hair colour, frequency of hair 
washing, chemical treatment of hair, breastfeeding, and MetS), n = 69 
Simple linear regression model: F (2, 66) = 1.41 (p = 0.253), Adj R² = 0.012 
Multiple linear regression model: F (10, 58) = 2.75 (p = 0.008*), Adj R² = 0.204 
HCC, hair cortisol concentrations; MetS, metabolic syndrome; PD, Parkinson’s disease; PTSD, 
posttraumatic stress disorder; NPD, neuropsychiatric disorder; SCZ, schizophrenia 
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Hair cortisol as a biomarker of stress and resilience in South African 
mixed ancestry females  
Abstract 
Background: Hair cortisol concentrations (HCC) are increasingly used as a biomarker of stress, 
however limited research exists regarding the relationship between HCC and protective factors, such 
as resilience. Additionally, studies measuring HCC need to account for possible confounders, and 
these factors have not been examined in sufficiently diverse settings. 
Objectives: Our objectives were to identify determinants of HCC in a sample of mixed ancestry adults 
and investigate the association of HCC with measures of self-perceived stress and resilience. 
Methods: Our sample comprised 164 females (mean age 46.5 years, SD = 15.0), self-identifying as 
mixed ancestry, who were control participants in a cross sectional case-control study (SHARED 
ROOTS), conducted in Cape Town, South Africa from May 2014 until June 2017. We examined which 
socio-demographic, hair related, clinical and behavioural factors were associated with HCC in both 
unadjusted and adjusted linear regression models.  Furthermore, the relationship of HCC with self-
perceived stress and resilience scores were also examined.   
Results: HCC (Mdn 4.4 pg/ml; IQR 2.8; 11.4) were significantly positively associated with hair product 
use and breastfeeding, and significantly negatively associated with age, level of education, duration of 
sun exposure, duration of storage, and demonstrated a trend towards significance with frequency of 
hair washing, in adjusted models. HCC were inversely associated with CD-RISC scores (adj β = -
0.179, p = 0.012) scores but were not significantly associated with PSS scores (adj β = -0.001, p = 
0.989).   
Conclusions: We identified specific determinants of HCC in our sample, including the first indication 
that sun exposure has an effect on HCC under naturalistic conditions. These potential confounders 




resilience to stress, rather than perceived stress. Further research measuring HCC in more diverse 
settings and populations and including constructs related to resilience are needed.  





















One of the central pathways involved in the physiological response to stress is the hypothalamic-
pituitary-adrenal (HPA) axis, with many of the ensuing effects of stress facilitated through cortisol. 
Cortisol has thus long been investigated as a stress biomarker in various contexts (Chrousos, 2009). 
Utilising cortisol as a biomarker is, however, complicated by the diverse components that can influence 
cortisol secretion, such as diurnal fluctuations, physical activity, food intake and substance use (Stalder 
& Kirschbaum, 2012; Wosu, Valdimarsdóttir, Shields, Williams, & Williams, 2013). Additionally, 
traditional sampling methods used, such as blood, saliva and urine, are more suited to estimating acute 
cortisol levels (Stalder & Kirschbaum, 2012). The measurement of hair cortisol concentrations (HCC) 
provides distinct advantages over traditional cortisol measurement techniques, potentially making it the 
ideal measure of longer-term HPA axis function. HCC are assumed to capture cumulative cortisol 
secretion over periods of several months (Stalder & Kirschbaum, 2012). Hair sampling is non-invasive, 
inexpensive, less influenced by sampling and environmental factors, and samples can be stored at 
room temperature (Wosu et al., 2013). Although hair cortisol appears to be a robust measure, there are 
also confounding factors that need to be accounted for when HCC are investigated as a marker of 
stress. 
Considering that the neuroendocrine effects demonstrated in relation to stress have generally been of 
small magnitude, it is important to identify confounders that can potentially obscure the relationship 
between stress and cortisol (Staufenbiel, Penninx, de Rijke, van den Akker, & van Rossum, 2015). To 
this end, previous studies have been conducted to determine the socio-demographic, hair related, 
behavioral and clinical factors that may be potential confounders (Abell et al., 2016; Dettenborn, Tietze, 
Kirschbaum, & Stalder, 2012; Feller et al., 2014; Garcia-Leon et al., 2018; Staufenbiel et al., 2015). 
Meta-analyses and systematic reviews have also sought to identify the most relevant factors by 
aggregating the results of individual studies (Gray et al., 2018; Stalder et al., 2017; Wosu et al., 2013). 
Some key relationships that have been identified include higher HCC in males, positive associations 
with age and anthropometry, and the impact of hair care practices, such as decreased HCC with 




2013). Raised HCC have also been found in relation to physical or psychological stressors, such as 
shift work, unemployment, caregiving stress and chronic pain (Stalder et al., 2017; Wosu et al., 2013). 
HCC have further been investigated as a correlate of psychometric measures of stress, with self-
perceived stress being the most frequently utilised construct (Stalder et al., 2017). Although there have 
been some significant findings, meta-analyses and systematic reviews have largely found that HCC 
are not associated with self-perceived stress (Stalder et al., 2017; Staufenbiel, Penninx, Spijker, 
Elzinga, & van Rossum, 2013; Wosu et al., 2013). Authors have suggested that the heterogeneous 
results may be related to the complexity in classifying and evaluating stress (Gray et al., 2018). 
To understand the stress response more broadly, it is also important to consider factors that may be 
protective. Generally, more is known about the biological factors related to risk and pathology than 
biological factors related to protection and resilience (Bowes & Jaffee, 2013). Resilience is commonly 
defined as the dynamic process whereby an individual demonstrates positive adaption following 
adversity or stressful situations (Luthar, Cicchetti, & Becker, 2000). Although not all results converge, 
protective factors, such as positive affect and resilience, have generally been associated with lower 
cortisol levels (Dockray & Steptoe, 2010; Steptoe, Dockray, & Wardle, 2009). For instance, a study in 
caregivers of people with autism found that caregiver resilience was significantly negatively correlated 
with the cortisol awakening response (CAR). Furthermore, cortisol levels were significantly higher in the 
low resilience group as compared to the medium and high resilience groups (Ruiz-Robledillo, De 
Andrés-García, Pérez-Blasco, González-Bono, & Moya-Albiol, 2014). In contrast to self-perceived 
stress, the relationship between HCC and resilience has not been extensively examined. A study in 80 
university students found that HCC were significantly negatively correlated with resilience scores 
(Garcia-Leon et al., 2018). Similarly, a study in 27 adolescents demonstrated that HCC were 
significantly inversely associated with dispositional optimism (Milam, Slaughter, Verma, & McConnell, 
2014), while a pilot study in 40 students found that HCC were non-significantly negatively correlated 
with resilience (Ullmann et al., 2016).  
Thus, increased efforts are required to understand the biological processes underpinning resilience 




stress, resilience and HPA-axis functioning (Gray et al., 2018). A major limitation of the existing body of 
research examining hair cortisol as a biomarker of stress, is the lack of geographic, ethnic and cultural 
diversity in samples that have been studied (Wosu et al., 2013). Previous studies seeking to identify the 
basic determinants of HCC have largely been conducted in samples representative of European and 
Caucasian populations (Abell et al., 2016; Dettenborn et al., 2012; Feller et al., 2014; Garcia-Leon et 
al., 2018; Staufenbiel et al., 2015). Investigations have revealed that HCC can vary significantly 
between ethnic groups (Abell et al., 2016; Schreier et al., 2016). These differences may be due to 
biological factors, haircare practices, socio-economic- and contextual- factors (Abell et al., 2016; Wosu 
et al., 2013). Data gleaned from diverse populations can serve to enhance the design, interpretation 
and understanding of stress-related hair cortisol biomarker studies (Wosu et al., 2013).   
We sought to examine whether HCC was a potential biomarker of stress and/or resilience in a South 
African mixed ancestry sample. As no studies utilising hair cortisol have been conducted in this 
population we also wanted to identify the determinants of HCC in a sample drawn from this cultural and 
ethnic group. Identifying potential confounders of HCC is a necessary first step in investigating 
associations between HCC and clinical variables of interest in a specific population. Identification of 
variables that influence HCC can also inform future research utilising HCC in representative 
populations. The variables (or determinants) were selected based on those that have been found to be 
associated with HCC in other settings. We adopted a similar approach to other studies that have 
examined the basic determinants of HCC. We selectively chose a set of variables, each representing 
sociodemographic, hair related, clinical and behavioural features, that we considered to be of relevance 
based on prior research and the specific features of our sample. 
2 Methods 
2.1 Study design 
The objectives addressed here are part of the original aims of a study examining the role of chronic 
stress, as mediated through long-term HPA-axis dysfunction (HCC), in the interaction between 




ancillary study to ‘Understanding the SHARED ROOTS of Neuropsychiatric Disorders and Modifiable 
Risk Factors for Cardiovascular Disease’ or the SHARED ROOTS project. The main aim of the 
SHARED ROOTS (SR) study is to determine the factors that contribute to comorbidity of NPDs and 
MetS, as a marker of cardiovascular disease (CVD) risk. This research question was investigated in 
three cohorts of NPDs, namely posttraumatic stress disorder (PTSD), schizophrenia and Parkinson’s 
disease. The SR study was a cross-sectional matched case-control study. The current aims are 
addressed in the control sample included in SR. 
2.2 Ethical aspects 
This study was approved by the Health Research Ethics Committee at Stellenbosch University (HREC 
N13/08/115) and conducted according to ethical guidelines and principles of the seventh revision of the 
Declaration of Helsinki (World Medical Association, 2013). A tiered informed consent process was 
adhered to, allowing participants to opt-out of the hair sampling procedure. Participants were referred to 
their usual health care service providers for any medical or psychiatric problems warranting further 
investigation and treatment.  
2.3 Setting 
Participants were assessed over 3 years from May 2014 until June 2017. The neuroendocrine ancillary 
study was conceived prior to initiating recruitment and thus all participants were eligible for inclusion. 
We utilised a purposive sampling approach and participants were recruited utilising multi-pronged 
strategies. Control participants were recruited through (i) print, radio and web advertisements; (ii) active 
recruitment within communities by a registered nurse; and (iii) word of mouth by participants already 
recruited. Participants were evaluated at two research sites located in Cape Town, Western Cape, 
South Africa.   
2.4 Participants 
The SR study sample was limited to individuals who self-identified as belonging to the mixed ancestry 
(coloured) ethnic group. The decision to limit the study to one ethnic group was to avoid the effects of 
population stratification on genomic analyses. All participants had to be 18 years and older, willing and 




predominant languages spoken within the Western Cape mixed ancestry population). Participants 
were excluded from hair sampling if they had hair length shorter than 3cm. Hair samples were obtained 
in 241 (51.9%) of the 464 control participants included in SR and the main factor limiting sampling was 
short hair length (see Figure 1 for a flow-diagram of control participants included in this study). Further 
exclusions applied to this sample were (i) any current psychiatric disorder as determined by history, 
diagnostic interview or current psychotropic medication use, (ii) significant medical morbidity (such as 
cancer, auto-immune disorders or chronic infections), (iii) systemic or scalp steroid medication use, (iv) 
current pregnancy or pregnancy within the prior three months. These exclusions were applied as we 
wanted our sample to reflect generally healthy adults without significant psychiatric or medical 
morbidity. 
2.5 Procedures 
Participants attended two to three study visits, each lasting around 3 hours. At the first visit, diagnostic, 
clinical measures and participant-administered measures were completed. The second visit occurred 
within 24-96 hours of the first visit and entailed physical procedures and administration of additional 
lifestyle measures. Assessments were conducted in English or Afrikaans, depending on the language 
preference of participants. Psychiatrists and physicians with experience in psychiatry conducted 
diagnostic and clinical assessments. Research nurses performed the physical procedures and 
personally administered the participant-administered measures to aid comprehension and to 
accommodate the variation in reading level. 
2.5.1 Hair sampling 
About 20mg (3mm diameter) samples of hair were cut with scissors from the posterior vertex scalp. 
Samples were secured, placed into aluminium foil, labelled and sealed inside an envelope. All the 













2.5.2 Hair analysis 
Hair analyses were performed at the TU Dresden laboratory (Prof. Clemens Kirschbaum). Samples 
were analysed in two batches.  A pilot sample comprising the first 21 hair samples obtained were sent 
for analysis in September 2014. The remaining samples were sent for analysis in December 2017. 
Samples were analysed using an established liquid chromatography-tandem mass spectrometry (LC-
MS/MS) protocol (Gao et al., 2013). The proximal 3cm of the hair segments were used for analysis, 
representing cortisol secretion for the prior 3 months based on an accepted growth rate of 1cm per 
month (Wennig, 2000).   
2.6 Measures 
2.6.1 Demographic questionnaire 
Demographic details were collected with a demographic questionnaire. Variables included in this 
manuscript are self-identified gender (male or female), age in years, highest level of education (whether 
secondary education was completed), employment status (being employed for the greater part of the 
prior 12 months), and monthly household income (refused/don’t know, less than ZAR3000, ZAR3000 – 
ZAR6000, more than ZAR6000). 
2.6.2 Medical history questionnaires 
Medical and psychiatric histories were collected with comprehensive medical questionnaires. Clinical 
items reported on in this manuscript are: (i) steroid use in the prior 6 months (split according to systemic 
steroids (oral or parenteral), topical steroids used on the scalp, and any other topical steroid use 
(dermatologic, inhaled, nasal), (ii) hormonal contraceptive use in prior 6 months (including oral 
contraceptives and other formulations, such as injectable contraceptives), (iii) whether a woman was 
currently breastfeeding, and (iv) self-reported tobacco and alcohol use in the prior six months.  
2.6.3 The Mini International Neuropsychiatric Interview (MINI) (Sheehan et al., 1998) 
The MINI is a short structured diagnostic interview developed to diagnose psychiatric disorders based 
on Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) and International Classification of 
Diseases (ICD-10) criteria. The MINI is administered by trained clinicians and takes about 15 minutes 




Participants with any current or major lifetime (psychotic, bipolar) disorders were excluded from this 
analysis. 
2.6.4 The WHO STEPwise approach to chronic disease risk factor surveillance (WHO 
STEPS) (World Health Organization, 2005) 
Height (cm) and weight (kg) were measured according to the WHO STEPS and were used to 
determine body mass index (BMI, kg/m2). The level of physical activity was determined with the global 
physical activity questionnaire (GPAQ) in the WHO STEPS. The GPAQ assesses average physical 
activity in a week occurring in three domains, namely work, travel and recreation. Level of physical 
activity (high, moderate, and low) was determined according to the GPAQ guidelines (World Health 
Organization, 2005).  
2.6.5 The Perceived Stress Scale (PSS) (Cohen, Kamarck, & Mermelstein, 1983) 
We used the 10-item PSS (PSS-10) to measure self-perceived stress. Individuals rate to what extent 
they found their lives unpredictable, uncontrollable or overloaded in the prior month. Each item is rated 
on a 5-point Likert scale (0 = Never; 1 = Almost Never; 2 = Sometimes; 3 = Fairly often; 4 = Very often) 
with a total score ranging from 0 – 40, and higher scores indicate higher perceived stress. The PSS 
has been widely used and has demonstrated adequate psychometric properties in multiple settings 
and languages (Lee, 2012) and Cronbach’s α in this sample was 0.83. The PSS has been the most 
widely used measure of self-perceived stress in hair cortisol research (Stalder et al., 2017).  
2.6.6 Connor-Davidson Resilience Scale (CD-RISC) (Connor & Davidson, 2003) 
The CD-RISC is a 25-item self-rated scale to measure resilience, conceptualised as stress-coping 
ability in the prior month. Items are rated on a 5-point Likert scale (0 = not true at all; 1 = rarely true; 2 = 
sometimes true; 3 = often true; 4 = true nearly all of the time), and scores range from 0-100, with higher 
scores reflecting greater resilience. The CD-RISC has been translated into many languages and 
studied in a variety of populations and a methodological review of resilience scales identified the CD-
RISC as one of the three scales demonstrating the best psychometric properties (Windle, Bennett, & 




2.6.7 Hair questionnaire 
Participants who provided hair samples were questioned about their hair characteristics and hair care 
practices. Hair related variables reported in this manuscript include (i) natural hair colour (black versus 
any other colour), (ii) whether hair had been chemically treated in the prior three months (including 
colouring, relaxing and perming), (iii) the frequency of hair washing (2 or more times a week, once a 
week, less than once a week), (iv) whether any additional hair products had been used in the prior 
three months (such as hair styling and care products e.g. gels, oils and creams, excluding products 
used during hair washing [see Supplementary Table 1]), and (v) average hours per day that hair was 
exposed to sunlight (less than one hour, 1-2 hours, more than 2 hours). Additional hair related factors 
derived from the date sampling occurred included the season sampled (based on the month the 
sample was obtained in) and the duration of storage before sending the samples for analysis (less than 
1 year, 1-2 years, 2-3.5 years). 
2.7 Statistical analysis 
A priori sample size estimations were computed based on the main outcomes of the neuroendocrine 
study. Post-hoc power analysis using G*Power 3.1.9.4 (Faul, Erdfelder, Buchner, & Lang, 2009) with 
the effect size determined based on a linear regression model including all the variables simultaneously 
(adj R2 = 0.182, n = 161, df = 28, α = 0.05) provided an estimated power of 99% in this sample. Due to 
the small number of males with hair cortisol data available (n = 3) we decided to limit our analysis to 
females only to allow us to consider female specific variables. As found in other studies, HCC were not 
normally distributed and were positively skewed (Clark, Osborne, Gallagher, & Watson, 2016). We 
utilised the box-cox family of power transformations to find the optimal normalising transformation, 
utilising the approach and syntax outlined in Osborne, 2010 (Osborne, 2010). The transformation that 
best reduced skewness was a reciprocal square root transformation and the transformed HCC met the 
assumption of normality. We excluded two samples where HCC were not detectable and one outlier 
with transformed HCC 3SD beyond the mean (3955.5 pg/mg), resulting in a final sample of 164 
participants (Figure 1). We compared the included and excluded sample with Pearson chi-square or 




identify the factors associated with HCC in our sample we first conducted simple linear regression with 
each variable, then multiple linear regression controlling for age and other variables found to be 
significantly associated with HCC in simple linear regression. The only missing data were three missing 
responses on the item ‘average hours per day that hair was exposed to sunlight’ and these were 
excluded from analysis listwise, resulting in a sample size for the adjusted models of 161. We 
constructed similar regression models for PSS and CD-RISC total scores, again controlling for the 
same variables in adjusted models. We also assessed for interactions effects between PSS and CD-
RISC scores and interaction effects between these and all other variables. For ease of interpretation, 
reverse transformed geometric means of HCC are also reported. Limited sensitivity and post-hoc 
analyses were conducted to allow for additional interpretation of the data. Data were analysed with 
SPSS for windows, version 25.0, all tests were 2-tailed and the level of significance was set at .05. 
3 Results 
3.1 Participants 
Hair samples were obtained in 241 (51.9%) of the 464 control participants enrolled. A further 77 
participants who provided hair samples were excluded from analysis, resulting in a final sample of 164 
participants (see Figure 1 for details). A comparison of the included (n=164) and excluded participants 
(n=300) are detailed in Table 1. When we controlled for gender differences in BMI, tobacco use, 
alcohol use and level of physical activity were no longer significant between included and excluded 
groups. The duration of storage was no longer significant when we controlled for batch effects and this 
could be explained by the shorter duration of storage (p < 0.001) of the pilot sample. The mean age of 
participants was 46.5 years, ranging from 18 to 79 years and the mean HCC was 16.0 pg/mg (SD 
54.3). The mean PSS score was 16.0 (SD 7.6) and the mean CD-RISC score was 83.1 (SD 14.4). 







Table 1 Comparison of included and excluded participants 
 
Variables Included Excluded Test statistic p-value 
 Number (%) Number (%)   
Total sample 164 (100) 300 (100)   
Socio-demographic     
 Age 48.5 (33.2, 58.5)a 45.3 (33.2, 56.2)a U=23037; Z=-1.13 0.258 
 Gender   χ²(1) = 117.63 < 0.001* 
  Male 0 153 (49.0)   
  Female 147 (100) 164 (51.0)   
 Secondary education complete   χ²(1) = 0.81 0.397 
  No 110 (67.1) 188 (62.9)   
  Yes 54 (32.9) 111 (37.1)   
 Employed   χ²(1) = 0.72 0.367 
  No 104 (63.4) 177 (59.4)   
  Yes 60 (36.6) 121 (40.6)   
 Monthly income   χ²(3) = 2.90 0.408 
  Refused/don’t know 6 (3.7) 16 (5.4)   
  < ZAR3000 51 (31.1) 100 (33.6)   
  ZAR3000 – ZAR6000 52 (31.7) 74 (24.8)   
  > ZAR6000 55 (33.5) 108 (36.2)   
Hair relatedb      
 Natural hair colour black   χ²(1) = 0.23 0.634 
  No 89 (54.3) 46 (57.5)   
  Yes 75 (45.7) 34 (42.5)   
 Hair chemically treated   χ²(1) = 0.10 0.750 
  No 50 (30.5) 26 (32.5)   
  Yes 114 (69.5) 54 (67.5)   
 Frequency of hair washing   χ²(2) = 2.59 0.273 
  ≥ 2 times a week 44 (26.8) 16 (20.0)   
  1 time a week 81 (49.4) 38 (47.5)   
  < 1 time a week 39 (23.8) 26 (32.5)   
 Add on hair products   χ²(1) = 3.36 0.067 
  No 84 (51.2) 31 (38.8)   
  Yes 80 (48.8) 49 (61.3)   
 Average hours in sun   χ²(2) = 0.02 0.989 
  < 1 hour 74 (45.7) 36 (46.2)   




  > 2 hours 39 (24.1) 19 (24.4)   
 Season sampled   χ²(3) = 0.77 0.857 
  Summer 33 (20.1) 15 (19.5)   
  Autumn 45 (27.4) 24 (31.2)   
  Winter 49 (29.9) 24 (31.2)   
  Spring 37 (22.6) 14 (18.2)   
 Duration of storage   χ²(2) = 12.3 0.002* 
  < 1 year 28 (17.1) 29 (37.7)   
  1 - 2 years 58 (35.4) 21 (27.3)   
  2 – 3.5 years 78 (47.6) 27 (35.1)   
Clinical      
 Hormonal contraceptive   χ²(1) = 0.02 0.891 
  No 133 (81.1) 125 (81.7)   
  Yes 31 (18.9) 28 (18.3)   
 Currently breastfeeding   χ²(1) = 0.47 0.494 
  No 157 (95.9) 142 (94.0)   
  Yes 7 (4.3) 9 (6.0)   
 Topical steroid use   χ²(1) = 0.90 0.264 
  No 157 (95.7) 258 (93.1)   
  Yes 7 (4.3) 19 (6.9)   
 Body mass index (BMI) 30.0 (25.8, 35.6)a 27.2 (22.7, 33.2)a U=18380; Z=-3.62 <0.001* 
Behavioural      
 Tobacco use   χ²(1) = 5.55 0.019* 
  No 110 (67.1) 167 (55.9)   
  Yes 54 (32.9) 132 (44.1)   
 Alcohol use   χ²(1) = 8.54 0.003* 
  No 91 (55.5) 124 (41.3)   
  Yes 73 (44.5) 176 (58.7)   
 Level of physical activity   χ²(2) = 7.08 0.029* 
  High 16 (9.8) 54 (19.1)   
  Moderate 56 (34.1) 91 (32.3)   
  Low 92 (56.1) 137 (48.6)   
HCC (pg/mg) 4.4 (2.8, 11.4)a 5.5 (3.0, 9.0)a U=5847.5; Z=-0.92 0.355 
Perceived stress scores 16.0 (11.0, 21.0)a 17.0 (10.0, 23.0)a U=18380; Z=-3.62 0.218 
Resilience scores 86.0 (73.0, 95.8)a 87.0 (73.8, 95.0)a U=18380; Z=-3.62 0.826 
a Median and interquartile range 
b Data on hair related features were only collected in participants who provided hair samples 
* P < 0.05 




Table 2 Regression analyses of factors associated with hair cortisol concentrations (HCC) 
 
Variables Number (%) Simple linear regression Multiple linear regressiona 
    Mean HCCb ß p-value ß p-value 
Total sample 164 (100) 4.93      
Socio-demographic       
 Age 46.5 (15.0)c  -0.115 0.143 -0.177 0.032* 
 Secondary education complete       
  No 110 (67.1) 5.44  Ref  Ref  
  Yes 54 (32.9) 4.05  -0.154 0.049* -0.160 0.040* 
 Employed       
  No 104 (63.4) 4.73  Ref  Ref  
  Yes 60 (36.6) 5.29  0.059 0.451 0.046 0.558 
 Monthly income    0.839  0.901 
  Refused/don’t know 6 (3.7) 4.44 -0.033 0.807 0.021 0.779 
  < ZAR3000 51 (31.1) 5.39 0.033 0.585 0.034 0.699 
  ZAR3000 – ZAR6000 52 (31.7) 4.61 -0.020 0.742 -0.026 0.759 
  > ZAR6000 55 (33.5) 4.89 Ref  Ref  
Hair related       
 Natural hair colour black       
  Nod 89 (54.3) 4.78  Ref  Ref  
  Yes 75 (45.7) 5.21 0.036 0.643 0.031 0.682 
 Hair chemically treated       
  No 50 (30.5) 5.95  Ref  Ref  
  Yes 114 (69.5) 4.55  -0.134 0.087 -0.014 0.854 
 Frequency of hair washing    0.238  0.078 
  ≥ 2 times a week 44 (26.8) 4.88  -0.106 0.278 -0.094 0.326 
  1 time a week 81 (49.4) 4.49  -0.166 0.091 -0.182 0.047* 
  < 1 time a week 39 (23.8) 6.10  Ref  Ref  
 Add on hair products       
  No  84 (51.2) 4.32    Ref  
  Yes 80 (48.8) 5.68  0.151 0.054 0.164 0.025* 
 Average hours in sune    0.012*  0.033* 
  < 1 hour 74 (45.7) 5.24  Ref  Ref  
  1-2 hours 46 (28.4) 3.64  -0.186 0.027* -0.163 0.035* 
  > 2 hours 39 (24.1) 6.37  0.089 0.284 0.056 0.477 
 Season sampled    0.788  0.754 




  Autumn 45 (27.4) 5.36  0.090 0.371 0.046 0.648 
  Winter 49 (29.9) 4.72  0.029 0.774 0.101 0.282 
  Spring 37 (22.6) 4.46  Ref  Ref  
 Duration of storage    0.001*  <0.001* 
  < 1 year 28 (17.1) 8.10  Ref  Ref  
  1 - 2 years 58 (35.4) 5.45  -0.192 0.073 -0.260 0.011* 
  2 – 3.5 years 78 (47.6) 3.90  -0.388 < 0.001* -0.461 < 0.001* 
Clinical        
 Hormonal contraceptive       
  No 133 (81.1) 4.70 Ref  Ref  
  Yes 31 (18.9) 6.04  0.106 0.178 -0.009 0.909 
 Currently breastfeeding       
  No 157 (95.9) 4.69  Ref  Ref  
  Yes 7 (4.3) 18.7  0.252 0.001* 0.186 0.013* 
 Topical steroid use       
  No 157 (95.7) 4.86  Ref  Ref  
  Yes 7 (4.3) 6.90  0.075 0.340 0.072 0.323 
 Body mass index (BMI) 31.2 (8.2)c  -0.059 0.457 -0.049 0.523 
Behavioural        
 Tobacco use       
  No 110 (67.1) 4.88  Ref  Ref  
  Yes 54 (32.9) 5.03  0.016 0.837 0.057 0.440 
 Alcohol use       
  No 91 (55.5) 4.87 Ref  Ref  
  Yes 73 (44.5) 5.00 0.014 0.858 -0.006 0.940 
 Level of physical activity    0.693  0.863 
  High 16 (9.8) 5.90 0.058 0.471 0.054 0.478 
  Moderate 56 (34.1) 4.71 -0.022 0.782 0.021 0.781 
  Low 92 (56.1) 4.91 Ref  Ref  
 Perceived stress score 15.9 (7.6)c  0.125 0.111 -0.001 0.989 
 Resilience score 83.1 (14.4)c  -0.213 0.006* -0.179 0.012* 
a Multivariate adjusted model (adjusted for age, education, average hours in the sun, duration of storage, breastfeeding), n = 161; The multivariate model 
including age and the variables significantly associated with HCC in unadjusted analyses was significant (F (7,153) = 6.46, p < .001), with an R² of 0.228. 
b Reverse transformed geometric means 
c Mean and standard deviation 
d 87 (53.0%) had brown hair, 1 (0.6%) had blonde and 1 (0.6%) red hair colour 
e Three responses were missing for this item, n = 161 
* p-value < 0.05 




3.2 Determinants of hair cortisol concentrations (HCC) (Table 2) 
3.2.1 Socio-demographic 
HCC decreased with increasing age, although this association was only significant in the adjusted 
model (p = 0.032). HCC were significantly lower in those who had completed secondary education 
compared to those who had not in unadjusted (p = 0.049) and adjusted (p = 0.040) models. 
Employment status and income were not significantly associated with HCC in any of the models.  
3.2.2 Hair related 
Hair washing frequency was not associated with HCC overall, though HCC were significantly lower in 
those who washed their hair once a week compared to those washing their hair less frequently in the 
adjusted (p = 0.047) model. HCC were significantly higher in those using additional hair products in the 
adjusted model (p = 0.025), with a trend towards significance in the unadjusted (p = 0.054) model. 
When analysed by hair product category in post-hoc analysis, HCC were significantly higher in those 
who only used hair treatment products (β = 0.166, p = 0.045), but not those who used only hair styling 
products (β = 0.092, p = 0.248) or both treatment and styling products (β = 0.068, p = 0.410), 
compared to those who did not use any additional hair products (see Supplementary Table 1 for hair 
product types). Duration of sun exposure was significantly associated with HCC in both unadjusted (p = 
0.012) and adjusted (p = 0.033) models. HCC were significantly lower in those reporting 1-2 hours of 
sun exposure per day than in those reporting less than 1 hour of sun exposure in unadjusted (p = 
0.027) and adjusted (p = 0.035) models. However, HCC were non-significantly higher in those 
reporting more than 2 hours of sun exposure per day as compared to those with less than 1 hour of 
sun exposure. HCC were significantly associated with duration of storage in unadjusted (p = 0.001)  
and adjusted models (p < 0.001). HCC decreased with longer duration of storage and this relationship 
was significant in unadjusted and adjusted (p < 0.001) models when 2-3.5 years of storage were 
compared to less than 1 year, and significant in the adjusted model (p = 0.011) when 1-2 years of 
storage where compared to less than 1 year of storage. There was also a negative correlation between 
HCC and duration of storage (rs (164) = -0.277, p < 0.001) in post-hoc analysis. Sensitivity analysis 




the final batch than in the pilot batch and duration of storage remained significantly associated with 
HCC (p < 0.001) when we controlled for batch. HCC were not significantly associated with natural hair 
colour, chemically treated hair, and season sampled in any models. 
3.2.3 Clinical factors 
HCC were significantly higher in women who were breastfeeding in unadjusted (p = 0.001) and 
adjusted (p = 0.013) models. HCC were not significantly associated with hormonal contraceptive use, 
topical steroid use, and BMI in any models. On further examination a cubic curve better represented 
the association between BMI and HCC (R² change = 0.036, p = .054) although the model only 
demonstrated a trend to significance (F (3,160) = 2.17, p = .094). When we assessed according to BMI 
categories, HCC were lowest in the overweight group (BMI = 25.0 – 29.9, n = 45, mean HCC = 4.13) 
and were significantly lower than the normal weight group (BMI = 18.5 – 24.9, n = 34, mean HCC = 
6.43, p = 0.035), but not the obese group (BMI ≥ 30, n = 82, mean HCC = 4.74, p = 0.405). HCC were 
also not significantly associated with systemic steroid use (adj β = 0.034, p = 0.623) or with any steroid 
use (systemic and topical combined, adj β = 0.071, p = 0.296) in sensitivity analysis including those 
with systemic steroid use (n = 168). 
3.2.4 Behavioural factors 
HCC were not associated with tobacco or alcohol use, nor with level of physical activity, in any of the 
models.  
3.2.5 Stress and resilience 
PSS scores were significantly inversely correlated with CDRISC scores (rs (164) = -0.386, p < 0.001). 
HCC increased with increased severity of perceived stress but there was no significant relationship 
demonstrated in any of the models.  HCC were significantly inversely associated with CD-RISC scores 
(Figure 2) in unadjusted (p = 0.006) and adjusted models (p = 0.012). Neither PSS, nor CD-RISC 
scores demonstrated significant curvilinear associations with HCC when quadratic and cubic terms 
were added to the models. There was a significant interaction demonstrated between CD-RISC scores 
and level of education (p = 0.023), such that CD-RISC scores remained significantly inversely 




and was not significantly associated with HCC in those who had (adj β = 0.076, p = 0.572). There were 
no other significant interactions demonstrated for PSS or CD-RISC scores and the other variables 
investigated. In sensitivity analysis including participants with common mental disorders (n = 198), the 
results remained unchanged with no significant association demonstrated between PSS scores and 
HCC (adj β = 0.014, p = 0.847) and an inverse significant association demonstrated between CD-RISC 
scores and HCC (adj β = -0.179, p = 0.008). 
 
Figure 2 Scatterplot demonstrating significant inverse relationship between hair cortisol 
concentrations (HCC) and resilience scores 





We investigated the relationship between HCC and key factors previously demonstrated to influence 
HCC, in a sample of South African mixed ancestry females. HCC were significantly associated with 
age, level of education, hair product use, duration of sun exposure, duration of storage and 
breastfeeding, and demonstrated a trend towards significance with frequency of hair washing, in 
adjusted models. Additionally, we demonstrated that HCC were significantly inversely associated with 
resilience scores, but were not significantly associated with self-perceived stress scores. HCC were not 
significantly associated with natural hair colour, chemically treated hair, season sampled, hormonal 
contraceptive use, topical steroid use, tobacco use, alcohol use, level of physical activity, BMI, and 
employment status in any of the models.  
We demonstrated an inverse relationship between age and HCC, which is contrary to what has been 
found overall, with HCC increasing with advancing age in adults (Stalder et al., 2017; Wosu et al., 
2013). Although some studies have not found HCC to be associated with level of education (Kuehl et 
al., 2015; Staufenbiel et al., 2015), our results align with other studies that have demonstrated higher 
HCC in individuals with less formal education (Orta et al., 2018; Wosu et al., 2013). An earlier 
systematic review suggested that HCC are increased in unemployed individuals (Wosu et al., 2013), 
but we did not demonstrate a relationship between employment status and HCC, although our results 
may have been influenced by the high rate of unemployment (63.4%). We also did not demonstrate an 
association between monthly income and HCC, though some studies have demonstrated higher HCC 
in lower income groups (Serwinski, Salavecz, Kirschbaum, & Steptoe, 2016; Ursache, Merz, Melvin, 
Meyer, & Noble, 2017). 
Unlike other studies, we did not demonstrate higher HCC in individuals with black hair colour (Abell et 
al., 2016; Staufenbiel et al., 2015). This relationship is, however, usually found when black hair is 
compared to blonde hair and 98.8% of our sample had either black or brown hair. Contrary to a recent 
meta-analysis (Stalder et al., 2017) we did not demonstrate a significant association between 
chemically treated hair and HCC. Lower HCC have been associated with an increased frequency of 




of hair washing in our sample, with lowest levels reported in those washing their hair once a week than 
in those washing their hair less frequently. We also found that individuals who reported using any 
additional hair products on their hair had higher HCC and this effect was strongest for those who only 
used hair treatment products. As has previously been suggested, more frequent hair washing may lead 
to a washout effect (Staufenbiel et al., 2015), and chemical treatments of hair may damage the hair 
structure further contributing to this washout effect (Cooper, Kronstrand, & Kintz, 2012). We postulate 
that using additional hair products, particularly treatment products, may form a protective layer over 
hair, thus slowing degradation and washout effects.  
Similar to other studies (Abell et al., 2016; Steudte-Schmiedgen et al., 2017; Wikenius et al., 2016) we 
demonstrated a significant decline in hair cortisol with increased storage time and we also found that 
HCC differed significantly according to the batch analysed in sensitivity analysis. Most studies do not 
report on the duration of storage nor the batch analysed and our results indicate that these factors 
should be considered in study design and analyses.  
In experimental paradigms exposure to ultraviolet (UV) radiation have been associated with reductions 
in HCC (Grass et al., 2016; Wester, van der Wulp, Koper, de Rijke, & van Rossum, 2016). We included 
two variables generally considered to be associated with UV exposure, namely season sampled and 
the average daily duration of sunlight exposure. According to our knowledge, our study is the first to 
demonstrate a significant association between HCC and duration of sun exposure under naturalistic 
conditions. HCC were significantly lower in individuals reporting 1-2 hours of sun exposure per day, as 
compared to those reporting less than one hour of sun exposure per day, however, HCC were highest 
in those reporting more than 2 hours of sun exposure per day. Duration of sun exposure per day may 
also be linked to factors other than UV exposure, such as increased sweating, which has been 
associated with increased HCC in other samples (Wester et al., 2017), although experimental work did 
not find evidence for the acute effects of sweating on HCC (Grass et al., 2016).  
Similar to findings from other studies, hormonal contraceptive use did not appear to be a major factor 
influencing HCC in our sample (Stalder et al., 2017; Wosu et al., 2013). We, however, demonstrated 




excluded women who had delivered within the prior three months and post-hoc analysis demonstrated 
that results remained unchanged when duration since last pregnancy was included in the model. 
Breastfeeding was also not associated with any socio-economic factors (e.g. education, employment 
and income), suggesting breastfeeding may influence the HPA-axis directly. Although some studies 
specifically exclude breastfeeding women (Jackson, Kirschbaum, & Steptoe, 2017), most studies do 
not account for women who may be breastfeeding. Although preliminary, our results suggest 
breastfeeding may have a significant effect on HPA-axis function. Similar to other studies, neither 
topical, nor systemic steroid use were associated with HCC in our sample (Schreier et al., 2016; 
Wester et al., 2017). Synthetic steroids can decrease endogenous production of cortisol and cause 
cross-reactivity (Raul, Cirimele, Ludes, & Kintz, 2004), although the latter is less likely with LC-MS/MS 
than with immunoassay methods (Abell et al., 2016; Russell et al., 2015). Although a large 
epidemiological study also utilising LC-MS/MS demonstrated significantly higher HCC  in relation to 
topical and systemic steroid use (Abell et al., 2016), suggesting our sample may have been under 
powered to detect a significant effect. To assess for effects of anthropometry we included BMI. 
Overwhelmingly research has demonstrated a positive relationship between HCC and BMI  (Abell et 
al., 2016; Stalder et al., 2017). Although not significant, our results suggest a more complex curvilinear 
(cubic) relationship between BMI and HCC with lowest levels in the overweight group and levels 
increasing as BMI changes in both directions. Importantly, our sample likely had an overrepresentation 
of obese individuals as 50% of our sample had a BMI falling within the obese category. This was likely 
due to the sampling strategy used, where efforts were directed towards recruiting more participants 
with possible MetS.  
In alignment with the majority of previous research (Stalder et al., 2013; Staufenbiel et al., 2015), 
neither tobacco use nor alcohol use was associated with HCC in our sample. Of note, we excluded 
individuals with substance use disorders and studies have reported altered HCC in relation to alcohol 
use disorders (Muehlhan et al., 2018; Stalder et al., 2010). We demonstrated no clear relationship 
between level of physical activity and HCC in our sample. Although some studies have similarly not 




2015), other studies have found higher HCC in relation to higher levels of physical activity (Garcia-Leon 
et al., 2018; Ullmann et al., 2016). The small number of individuals reporting high levels of physical 
activity likely affected our results. Males reported higher rates of tobacco use, alcohol use and higher 
levels of physical activity, thus a sample representing both genders might have exhibited altered 
relationships. 
We demonstrated a non-significant positive association with perceived stress scores and a significant 
negative association with resilience scores and HCC. Furthermore, similar to other studies, perceived 
stress scores and resilience scores were inversely correlated (García-León, Pérez-Mármol, Gonzalez-
Pérez, García-Ríos, & Peralta-Ramírez, 2019). Our results align with a model whereby increased 
perceived stress is associated with increased long-term cortisol levels and resilience with lower long-
term cortisol levels. Generally, the extant literature demonstrates the lack of a significant relationship 
between self-perceived stress and HCC (Stalder et al., 2017; Staufenbiel et al., 2013; Wosu et al., 
2013) and this may be related to the way self-perceived stress is conceptualised and measured (Gray 
et al., 2018). Our results, in conjunction with other recent studies (García-León et al., 2019; Milam et al., 
2014), suggest that HCC may be a biomarker of stress resilience. It is also apparent that a 
unidimensional approach to assessing psychological constructs related to stress does not adequately 
capture the picture and that additional insights can be gleaned by incorporating assessments of 
resilience and other protective factors. Although sensitivity analysis revealed that resilience scores 
remained significantly associated with HCC when individuals with common mental disorders were 
included the relationship between resilience and HCC warrants further investigation as research 
suggests the interaction between resilience and HPA-axis function may vary according to 
psychopathology and environmental exposures. For instance, in a sample of low-income children, 
lower morning saliva cortisol levels were associated with higher resilience in non-maltreated children, 
but not in maltreated children (Cicchetti & Rogosh, 2007). We also demonstrated a significant 
interaction between level of education and resilience on HCC, suggesting that resilience was primarily 




A review of biomarkers for resilience identified salivary cortisol as a potentially suitable biomarker due to 
the demonstrated relationship, and saliva samples being fairly simple, cost-effective, and non-invasive 
to collect and analyse (Walker, Pfingst, Carnevali, Sgoifo, & Nalivaiko, 2017). Based on the results from 
our study and other recent studies (García-León et al., 2019; Milam et al., 2014), as well as the 
simplicity of collecting and storing hair samples, HCC may be even better suited. There are, however, 
also important limitations influencing the use of hair samples. The major factor limiting sampling in our 
study was the requirement that scalp hair had to be 3cm or longer. This contributed to the exclusion of 
the majority of males. The scalp hair length requirement has been demonstrated to lead to 
disproportionate exclusion of males and individuals of specific cultural and ethnic groups in other 
settings as well (Kalmakis, Meyer, Chiodo, & Leung, 2015; Pacella, Hruska, Steudte-Schmiedgen, 
George, & Delahanty, 2017; Simmons et al., 2016). Investigators have instituted approaches to 
circumvent this limitation, such as to use hair samples of shorter length and to shave hair from the 
forearm in military samples (Groer, Kane, Williams, & Duffy, 2015; Mewes, Reich, Skoluda, Seele, & 
Nater, 2017). Although the ideal method of sampling has not been established, it is clear that methods 
need to take cognisance of cultural, sex based and ethnic practices related to hairstyling and hair care. 
4.1 Strengths and limitations 
Our study is cross-sectional and we cannot comment on any cause-effect relationships. Moreover, 
although post-hoc analyses demonstrated overall adequate power, our sample may still have been 
underpowered to detect specific associations. Similar to other studies examining the determinants of 
HCC (Abell et al., 2016; Dettenborn et al., 2012; Feller et al., 2014; Garcia-Leon et al., 2018; 
Staufenbiel et al., 2015) and due to the exploratory nature of our study, we did not control for multiple 
comparisons. We utilised a purposive sampling approach and thus our sample does not reflect a 
random selection and results obtained must be viewed in this light. Furthermore, our sample was 
limited to a single ethnic group and sex. Notwithstanding, our sample appeared to be representative of 
South African mixed-ancestry women in terms of education and employment status, with the 
percentage that had completed secondary education (32.9%) roughly equivalent to the national 




employed (40.8%) was also roughly equivalent to the national average (42.3%) (Statistics South Africa, 
2013). Investigation and validation of the factors identified in this study in larger community based 
cohorts with broader ethnic and cultural representation would be a prudent next step. However, our 
study is one of the first to examine the basic determinants of HCC in a sample representing a different 
geographic, ethnic and cultural setting than in most studies conducted thus far. In this context, our 
study can be considered as a starting point to guide further research in more diverse groups. Our study 
is also one of the first studies to include measures of resilience alongside measures of self-perceived 
stress and to demonstrate the importance of doing so. 
4.2 Conclusions 
The main determinants of HCC in our sample of mixed ancestry females included age, level of 
education, hair product use, duration of sun exposure per day, duration of sample storage, batch 
analysed and breastfeeding. These factors need to be taken into consideration in the design, 
implementation and analysis of future studies. Future studies are also required to replicate and further 
interrogate the novel associations demonstrated between hair product use, breastfeeding, duration of 
sun exposure and HCC. Hair sampling procedures also need to be adapted to allow for equivalent 
inclusion of participants of different sexes and ethnic groups. We demonstrated a significant inverse 
association between HCC and resilience scores, alongside a non-significant positive association 
between self-perceived stress and HCC. The association between resilience and HCC was primarily 
found in women who had not completed secondary level of education, suggesting resilience may have 
a greater protective effect on long-term HPA-axis function in women with lower levels of education. Our 
results underscore the importance of taking a broader perspective in stress research, which is largely 
pathology driven. Including assessments to tap into constructs related to protective factors, in addition 
to assessments of risk/psychopathology, can provide additional insights into the links between 
stressors, psychological responses and biological processes. Akin to biomedical research overall, there 
is a lack of ethnic, geographic and cultural diversity in research utilising HCC. Further research utilising 
HCC in more diverse settings and populations will improve our understanding of hair cortisol as a 




5 Supplementary materials 
Supplementary Table 1 Types of hair products used according to indication 
 
Hair product type Total Hair product indication 
  Styling Treatment 
 Number (%) Number (%) Number (%) 
Total 164  42  72  
Product types    
 Gel 16 (9.8) 16 (36.4) 6 (8.3) 
 Mousse 2 (1.2) 2 (4.5) 0 (0.0) 
 Spray 10 (6.1) 4 (9.5) 6 (8.3) 
 Cream 33 (20.1) 6 (13.6) 33 (45.8) 
 Serum 19 (11.6) 17 (38.6) 2 (2.8) 
 Grease 3 (1.8) 2 (4.5) 2 (2.8) 
 Oil 26 (15.9) 1 (2.3) 26 (36.1) 
 Silicone 8 (4.9) 5 (11.4) 4 (5.6) 
 Leave-in conditioner 4 (2.4) 0 (0.0) 4 (5.6) 
 Placenta 5 (3.0) 0 (0.0) 5 (6.9) 
None of the individual product types were significantly associated with HCC 
HCC, hair cortisol concentrations 
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The association between cognitive functioning and hair cortisol 
levels in South African mixed ancestry females  
Abstract 
Background: Glucocorticoids can influence cognitive function, particularly declarative memory and 
executive functions. Hair cortisol concentrations (HCC) reflect longer-term hypothalamic pituitary 
adrenal (HPA) axis function and can thus provide insight as to whether chronically dysregulated cortisol 
is associated with cognitive impairments.  
Objectives: Our objectives were to investigate whether cognitive function in domains sensitive to 
glucocorticoids (declarative memory, executive functions) were associated with higher HCC as 
compared to other cognitive domains and global cognitive functioning in a sample of 153 mixed 
ancestry females, aged between 18 and 79 years. 
Methods: Our sample comprised 153 females (mean age 46.1 years, SD = 15.1) who were control 
participants in a cross sectional case-control study (SHARED ROOTS), conducted in Cape Town, 
South Africa from May 2014 until June 2017. We examined whether performance on neurocognitive 
tests were associated with HCC in both unadjusted and adjusted linear regression models.     
Results: Verbal working memory (digit span backwards) demonstrated a significant inverse 
association with HCC in both unadjusted (p = 0.010) and adjusted (p = 0.043) analyses. Performance 
on the other domains assessed (immediate and delayed memory, visuospatial, language, attention, 
and executive function) as well as global cognitive function were not associated with HCC in 
unadjusted and adjusted analyses.  
Conclusions: Poorer performance on tests of working memory were associated with higher HCC, 
suggesting stress related effects may impair working memory. We thus demonstrated cortisol related 
effects in one of the cognitive domains frequently shown to be sensitive to the effects of glucocorticoids, 




























Glucocorticoids play a central role in learning and memory, especially pertaining to adaptations 
following exposure to stressors (de Kloet, Oitzl, & Joëls, 1999; Lupien, Maheu, Tu, Fiocco, & 
Schramek, 2007). Cortisol influences these processes by binding to glucocorticoid (GR) and 
mineralocorticoid (MR) receptors in the brain. MR are concentrated in the hippocampus, whereas GR 
are more widely distributed throughout the brain, with highest density demonstrated in the prefrontal 
cortex (de Kloet et al., 1999; Lupien et al., 2007; Lupien, McEwen, Gunnar, & Heim, 2009).  
Glucocorticoids can influence the structure and function of the hippocampus and prefrontal cortex 
through both genomic (gene-expression) and non-genomic (rapid-signalling) mechanisms (McEwen, 
Nasca, & Gray, 2016). MR receptors have a high affinity for cortisol and are usually occupied under 
basal conditions, whereas GR receptors have a low affinity and are occupied when cortisol levels 
increase, such as during stress (de Kloet et al., 1999; Lupien et al., 2007). GR and MR appear to play 
different roles in learning and memory processes and these are influenced by the comparative 
activation of GR and MR (de Kloet et al., 1999; Lupien et al., 2007). Mildly elevated glucocorticoids with 
associated increased GR activation enhance long-term potentiation (LTP), whereas when cortisol 
levels are too low, or too high LTP is decreased (de Kloet et al., 1999; Lupien et al., 2007). A 
dysregulated hypothalamic pituitary adrenal (HPA) axis can thus impair cognitive processes, 
particularly those related to the hippocampus (short and long-term memory) and the prefrontal cortex 
(executive functions and working memory) (Lupien et al., 2007; McEwen et al., 2016). 
Both exogenous administration, and endogenous increases in glucocorticoids following stressful 
exposures, can influence memory and executive functions (Het, Ramlow, & Wolf, 2005; Sauro, 
Jorgensen, & Pedlow, 2003; Shields, Bonner, & Moons, 2015). The acute effects of cortisol are related 
to both improved and worsened cognitive function which appear to be time-dependent. For instance, 
glucocorticoids administered prior to retrieval impaired recall, but demonstrated mixed effects when 
administered prior to learning, impairing recall in the morning and improving recall in the afternoon (Het 
et al., 2005). Similarly exogenously administered glucocorticoids initially impaired working memory 




converse was demonstrated for tests of inhibition (Shields et al., 2015). Meta-analyses have also 
demonstrated that acute stress exposure was associated with both increased glucocorticoid levels and 
poorer memory performance in animal and human studies, and in humans cortisol levels were 
correlated with declarative memory performance (Sauro et al., 2003). Although there are some 
inconsistencies, studies have also demonstrated that higher basal cortisol levels are associated with 
poorer performance on cognitive tests, particularly tests related to memory and executive functions 
(Feeney, O’Halloran, & Kenny, 2018; Franz et al., 2011; Li et al., 2006; Lupien et al., 2009; McLennan, 
Ihle, Steudte-Schmiedgen, Kirschbaum, & Kliegel, 2016; Pulopulos et al., 2014). 
The chronic effects secondary to a dysregulated HPA-axis are, however, likely to be different to the 
acute effects of cortisol and may be related to immune system dysfunction, and altered brain structure 
and function (Shields et al., 2015). Elevated glucocorticoids are associated with hippocampal atrophy 
and structural changes in the prefrontal cortex and amygdala (Lupien et al., 1998, 2009). The traditional 
samples utilised to measure basal cortisol levels (e.g. saliva, blood and urine) are better suited to 
determine acute cortisol levels (Stalder & Kirschbaum, 2012). In recent years hair cortisol 
concentrations (HCC) have been established as a useful marker of longer-term HPA axis function 
(Stalder et al., 2017). Studies are increasingly investigating the association between HCC and 
neurocognitive function in both clinical (Aas et al., 2019; Ben Assayag et al., 2017; Downey et al., 2015; 
Ogawa, Lee, Yamaguchi, Shibata, & Goto, 2017; Pereira et al., 2019) and community samples 
(Feeney et al., 2018; McLennan et al., 2016; Pulopulos et al., 2014). Most of the studies have, 
however, been conducted in developed regions and there is a lack of representation of studies 
examining associations between neuroendocrine markers of stress and cognitive performance from 
low and middle-income countries (James, Grace, Pan, Combrinck, & Thomas, 2019). Furthermore, as 
psychosocial stress exposure and HPA-axis function, including HCC, can vary according to ethnicity it 
is important to investigate for associations between HPA-axis function and cognitive performance in 
more diverse populations and settings (Abell et al., 2016; Schreier et al., 2016; Wosu, Valdimarsdóttir, 
Shields, Williams, & Williams, 2013). Our aim was to investigate, in a South African mixed ancestry 




(declarative memory, executive functioning and working memory) as compared to other cognitive 
domains and overall cognitive functioning.  
2 Methods 
2.1 Study design 
Here we investigate one of the original aims of a neuroendocrine ancillary study in the control sample 
included in a cross-sectional matched case-control study (SHARED ROOTS [SR]). The controls were 
group matched based on age and gender to three neuropsychiatric disease (NPD) cohorts 
(posttraumatic stress disorder (PTSD), schizophrenia and Parkinson’s disease). We have previously 
reported on the determinants of HCC in the current sample and for detailed methods consult Chapter 
6.  
Participants were assessed over 3 years from May 2014 until June 2017 in Cape Town, South Africa. 
This study was approved by the Health Research Ethics Committee at Stellenbosch University (HREC 
N13/08/115) and conducted according to ethical guidelines and principles of the seventh revision of the 
Declaration of Helsinki (World Medical Association, 2013).  
2.2 Participants 
Participants were mixed ancestry (coloured) adults, aged 18 years and older, who provided hair 
samples for neuroendocrine analyses. Further exclusions applied to this sample were (i) any current 
psychiatric disorder as determined by history, diagnostic interview or current medication use for a 
psychiatric condition, (ii) significant medical morbidity (such as cancer, auto-immune disorders or 
chronic infections), (iii) systemic or scalp steroid medication use, (iv) current pregnancy or pregnancy 
within the prior three months. We also excluded participants with any factors potentially influencing 
cognitive functioning, such a previous cerebrovascular incidents (CVAs, n = 4) and a history of a head 
injury with loss of consciousness (n = 7).  
2.3 Procedures 
Participants attended two to three study visits, each lasting around 3 hours. At the first visit, diagnostic, 




hours of the first visit and entailed neurocognitive testing, physical procedures and administration of 
additional lifestyle measures. Neurocognitive testing was performed by research and clinical 
psychologists.  
2.3.1 Hair analysis 
The proximal 3cm of hair samples cut from the posterior vertex scalp were analysed with liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) at the TU Dresden laboratory (Prof 
Clemens Kirschbaum).   
2.4 Measures 
2.4.1 Neurocognitive assessments 
2.4.1.1 The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) 
(Randolph, 1998) 
The RBANS is a brief neurocognitive battery, with an administration time of 30 minutes and includes 
the following domains and tests: (i) immediate memory (list learning and story memory); (ii) 
visuospatial/constructional (figure copy and line orientation); (iii) language (picture naming and 
semantic fluency); (iv) attention (digit span and coding); (v) and delayed memory (list recall, list 
recognition, story memory, and figure recall). A total score, reflecting overall cognitive performance is 
derived by summing the scores for the various domains. 
2.4.1.2 The Wechsler Abbreviated Scale of Intelligence (WASI) (Wechsler, 1999) 
The two subtest version of the WASI was used to estimate intellectual functioning. This is a short 
(administration 15 minutes) reliable measure of intelligence and scores on vocabulary (verbal 
intelligence) and matrix reasoning (non-verbal intelligence) are combined to provide an impression of 
global intellectual ability.  
2.4.1.3 Executive function and working memory tests 
Additional tests of executive function were administered as the RBANS does not include executive 
function tests. These tests were only administered in the controls included in the PTSD and 




specifically designed to assess cognition in individuals diagnosed with schizophrenia (Nuechterlein & 
Green, 2002). The following tests of executive function were included: The Ruff Figural Fluency Test 
(RFFT) (Ruff, 1996) to assess executive functioning and non-verbal fluency; (ii) The Stroop Color and 
Word Test (Golden & Freshwater, 1978) to assess selective attention, cognitive flexibility and 
resistance to interference from outside stimuli; Spatial span and digit span from the Wechsler memory 
scale (WMS-III) (Wechsler, 1997) to assess visuospatial (non-verbal) and verbal working memory 
respectively. 
Higher scores on all the tests and domains indicate better performance, excluding only the error ratio 
from the RFFT. 
Additional measures included demographic, medical history and hair questionnaires described in 
Chapter 6. Variables included in analyses were age, years of education completed, body mass index 
(BMI, kg/m2) and the determinants of HCC in this sample (see Chapter 6): (i) whether women were 
currently breastfeeding; (ii) whether any additional hair products had been used in the prior three 
months (such as hair styling and care products e.g. gels, oils and creams, excluding products used 
during hair washing); (iii) the average hours per day that hair was exposed to sunlight (less than one 
hour, 1-2 hours, more than 2 hours) and the duration of hair sample storage (less than 1 year, 1-2 
years, 2-3.5 years). 
2.5 Statistical analysis 
We decided to limit our analyses to females only due to the small number of males (n = 3) with HCC 
available. Descriptive data, numbers and percentages for categorical variable and means and standard 
deviations for continuous variables are reported. To assess whether performance on neurocognitive 
domains were associated with HCC neurocognitive scores raw scores were z-transformed and were 
regressed on reciprocal square root transformed HCC in unadjusted and adjusted linear regression 
models. We adjusted for factors known to be associated with cognitive performance (age, years of 
education, and BMI) and covariates of HCC (additional hair products used, average hours in the sun, 
duration of storage and breastfeeding). Data were analysed with SPSS for windows, version 25.0, all 






Descriptive details pertaining to the sample are available in Table 1. In brief, the mean age of 
participants was 46.1 years (SD 15.1), ranging from 18 to 79 years and the mean years of education 
completed were 10.4 (SD 2.5). The average raw scores for the neurocognitive domains evaluated are 
presented in Table 2.  
Table 1 Descriptive features of the sample  
 
Variables Number (%) 
    
Total sample 153 (100) 
Socio-demographic  
 Age 46.1 (15.1)a 
 Years of education completed 10.2 (2.5)a 
 Secondary education complete  
  No 101 (66.0) 
  Yes 52 (34.0) 
 Employed  
  No 97 (63.4) 
  Yes 56 (36.6) 
Hair related  
 Natural hair colour black  
  No 84 (54.9) 
  Yes 69 (45.1) 
 Hair chemically treated  
  No 46 (30.1) 
  Yes 107 (69.9) 
 Frequency of hair washing  
  ≥ 2 times a week 41 (26.8) 
  1 time a week 76 (49.7) 
  < 1 time a week 36 (23.5) 
 Add on hair products  
  No  77 (50.3) 
  Yes 76 (49.7) 
 Average hours in sund  
  < 1 hour 71 (46.4) 
  1-2 hours 42 (27.5) 
  > 2 hours 37 (24.2) 
 Season sampled  
  Summer 32 (20.9) 
  Autumn 41 (26.8) 
  Winter 45 (29.4) 
  Spring 35 (22.9) 
 Duration of storage  
  Less than 1 year 28 (18.3) 
  1 - 2 years 51 (33.3) 
  2 – 3.5 years 74 (48.4) 
Clinical   
 Hormonal contraceptive  
  No 124 (81.0) 




 Currently breastfeeding  
  No 147 (96.1) 
  Yes 6 (3.9) 
 Topical steroid use  
  No 146 (95.4) 
  Yes 7 (4.6) 
 Body mass index (BMI) 31.0 (8.0)b 
 Medical conditions  
  No 74 (48.4) 
  Yes 79 (51.6) 
Behavioural   
 Tobacco use  
  No 103 (67.3) 
  Yes 50 (32.7) 
 Alcohol use  
  No 83 (54.2) 
  Yes 70 (45.8) 
 Level of physical activity  
  High 15 (9.8) 
  Moderate 52 (34.0) 
  Low 86 (56.2) 
Hair cortisol concentrations 1.2 (0.3)a 
a Mean and standard deviation 
b Three responses were missing for this item, n = 150 
 
3.2 Neurocognitive function and hair cortisol concentrations (HCC) (Table 2) 
3.2.1 RBANS 
RBANS total and subscale scores (immediate memory, visuospatial/constructional, language, attention 
and delayed memory) were not significantly associated with HCC in unadjusted or adjusted analyses.  
3.2.2 WASI 
WASI verbal intelligence scores were inversely associated with HCC, demonstrating a trend towards 
significance in unadjusted (p = 0.086), but not adjusted (p = 0.134), analyses. WASI global and non-
verbal intelligence scores were not significantly associated with HCC.  
3.2.3 Executive function and working memory tests 
Verbal working memory performance, as assessed with the digit span backwards, was significantly 
inversely associated with HCC in both unadjusted (p = 0.010) and adjusted (p = 0.043) analyses. The 





Table 2 Regression analyses of neurocognitive test scores on hair cortisol concentrations (HCC) 
 
Variables Raw score  Simple linear regression Multiple linear regressiona 
 M(SD) ß (95% CI) p-value ß (95% CI) p-value 
Total sample n = 153     
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)      
 Total score 198.0 (28.8) -0.02 (-0.08; 0.03) 0.365 -0.03 (-0.09; 0.03) 0.352 
  Immediate memory 44.6 (7.7) -0.03 (-0.08; 0.03) 0.344 -0.04 (-0.10; 0.01) 0.126 
  Visuospatial/Constructional 31.8 (4.6) -0.04 (-0.09; 0.01) 0.149 -0.01 (-0.06; 0.04) 0.705 
  Language 27.6 (4.7) -0.03 (-0.08; 0.02) 0.267 -0.02 (-0.07; 0.03) 0.379 
  Attention 46.2 (12.6) -0.00 (-0.05; 0.05) 0.960 -0.00 (-0.06; 0.06) 0.982 
  Delayed memory 47.8 (7.1) -0.02 (-0.08; 0.03) 0.381 -0.02 (-0.08; 0.04) 0.446 
The Wechsler Abbreviated Scale of Intelligence (WASI)b      
 Total score 65.7 (15.1) -0.03 (-0.08; 0.03) 0.321 -0.02 (-0.08; 0.03) 0.407 
  Vocabulary  49.5 (9.9) -0.05 (-0.10; 0.01) 0.086 -0.04 (-0.10; 0.01) 0.134 
  Matrix reasoning  16.3 (7.7) 0.01 (-0.04; 0.06) 0.822 0.01 (-0.05; 0.06) 0.762 
Ruff Figural Fluency Testc      
  Error ratio 0.16 (0.2) 0.03 (-0.02; 0.08) 0.208 -0.00 (-0.05; 0.05) 0.929 
The Stroop Color and Word Testd      
  Interference -1.9 (8.2) 0.02 (-0.03; 0.07) 0.492 0.02 (-0.03; 0.07) 0.386 
Wechsler memory scalee      
  Spatial span backwards 6.0 (2.2) -0.03 (-0.08; 0.03) 0.358 0.01 (-0.05; 0.07) 0.702 
  Digit span backwards 5.0 (2.1) -0.07 (-0.12; -0.02) 0.010* -0.05 (-0.10; -0.00) 0.043* 
a Multivariate adjusted model (adjusted for age, education, BMI, additional hair products, average hours in the sun, duration of storage, breastfeeding), n = 150; three 
missing responses on the item ‘average hours per day that hair was exposed to sunlight’  
b Missing for a single participant, n = 152 
c Not administered in the controls included in the schizophrenia cohort, not completed in two other participants due to visual difficulties, n = 137 
d Not administered in the controls included in the schizophrenia cohort, not completed in three other participants due to visual difficulties, n = 136 
e Not administered in the controls included in the schizophrenia cohort, n = 139 
* p-value < 0.05 
BMI, body-mass index; HCC, hair cortisol concentrations; RBANS, The Repeatable Battery for the Assessment of Neuropsychological Status; RFFT, Ruff Figural Fluency 







We aimed to investigate for stress related effects, as reflected by HCC, on cognitive performance in a 
sample of South African mixed ancestry females. We demonstrated that performance on one of the 
domains known to be associated with stress and elevated cortisol levels, namely working memory, was 
inversely associated with HCC. No other cognitive domains, as well as global cognitive functioning, 
were associated with HCC, including the other domains sensitive to glucocorticoids (declarative 
memory and executive function).  
Other studies of HCC in non-clinical samples have demonstrated mixed results. A study in nurses 
(aged 21 - 62) found that HCC were not associated with performance on any of the cognitive domains 
assessed (McLennan et al., 2016). Whereas a study in healthy older adults (aged 56 – 77) found that 
higher HCC were associated with better cognitive performance (including working memory, learning 
and short- and long-term verbal memory) (Pulopulos et al., 2014). They also demonstrated that higher 
diurnal salivary cortisol levels were associated with poorer cognitive performance, thus suggesting 
diurnal salivary cortisol and hair cortisol reflect different aspects of HPA-axis function (Pulopulos et al., 
2014). Conversely, in a large community cohort of older adults (aged 54 – 94 years) HCC were 
inversely associated with cognitive performance, including immediate and delayed recall (Feeney et al., 
2018). Possible factors that may have influenced these differential results are that the two studies 
demonstrating significant results were limited to older individuals and the participants in Pulopulos et al. 
were older adults participating in a university study program and thus likely represented high 
functioning older individuals. Two randomised controlled trials (RCTs) evaluating psychosocial and 
physical interventions, one in adolescents (Panter-Brick, Wiley, Sancilio, Dajani, & Hadfield, 2019) and 
one in older adults (Jansen, Dahmen-Zimmer, Kudielka, & Schulz, 2017), also found that HCC were 
not associated with change in cognitive functioning over time.  
The association between HCC and cognitive function may be more evident in individuals with 
increased vulnerability for cognitive impairment, such as those with existing brain disorders. For 




inversely associated with working memory in the patient groups, but not in the control group (Aas et al., 
2019). Similarly a study in children found that HCC were negatively correlated with spatial working 
memory performance in children with autism spectrum disorder (ASD), but not in typically developing 
children (Ogawa et al., 2017). Additionally, higher HCC in samples obtained directly following a stroke 
were associated with poorer cognitive performance post--stroke and at 24-months follow-up (Ben 
Assayag et al., 2017). In patients with multiple sclerosis (MS), however, HCC were not associated with 
executive dysfunction and processing speed (Pereira et al., 2019).  A study in 3.4-
methylenedioxymethamphetamine (MDMA) or ‘Ecstasy’ users and controls also demonstrated no 
correlations between memory function (immediate recall, delayed recall) and subjective memory 
problems and HCC (Downey et al., 2015).  
Most studies demonstrate cognitive impairments in relation to elevated cortisol in cognitive domains 
related to brain regions with high MR and GR receptor densities, namely the hippocampus (declarative 
memory) and prefrontal cortex (working memory and executive functions). In our sample we only 
demonstrated significant associations for working memory (digit span backward) and not declarative 
memory and other executive function domains. Working memory appears to be more sensitive to the 
effects of glucocorticoids (Lupien et al., 2007) and working memory impairments have been 
demonstrated to be related to a GR mediated increase in dopamine release in the prefrontal cortex 
(Butts, Weinberg, Young, & Phillips, 2011). Working memory impairments have been demonstrated 
following glucocorticoid administration (Lupien, Gillin, & Hauger, 1999; Shields et al., 2015; Young, 
Sahakian, Robbins, & Cowen, 1999) and studies have also demonstrated that increased cortisol levels 
following psychosocial stressor exposures were associated with working memory impairments (Oei, 
Everaerd, Elzinga, Van Well, & Bermond, 2006; Taverniers, Van Ruysseveldt, Smeets, & Von 
Grumbkow, 2010). Contrary to our results, another HCC study in older adults demonstrated that higher 
HCC were associated with better performance on the digit span backward test (Pulopulos et al., 2014). 
Other studies utilising HCC have not demonstrated associations between HCC and working memory 




although inverse associations have been demonstrated in clinical samples (Aas et al., 2019; Ogawa et 
al., 2017).  
Contrary to our results two studies have demonstrated significant inverse associations between HCC 
and short- and long-term memory (Ben Assayag et al., 2017; Feeney et al., 2018) although another 
demonstrated a positive association (Pulopulos et al., 2014). The relationship between cortisol levels 
and declarative memory appear to follow an inverse u-shaped curve and thus only cortisol levels below 
or exceeding a certain threshold may contribute to memory dysfunction (Lupien et al., 2007). For 
instance, a study administering low and high dose cortisol for four days, representing mild and more 
significant stress, found that high dose, but not low dose, cortisol resulted in impairments in verbal 
memory (Newcomer et al., 1999). It is possible that cortisol levels were not above the threshold 
associated with memory impairment for the majority of participants, possibly due to the inclusion of 
younger individuals and the exclusion of individuals with significant medical and psychiatric disorders. 
The lack of association between HCC and declarative memory could potentially also be ascribed to 
other factors related to stress influencing memory performance. A meta-analyses found that although 
stress led to both increased cortisol levels and memory impairments, that cortisol levels did not 
moderate the memory impairments (Shields, Sazma, McCullough, & Yonelinas, 2017). Stress 
therefore likely influences memory function through a combination of pathways in addition to cortisol, 
such as through effects of the sympathetic nervous system, other hormones and the immune system 
(Shields et al., 2017).  
4.1 Strengths and limitations 
Our study is cross-sectional and we cannot comment on any cause-effect relationships. Indeed, pre-
morbid cognitive function may also be a vulnerability factor for HPA-axis dysfunction. In one longitudinal 
study cognitive performance at age 20 years was inversely associated with cortisol levels at age 55 
years (Franz et al., 2011). The hippocampus regulates HPA-axis activity and thus hippocampal 
dysfunction may also contribute to HPA-axis dysregulation (Lupien et al., 2009). Smaller hippocampal 




impairments and may represent greater vulnerability to environmental exposures (Lupien et al., 2009). 
Longitudinal studies utilising HCC are required to explicate these pathways.  
Due to the small number of males with hair long enough to be sampled our sample was limited to a 
single sex and ethnicity limiting the generalisability of our findings. For instance, meta-analyses have 
revealed that stress related increases in cortisol levels are more pronounced in males (Shields et al., 
2017) and thus sex may influence the association between HCC and cognitive performance. One of 
the benefits of our sample being limited to a single ethnicity and gender is that lifetime stress, and 
associated HPA-axis function, may vary according to gender and ethnicity (Abell et al., 2016; Schreier 
et al., 2016; Wosu et al., 2013), particularly in South Africa, a country with both a history of and ongoing 
racial and gender inequality (James et al., 2019; Mayosi et al., 2012), and that these factors may be 
more equivalent within our sample. Our sample is also unique in representing a geographic and 
cultural setting where there are notable psychosocial stressors, including high rates of trauma 
exposure, socio-economic strain and historical racially based trauma with enduring racial inequity. 
Indeed, only one other study has been conducted examining the association between cortisol levels 
and cognitive function in South Africa. Similar to our study they found that in older adults saliva cortisol 
levels were not significantly associated with overall cognitive and memory performance, in both the 
controls and patients with Alzheimer’s disease (James et al., 2019). It also important to note that our 
control sample was recruited using purposive sampling approaches and does not represent a random 
population sample. Self-selection bias, such as employment status influencing the availability to 
participate in research, means that, for instance, our sample may be over-represented by individuals 
with specific stressors and factors influencing cognitive performance (such as unemployment). 
Notwithstanding, our sample appeared to be representative of South African mixed-ancestry women in 
terms of education and employment status, with the percentage that had completed secondary 
education (34.0%) roughly equivalent to the national average (30.0%), and if we excluded individuals 
aged 65 years and older the percentage who were employed (40.6%) was also roughly equivalent to 
the national average (42.3%) (Statistics South Africa, 2013). Considering the high stress burden in 




including large community cohorts with broader ethnic, gender and cultural representation. Studies in 
clinical samples are also warranted as there appear to be greater associations between HCC and 
cognitive performance in individuals with known brain disorders (Aas et al., 2019; Ben Assayag et al., 
2017; Ogawa et al., 2017). Further strengths of our study included that HCC were determined with LC-
MS/MS, the gold standard method for HCC determination (Russell et al., 2015). Our cognitive battery 
included various domains thus ensuring we examined for associations between HCC and the major 
cognitive domains. Though the additional tests of executive function were not performed in the 
schizophrenia cohort, as they were administered a different cognitive battery specific to schizophrenia, 
and thus those analyses were conducted in a smaller sample. 
4.2 Conclusions 
In a sample of mixed ancestry females, poorer verbal working memory performance was associated 
with higher stress, as reflected by HCC. Performance on other domains know to be impaired by stress 
and elevated cortisol levels, including other tests of executive function and short- and long- term 
memory, were not associated with HCC. Studies combining HCC, acute basal and stress induced 
evaluations of cortisol may help to further elucidate the intricate pathways by which glucocorticoids 
influence cognitive function. Incorporating neuro-imaging alongside neurocognitive testing may also 
assist in determining whether HCC are associated with structural and functional changes in brain 
regions sensitive to glucocorticoids, such as the hippocampus and prefrontal cortex, and whether these 
align with performance on neurocognitive domains. Future studies in geographically, culturally and 
ethnically diverse populations are also required to better delineate how stress, HPA-axis dysfunction 
and cognitive performance are linked across different settings. 
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The key findings and scientific contributions of this study are summarised and then elaborated for each 
chapter. Suggestions and recommendations for future research are then outlined, including further 
research planned in this sample. 
1 Summary of contributions to existing knowledge 
Our study demonstrated that HPA-axis function was altered in the three neuropsychiatric disorders 
(NPDs), with higher hair cortisol concentrations (HCC) in posttraumatic stress disorder (PTSD) patients 
than trauma exposed controls (TEC), lower HCC in patients with schizophrenia than controls and 
higher hair cortisone levels, but not HCC, in Parkinson’s disease patients than controls. These findings 
align with our hypotheses, excluding the schizophrenia cohort where we expected to find higher HCC 
in patients than controls. Furthermore, HCC were associated with severity of PTSD and hair cortisone 
with non-motor symptoms related to depression and anxiety in Parkinson’s disease patients. Thus our 
results suggest that stress, as reflected by long-term HPA-axis dysfunction, is associated with 
psychopathology. These results underscore the need to address stress occurring in NPDs and 
consideration of interventions are required to improve resilience and stress coping ability, especially as 
greater resilience was also associated with lower HCC in the control sample. 
We found that metabolic syndrome (MetS) was not associated with HCC in the three NPD cohorts, 
excluding only significant positive associations demonstrated in the longitudinal investigation conducted 
in the schizophrenia cohort. We also found that in our combined analysis that there was a trend toward 
significance demonstrated for higher HCC in those with MetS when we excluded PTSD patients, the 
only group where HCC were lower in those with MetS. The findings did not completely align with our 
hypothesis as we expected to find higher HCC in NPD patients with MetS than in patients without 
MetS. The lack of significant findings related to MetS may be due to the small samples and lack of 




Our exploratory analyses investigating associations between the individual cardiovascular disease 
(CVD) risk factors and HCC demonstrated persistent associations between high density lipoprotein 
cholesterol (HDL-C) and HPA-axis function, with low HDL-C associated with elevated glucocorticoids 
across the different cohorts. Furthermore, waist-to-hip ratio demonstrated a positive association with 
hair cortisone in the Parkinson’s disease cohort and an inverse association with HCC in patients with 
PTSD. Our results thus suggest that these CVD risk factors may be associated with HPA-axis 
dysfunction in NPDs and warrant closer investigation in studies of HCC in these NPDs. 
Very few studies have directly investigated links between hypothalamic pituitary adrenal (HPA) axis, 
NPDs and cardiovascular disease (CVD) risk and our study is the first study to utilise a measure of 
longer-term HPA axis dysfunction to address this. Considering the high burden of CVD in NPDs, our 
study provides a step towards better understanding of the role played by chronic stress, as reflected by 
long-term HPA axis dysfunction, in the co-occurrence of CVD in NPDs. Our results suggest that the 
pathways whereby HPA-axis dysfunction and MetS in NPDs are linked may be complex and vary 
according to NPD. 
Regarding our secondary aims, contrary to what we hypothesized we demonstrated that HCC were 
lower in patients with first episode psychosis (FEP) than controls at baseline and increased following a 
course of treatment with a flupenthixol decanoate, demonstrating a trend towards significance. Our 
results suggest that in a subset of FEP patients that acute psychosis may be associated with a blunted 
HPA-axis with lower HCC and that this may be normalised with antipsychotic treatment. In our control 
sample we found some analogous associations between HCC and basic determinants to what has 
been found before (lower HCC with higher level of education and increased duration of storage) as well 
as some dissimilarities (inverse associations between HCC and age). Our results provide insight as to 
the main determinants of HCC in South African mixed ancestry females thus informing future research 
in representative populations. We also identified novel associations with HCC (duration of sun 
exposure, hair product use and breastfeeding in women) that warrant further investigation. In alignment 
with our hypothesis we also demonstrated that HCC were inversely associated with resilience, 




importance of investigating the biological pathways underpinning resilience and taking a broader 
perspective in stress research. In partial alignment with our hypothesis we also found that poorer 
working memory performance, but not semantic memory and other executive functions, was 
associated with higher HCC. Our results thus suggest that chronic stress, as reflected by long-term 
cortisol levels, may be associated with working memory impairments.  
This study is one of the first studies to utilise HCC as a marker of longer-term HPA axis function in a 
South African sample. Our study thus provides insights into the role of chronic stress and associated 
HPA-axis dysfunction in clinical conditions of relevance to South Africa and contributes to broader 
geographic, cultural and ethnic representation in hair cortisol research. Limitations identified in this 
study, such as those pertaining to hair length, also suggest ways in which hair neuroendocrine studies 
need to be adapted to allow for greater gender and ethnic representation across different cultures and 
settings. Our study is also notable in that we investigated the role of HPA-axis dysfunction across three 
different NPDs and thus were able to identify possible shared and unique pathways across NPDs. 
A significant limitation to this study is that the cross-sectional design does not allow for the 
establishment of cause-effect relationships. This study addresses the question of whether HPA-axis 
dysfunction, as measured by HCC, is associated with the diagnosis of the three NPDs and furthermore 
the comorbidity of MetS within these NPDs. This study does not address the pathways through which 
HPA-axis dysfunction, NPDs and MetS are linked, but only investigates for possible associations. It 
thus remains unclear exactly how the NPDs, MetS and a dysregulated HPA axis, as measured by 
HCC, relate to each other. Each of these factors could theoretically increase the risk for the developing 
the others and it is very likely that these factors inter-relate and influence each other. For instance, 
HPA-axis dysfunction occurring within the context of NPDs could contribute to metabolic derangement 
and increase the risk for MetS, but conversely MetS could contribute to HPA-axis dysfunction observed 
in NPDs. Alternatively MetS and HPA-axis dysfunction, by influencing brain function, could increase the 
risk of developing NPDs. There may also be other shared pathways contributing to the co-occurrence 
of these factors. Longitudinal studies will be required to better delineate how these factors are related to 




A further limitation is the way the groups have been categorised, both in terms of NPD diagnoses, and 
MetS status, and that these rely on existing conceptualisations of the disorders and do not take a more 
trans-diagnostic or dimensional approach. As the classification of NPDs and MetS are a component of 
the SHARED ROOTS study design they need to be considered in analyses employed, however 
alternative statistical modelling approaches can be utilised to further examine the how the various 
factors interact and relate to each other. For instance, different methods of determining cardiovascular 
risk can be employed, such as using alternative risk stratification algorithms, such as the Framingham, 
SCORE, and CUORE risk scores (Castelli, Anderson, Wilson, & Levy, 1992; Conroy et al., 2003; 
D’Agostino et al., 2008; Gaziano et al., 2013; Giampaoli et al., 2007; Joseph et al., 2018) or using 
modelling techniques, such as latent class analysis (LCA) or latent profile analysis (LPA) to identify 
subtypes of cardiovascular risk groups (Hajian-Tilaki, 2018; Khodarahmi, Asghari-Jafarabadi, & 
Farhangi, 2019; Roman-Urrestarazu et al., 2016). LCA, or other modelling techniques, can also be 
employed to identify subtypes within and across the NPDs (Rahman et al., 2018; Starkstein et al., 
2011; Tsai & Rosenheck, 2013; Zahodne, Marsiske, & Bowers, 2013). The association between these 
subtypes of NPDs, CVD risk and HCC can then be examined utilising structural equation modelling 
(SEM) or machine learning based approaches (Adams & Boscarino, 2011; Galatzer-Levy, Ma, 
Statnikov, Yehuda, & Shalev, 2017; M. W. Miller, Wolf, Martin, Kaloupek, & Keane, 2008).  
1.1 Chapter 2 - Hair cortisol levels in posttraumatic stress disorder and metabolic syndrome: 
A case-control study in South African mixed ancestry females 
We demonstrated higher HCC in patients with PTSD as compared to TEC. Although this association is 
the converse of what has generally been found (Meewisse, Reitsma, de Vries, Gersons, & Olff, 2007; 
Morris, Compas, & Garber, 2012; Schumacher et al., 2019), the context of ongoing stress and trauma 
in which our study was conducted may explain the contrasting findings  (G. E. Miller, Chen, & Zhou, 
2007; Steudte-Schmiedgen, Kirschbaum, Alexander, & Stalder, 2016). Moreover, we demonstrated a 
dose-response association between PTSD severity and HCC with the clinical phenotype (PTSD), 
rather than trauma load, significantly associated with HCC. Furthermore, self-perceived stress was also 




sufferers that is associated with increased cortisol output. We did not find an association between MetS 
and HCC, although HCC were significantly higher in individuals with low HDL-C. We also found that in 
PTSD patients there was an inverse association between waist-to-hip ratio and HCC, which is counter 
to what is generally found (Stalder et al., 2017). Our study is one of the largest investigations of the 
association between PTSD and HCC to date and represents a different context than the studies that 
have been conducted so far. It is furthermore, one of the few studies (Blessing et al., 2017) that have 
directly examined the association between PTSD, CVD risk and cortisol levels and the first to use HCC 
to address this aim. 
1.2 Chapter 3 - Hair glucocorticoid levels in females with Parkinson’s disease  
We found that hair cortisone, but not hair cortisol, levels were significantly higher in patients with 
Parkinson’s disease than in controls. Furthermore, hair cortisone was positively associated with non-
motor symptoms of Parkinson’s disease related to depression, anhedonia and anxiety and with waist-
to-hip ratio. Similar to other studies (Davison, Singh, & McFarlane, 2019; Stalder et al., 2013) we 
demonstrated stronger associations and less variability in hair cortisone than hair cortisol, supporting 
the utility of hair cortisone levels as an additional biomarker of HPA-axis function. This study is the first 
to report on hair glucocorticoid levels in Parkinson’s disease and provides further evidence that patients 
with Parkinson’s disease exhibit a dysregulated HPA-axis and that stress and symptoms of depression 
and anxiety may play a role. It is also the first study to directly examine the association between 
Parkinson’s disease, CVD risk and cortisol levels. 
1.3 Chapter 4 – Hair cortisol levels in schizophrenia and metabolic syndrome 
We demonstrated that HCC were significantly lower in patients with schizophrenia than controls, and in 
particular in first-episode psychosis (FEP) patients than controls. These findings are contradictory to the 
majority of studies that have examined basal cortisol levels in schizophrenia (Borges, Gayer-Anderson, 
& Mondelli, 2013; Bradley & Dinan, 2010; Gajsak, Gelemanovic, Kuzman, & Puljak, 2017; Girshkin, 
Matheson, Shepherd, & Green, 2014; Hubbard & Miller, 2019). Findings of studies investigating HCC 
in schizophrenia have been mixed, with most demonstrating no association between schizophrenia 




studies, particularly in FEP samples, have demonstrated lower cortisol levels in patients than controls 
(Bradley & Dinan, 2010; Mondelli et al., 2015; Seitz et al., 2019). We also found that HCC increased 
following treatment with a depot antipsychotic, demonstrating a trend toward significance, and in 
exploratory analysis that HCC were lower in non-remitted patients than in controls and in putatively 
remitted patients, suggesting that lower HCC are associated with symptomatic status. In the context of 
a large body of literature demonstrating higher basal cortisol levels and increased stress in patients with 
schizophrenia and those at increased risk of developing schizophrenia we postulate that in a subset of 
patients lower long-term cortisol levels may reflect an overburdened HPA-axis that becomes 
decompensated during periods of active psychosis, particularly during the first episode of illness. This 
theory is also partly supported by the inverse association demonstrated between self-perceived stress 
scores and HCC in this cohort. These findings can at best be considered as preliminary and in view of 
the very small sample will require replication in larger samples. Similar to the other samples we 
demonstrated that at baseline MetS and CVD risk factors were not associated with HCC, although 
HCC increased from baseline to month-12 in those with MetS and MetS and low HDL-C were 
associated with higher HCC at month-12. This is one of the few studies (Manzanares et al., 2014; 
Vuksan-Cúsa, Sǎgud, Mihaljevic-́Peleš, Jaksǐć, & Jakovljev́ic, 2014) that have examined cortisol levels 
in relation to CVD risk in schizophrenia and the first utilising HCC. Although the schizophrenia sample 
was very small, there were some notable findings and these require replication in larger samples. 
1.4 Chapter 5 - Hair cortisol as a neuroendocrine biomarker to evaluate the impact of chronic 
stress on the interaction between neuropsychiatric disorders and metabolic syndrome in 
females 
Our pooled analysis provided some additional insights. Firstly our analyses showed that HCC, as well 
as various other factors, differed significantly between the three cohorts overall, suggesting that within 
cohort case-control comparisons provided better estimates of the patterns of HPA-axis dysfunction in 
the NPDs than cross-cohort comparisons. Thus although HCC largely did not differ significantly 
between the three NPDs different patterns emerged in the individual cohorts as discussed above. The 




cohorts, providing some support for the veracity of results. The opposite direction of association 
between cases and controls and HCC in the PTSD and schizophrenia cohorts were also reflected in 
the association patterns between self-perceived stress and HCC in these cohorts, suggesting that 
psychological stress is associated with increased cortisol output in PTSD and a blunted HPA-axis in 
schizophrenia. MetS was not associated with HCC in the overall sample. When PTSD patients, the 
only group demonstrating an opposite direction, were excluded from the analysis there was a trend 
toward statistical significance demonstrated for higher HCC in individuals with MetS. Our results 
highlight that although there may be limitations to cross-disorder comparisons that including different 
disorders within the same study allow for a clearer delineation of unique versus shared pathways. 
1.5 Chapter 6 - Hair cortisol as a biomarker of stress and resilience in South African mixed 
ancestry females 
Our study is one of the first to examine the basic determinants of HCC in a sample of non-clinical 
controls representing a different geographic, ethnic and cultural setting than in most studies that have 
been conducted to date. Furthermore, our study is also one of the first to examine for associations 
between HCC and a measure of resilience alongside a measure of self-perceived stress. We 
demonstrated a number of expected associations between HCC and basic determinants, as well as 
some novel associations. Specifically, HCC declined with age, which is the converse to what has 
mostly been demonstrated (Stalder et al., 2017; Wosu, Valdimarsdóttir, Shields, Williams, & Williams, 
2013). Completion of secondary education was associated with lower HCC, which aligns with existing 
studies (Orta et al., 2018; Wosu et al., 2013). Our study is also one of the first studies to demonstrate 
that sun exposure has an effect on HCC under naturalistic conditions. We also demonstrated 
significant associations between HCC and other factors that are not frequently reported on in studies, 
such as hair product use, duration of storage and breastfeeding in women. We demonstrated a 
significant inverse association between HCC and resilience scores, alongside a non-significant positive 
association between self-perceived stress and HCC. As such, our results underscore the importance of 




highlights important limitations when hair sampling is used in different contexts and that methods need 
to be adapted to allow for proportionate inclusion of participants of different sexes and ethnic groups. 
1.6 Chapter 7 - The association between cognitive functioning and hair cortisol levels in 
South African mixed ancestry females 
We demonstrated that overall cognitive performance, as well as performance on the majority of 
cognitive domains were not associated with HCC. With respect to the cognitive domains (declarative 
memory, executive functions and working memory) that are sensitive to the effects of stress and 
cortisol, only verbal working memory was inversely associated with HCC. Our results align with other 
research suggesting working memory may be more sensitive to the effects of glucocorticoids (Lupien, 
Maheu, Tu, Fiocco, & Schramek, 2007). Our study is one of the few to examine for associations 
between cognitive performance and cortisol levels in South Africa (James, Grace, Pan, Combrinck, & 
Thomas, 2019) and represents a different ethnic and cultural context than the majority of studies thus 
far. 
2 Future research directions 
2.1 Further studies planned in this sample 
There are various research questions that remain to be addressed in the SR sample and some of the 
investigations planned are discussed here.  
To further examine the pathways connecting stress, NPDs, MetS and HPA-axis dysfunction we plan to 
use SEM based modelling techniques. An example of a theoretical model that can be tested with SEM 
is illustrated below (Figure 1). Stress experienced by individuals can contribute to the development of 
NPDs, increased CVD risk and HPA-axis dysfunction. Thus we postulate that there is a latent variable 
‘stress’ that is increasing the risk of developing brain, metabolic and HPA-axis dysfunction. We can 
utilise observed variables, such as childhood maltreatment, trauma exposures and socio-economic 
stressors to model the underlying latent variable ‘stress’. We can also utilise observed variables related 
to NPDs, CVD risk and HPA-axis function to model, or provide subtypes, of NPDs, CVD risk and HPA-




latent variables and how they inter-relate. The role of other potentially mediating/moderating factors, 
such as age, gender, social support, resilience and lifestyle or behavioural factors can also be tested. 
We plan to evaluate whether HCC are associated with structural and functional neuroimaging features 
and how this relates to phenotypes and clinical features. We also aim to investigate the interaction 
between HCC and inflammatory cytokines in the NPDs, and its role in comorbid CVD risk. We further 
plan to investigate whether HCC are associated with genomic, transcriptomic and epigenetic factors, 
particularly those related to cortisol [e.g. genes related to FK506 binding protein 51 (FKBP5), 
corticotrophin releasing hormone (CRH) receptors (CRHR1, CRHR2), corticotropin receptors (or 
melanocortin receptors, MC1R-MC5R), glucocorticoid receptors (NR3C1), and mineralocorticoid 
receptors (NR3C2)]. We demonstrated a dissociation between HCC and hair cortisone levels in 
relation to Parkinson’s disease and CVD risk factors. Further studies are planned combining different 
hair neuroendocrine levels (cortisone, testosterone, progesterone, and dehydroepiandrosterone 
[DHEA]) with HCC and examining their interaction in relation to clinical factors and other variables of 
interest. Studies have demonstrated that the association between HCC and cognitive performance 
differs between healthy controls and individuals with NPDs (Aas et al., 2019; Ogawa, Lee, Yamaguchi, 
Shibata, & Goto, 2017); we thus plan to investigate the association between HCC and cognitive 
performance in NPD patients compared to the controls. We also plan to investigate how factors 
associated with stress, such as trauma exposure, perceived stress and resilience influence the 
associations between HCC and cognitive performance. In our PTSD sample we want to perform more 
in-depth investigations of the association between trauma type and differential childhood maltreatment 
exposures and altered HCC observed in this sample. LCA, or alternative modelling techniques will also 
be employed to identify polytrauma typologies (Contractor, Brown, & Weiss, 2018; Sullivan, Contractor, 
Gerber, & Neumann, 2017). We also aim to investigate whether haircare practices are directly 
associated with clinical measures, as explained below. SR was designed to utilise a multi-omics 
approach combining different techniques to investigate the comorbidity of NPDs and MetS. The final 
aim will be to incorporate HCC along with these other measures to build a mechanistic model of how 





Figure 1 A theoretical model of how stress may be related to NPDs, CVD risk and HPA-axis dysfunction  
 
A theoretical model of how stress may be related to NPDs, CVD risk and HPA-axis dysfunction that can be evaluated utilising structural equation modelling 
approaches. The model illustrates how different observed variables, such as childhood maltreatment, traumatic exposures and socio-economic stressors can 
be modelled to represent the latent variable ‘stress’. In turn the observed variables representing NPDs, CVD risk and HPA-axis function can be modelled to 
represent each of those latent variables. The model can then examine how stress relates to NPDs, CVD risk and HPA-axis function and how these factors 
inter-relate. The role of other potentially mediating or moderating variables can also be tested.
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structural and functional neuro-imaging, the microbiome and inflammatory cytokines in contributing to 
increased CVD risk in NPDs. 
2.2 Optimising and standardising hair sampling procedures to ensure broader inclusion of 
participants 
There are certain limitations to the study and to using HCC that can inform future research. Although 
there are various benefits to utilising hair samples there are also notable limitations and some of these 
became evident in this study. The limitation with the largest influence was the requirement that hair 
samples had to be 3cm or longer resulting in exclusion of the majority of males as well as many 
females. Other studies have similarly demonstrated that males and certain ethnic groups are 
disproportionately excluded (Kalmakis, Meyer, Chiodo, & Leung, 2015; Pacella, Hruska, Steudte-
Schmiedgen, George, & Delahanty, 2017; Simmons et al., 2016). Investigators have employed 
different methods to circumvent the limitation of short hair length in males, such as using shorter 
samples of hair from the posterior vertex scalp, having hairdressers performing sampling whilst 
simultaneously providing complimentary haircuts, and shaving the forearm in military samples (Dajani, 
Hadfield, van Uum, Greff, & Panter-Brick, 2018; Groer, Kane, Williams, & Duffy, 2015; Mewes, Reich, 
Skoluda, Seele, & Nater, 2017). The length of hair samples have further implications, for instance, as 
hair length used across studies is not uniform this limits comparability across studies (Staufenbiel, 
Penninx, Spijker, Elzinga, & van Rossum, 2013). Furthermore, the period of time reflected by hair 
samples (e.g. 1cm representing one month window) needs to align better with the period of time 
specified in clinical measures (e.g. symptoms in the last month). In sum, methods used for hair 
sampling need to be standardised as well as adapted to allow for greater representation of different 
sexes and ethnicities. Utilising 1cm hair samples from the posterior vertex scalp may be the best 
strategy at present although adaptions should be made depending on the context in which the study is 
conducted. 
2.3 Identifying and controlling for potentially confounding factors in hair cortisol studies 
In our control sample we identified specific determinants (e.g. age, level of education, hair product use, 




HCC. Some of these factors, such as hair product use, duration of sun exposure and breastfeeding, 
have not previously been associated with HCC. These findings need to be replicated in other settings, 
particularly as they are not routinely assessed for or reported on in hair cortisol studies. We also 
identified an inverse association with age which is counter to what is generally found (Stalder et al., 
2017; Wosu et al., 2013). Furthermore, we identified that study design related factors, such as the 
duration of sample storage and the batch analysed were associated with HCC and very few studies 
report on these factors. Our results highlight that though HCC can offer great insights regarding longer-
term HPA-axis dysfunction that investigators need to take cognisance of potential confounders. These 
factors need to be considered in study design and conduct and in data analysis. Our results also 
highlight that determinants of hair cortisol may vary according to study population and setting and that 
future studies identifying the determinants of HCC in diverse settings and populations are required to 
provide greater representation as well as expand current understanding of how HCC are influenced by 
different factors. 
2.4 Optimising and utilising haircare data 
Hair care practices may vary according to culture and ethnicity and the influence of these factors on 
HCC need to be examined across different contexts and in more heterogeneous samples that are 
more representative of clinical and non-clinical populations. Although our study is a step in this 
direction, there is a need for greater population representivity in HCC research, and in health research 
in general.  
Additional work also needs to go into building a scientific database of haircare products. These 
products are largely commercially defined and thus names and branding may not fully capture the 
contents of these products. Developing a database of haircare products and core ingredients may 
assist in standardising and better identifying hair care practices and products that influence HCC and 
other hormones in hair.  
There is a general assumption that haircare practices directly influence cortisol levels in the hair 
samples. Another possibility is that haircare practices may reflect behavioural patterns that are linked to 




treatment of hair were observed across some of the groups in this study. Studies evaluating whether 
haircare practices are directly associated with psychosocial measures and clinical outcomes can assist 
in better delineating how these factors influence HCC. Furthermore, poor self-care practices are a 
diagnostic feature of various psychiatric disorders, but this is rarely quantified. Given that data 
pertaining to haircare practices are already being collected in hair neuroendocrine studies, these data 
can be utilised to investigate whether haircare practices provide a quantifiable proxy measure of self-
care and its relationship to psychopathology and well-being. 
2.5 Studies seizing on the benefits of hair sampling 
Due to the simplicity of hair sampling, hair neuroendocrine levels have also increasingly been 
investigated in animal research. HCC may be an ideal measure of long-term HPA-axis function to 
utilise in translational research. For instance, HCC have already been used in animal models of 
depression and Parkinson’s disease (Chu et al., 2014; Franke et al., 2016; Qin et al., 2019) and can 
assist in further elucidating the role of stress in various contexts and conditions.  
Another area where hair neuroendocrine research may be beneficial is in post-mortem research. In 
post-mortem studies hair neuroendocrine levels can be correlated with specific brain pathophysiologic 
abnormalities observed. This may also be of particular use in research pertaining to suicide. As HCC 
reflect systemic cortisol levels for the period leading up to suicide these can provide insight as to 
whether stress and dysregulated HPA-axis function are present in the weeks prior to suicide 
completion and may thus help identify pathways contributing to suicide and thereby possibly inform 
preventive strategies.  
2.6 Collaborations and studies with increased power 
Studies with larger sample sizes that provide greater statistical power to detect case-control differences 
are needed to further investigate the questions addressed in this study, but also in HCC research 
overall. For instance, the effects related to MetS appeared to be smaller in magnitude than those 
pertaining to NPDs, and thus to adequately investigate the association between HPA-axis, NPDs and 
CVD risk, larger samples of patients both with NPDs and MetS are required. One mechanism, 




participants in hair neuroendocrine studies. Another approach to increase power will be to conduct 
multicentre collaborative studies or to form consortia that will a priori apply harmonized protocols to 
allow for pooling of samples and clinical data (Boksa, 2013; Pinto, Moulin, & Amaral, 2017). These 
collaborations can also increase reproducibility, and by including members from lower resource 
settings improve the sharing of resources, knowledge and skills, and aid in capacity building. These 
efforts will also benefit by including samples across varied NPDs and implementing trans-diagnostic or 
dimensional approaches (Cuthbert & Insel, 2013; Insel, 2014). Limitations of our study can inform the 
design of cross-diagnostic studies, such as standardisation of sample characteristics across disorders, 
e.g. limiting samples to similar ages, stage of illness and with respect to treatment histories and 
methodological protocols. Furthermore, investigations across disorders, and evaluation of comorbidity 
of NPDs and somatic conditions, can increase cross-specialty collaborations and knowledge 
exchange. Cross-disorder and trans-diagnostic approaches align better with models whereby the 
traditional boundaries between mental and somatic disorders decrease allowing for a more holistic and 
integrated approach. 
2.7 Longitudinal studies 
Longitudinal studies with repeated hair sampling are required to determine the course and causal 
associations between NPDs, MetS and the HPA-axis. It is unclear how these factors are linked 
together and longitudinal studies can provide insights regarding the underlying mechanisms and the 
sequence in which the factors influence each other. Prospective studies can also elucidate the pathway 
between incident trauma, PTSD symptomatology and HPA-axis function. One of the key benefits of 
hair sampling is that it reflects retrospective systemic cortisol levels (Steudte-Schmiedgen et al., 2016). 
Hair samples obtained directly following trauma exposure will thus reflect cortisol levels prior to 
traumatisation. By conducting prospective studies in recently trauma exposed samples this will provide 
insights into HPA-axis dysfunction as a predisposing risk factor for the development of PTSD versus a 
consequential factor of trauma exposure and/or PTSD. In particular, repeated sampling will assist in 
tracing the course of cortisol levels following trauma exposure in those who develop psychopathology 




2.8 Integrating biomarkers 
In this study the focus has been on HCC and its relationship to various clinical outcomes. HCC reflects 
one method of determining HPA-axis functioning and there are various other methods available that 
are utilised to examine HPA-axis function, such as psychological and pharmacological stress tests and 
measuring other proteins and hormones related to the HPA-axis (Allen et al., 2017; de Kloet et al., 
2006; Gunnar, 2010; J.Yeo, Babic, Hannoush, & Weiss, 2000; Zorn et al., 2017). There is a need for 
more studies that combine different methods of HPA-axis function determination that will allow for a 
better integration of how HCC relates to other aspects of HPA-axis functioning. For instance, some 
studies have incorporated the Trier Social Stress Test (TSST) and other measures of HPA-axis 
function in hair cortisol studies (Muehlhan et al., 2018; Steudte-Schmiedgen et al., 2015, 2017). 
Furthermore, within the context of stress related adaptations, the HPA-axis does not function in 
isolation, but is one component of multiple integrated biological systems, including primary mediators of 
stress, such as stress hormones and inflammatory cytokines, and secondary outcomes, such a 
metabolic, cardiovascular and immune effects (Juster, McEwen, & Lupien, 2010). Biological markers of 
these different systems are frequently combined in studies to provide an allostatic load index, allowing 
for  better prediction of risk and greater insight into the overall effects associated with stress related 
dysregulation (Juster et al., 2010). Studies evaluating how HCC interact with current allostatic load 
index approaches, as well as whether HCC can potentially be integrated into allostatic load algorithms, 
are needed.  
Furthermore, similar to many other biomarkers, alterations in cortisol levels are non-specific and are 
observed across various disorders (Boksa, 2013; Pinto et al., 2017). To better distinguish specific 
disorders, multiple markers may need to be combined (Boksa, 2013). The HPA-axis regulates 
inflammatory and immune pathways and these are also altered in NPDs and in CVD and thus adding 
inflammatory markers to hair neuroendocrine studies can help determine how these factors intersect. 
There may also be shared genetic risk factors that underlie the co-occurrence of NPDs and CVD and 
that are also related to the HPA-axis. Genetic, transcriptomic and epigenetic studies incorporating HCC 




collected to existing consortia may be a step towards addressing these aims. Incorporating HCC in 
functional and structural neuro-imaging studies can address the question as to whether dysregulated 
HPA-axis is associated with structural and functional changes in the brain regions sensitive to these 
effects, such as the hippocampus, amygdala, and prefrontal cortices. Other variables, such as markers 
of autonomic nervous system (ANS) function, oxidative stress, other cortisol related measures and a 
combination of different neuroendocrine hormones, can be included in HCC studies to allow for a more 
holistic investigation of the pathways involved in NPD-CVD co-occurrence (De Hert, Detraux, & 
Vancampfort, 2018; Vancampfort et al., 2015). Alternative statistical modelling approaches, such as 
SEM and network analyses, can be employed to better delineate the pathways through which HCC 
and these factors relate. Indeed, very few HCC studies have employed these types of modelling 
approaches (Gerber et al., 2013; Khoury, Bosquet Enlow, Plamondon, & Lyons-Ruth, 2019; Mustonen 
et al., 2019; Stalder et al., 2012) which can expand on and provide a more in-depth understanding of 
the underlying pathways involved. 
2.9 Incorporating advances in technology  
Advances in technology have opened up new avenues in the ways research is conducted as well as 
how data are collected and analysed. Personal devices, such as smartphones and wearables, have 
enhanced monitoring of physiology, behaviour and symptoms. Mobile technologies allow for real-time 
assessments of affect, cognitions and behaviours or ‘Ecological Momentary Assessment (EMA)’ 
(Reinertsen & Clifford, 2018). Furthermore, various activities reflecting locomotor and social behaviours 
can be tracked with smartphones and wearables can monitor features of ANS function (Reinertsen & 
Clifford, 2018). With advances in machine learning and artificial intelligence it is now possible to extract 
useful information from complex data and these technologies can thus assist with improved 
phenotyping of mental disorders (Insel, 2017). These technologies are already in use to measure 
movements and behaviour patterns in Parkinson’s disease, schizophrenia and PTSD, although the 
studies in PTSD and schizophrenia are limited and there remains much scope for further investigations 
(Reinertsen & Clifford, 2018). Studies incorporating these advances in technology with hair 




behaviours are linked. For instance, ANS monitoring, reflecting another central stress mediation 
pathway can be correlated with HCC reflecting the same time periods, thereby further demonstrating 
how these pathways are linked and how stress related adverse effects may be mediated through them.   
These mobile technologies can also be used to better quantify stress and trauma exposure in contexts 
of ongoing stress and trauma. For instance, our sample had very complex trauma histories and the 
administered measures were limited in their ability to accurately capture the complexity and the severity 
of trauma exposure, particularly pertaining to ongoing trauma exposure. Many of our participants were 
from communities with high rates of community violence or had been exposed to intimate partner 
violence. They thus lived in settings of repeated traumatisation as well as ongoing exposure to trauma 
related cues. Within this context it is difficult to estimate the true extent of current stress and trauma and 
how this relates to the clinical picture. In-depth measures that better capture trauma histories and link 
these to biological markers, psychopathology and functioning are needed. This is a context where 
technology can be utilised to report real-time exposures as well as associated psychological measures. 
Conducting prospective studies in environments with high rates of ongoing trauma exposure, utilising 
mobile applications that allow for real-time reporting of trauma exposures or exposure to trauma related 
cues alongside EMA may allow us to better define trauma exposure as well as to how it correlates with 
environmental and clinical features. HCC and ANS system monitoring can also be incorporated into 
these studies to provide biological measures of stress alongside these in-depth trauma 
characterisations.  
Beyond these advances mobile technology also allows for participation in research by completing 
measures online thus obviating the need for physical contact and travel to study sites. Some of the 
benefits pertaining to hair sampling, namely simplicity of sampling procedures, minimal storage and 
transport requirements, make it an ideal biological measure to incorporate into studies involving 
minimal or no clinical contact. Hair sampling procedures can easily be adapted to allow participants to 
obtain samples within their home environments and can be transported to researchers using existing 
postal facilities. Commercial laboratories offering substance and micronutrient testing already provide 




children provided the parents who could not attend the study visits with instructions on how to collect 
hair samples from their children (Larsen, Fahrenkrug, Olsen, & Heitmann, 2016). Conducting research 
through these distance-based approaches decreases the costs and burden for both participants and 
researchers as participants can perform assessments at their own convenience and do not need to 
travel in to study sites and less research resources have to be expended on performing assessments. 
Hair sampling for neuroendocrine analyses is thus an ideal biological measure to incorporate into large 
population based studies utilising online or posted questionnaires. By utilising technological advances 
to improve the capacity to collect data and to provide mobile health (m-health) interventions to a greater 
number of people these technologies have the potential to affect global mental health (Insel, 2017).  
2.10 Interventions 
Delivery of adequate mental health services remains a major challenge globally (Patel et al., 2018). 
There is a need for mental health services to be integrated into other health care services and for 
special attention to be paid to the physical health of individuals with mental illness (Patel et al., 2018). 
Understanding the pathways contributing to increased CVD risk in NPDs can assist in informing 
interventions aimed at improving outcomes and reducing the burden of both CVD and NPDs. 
Considering the evidence positing that chronic stress plays a role in both NPDs and CVD, interventions 
aimed at reducing stress and increasing resilience can potentially address multiple negative sequelae. 
Studies are required to investigate whether interventions focused on alleviating stress, such as 
mindfulness and relaxation-based and exercise interventions, improve clinical outcomes pertaining to 
both NPDs and CVD and how such interventions can be incorporated into existing healthcare 
frameworks. For instance, South African patients with chronic medical conditions expressed a need for 
mental health services and agreed with the integration of these services within their chronic disease 
care, particularly counselling pertaining to stress coping strategies (Myers et al., 2018). Furthermore, 
HCC can be utilised as a marker of treatment response and there are already studies evaluating the 
efficacy of psychosocial interventions that have incorporated HCC to investigate how these relate to 




2.11 The role of HPA-axis function in resilience and positive adaptations 
Very few studies have investigated whether cortisol levels are associated with resilience or stress-
coping ability (Dockray & Steptoe, 2010; García-León, Pérez-Mármol, Gonzalez-Pérez, García-Ríos, & 
Peralta-Ramírez, 2019; Milam, Slaughter, Verma, & McConnell, 2014; Steptoe, Dockray, & Wardle, 
2009; Ullmann et al., 2016) and less is known about the biological processes underpinning resilience 
as compared to stress. We demonstrated that greater resilience was associated with lower HCC in our 
control sample. This research needs to be extended into clinical samples. For instance, another 
outcome of trauma exposure is posttraumatic growth (PTG). Unlike resilience and stress coping that 
focus on adaptations that allow for return to or continued functioning despite adversity, PTG denotes an 
increase in psychological functioning following trauma or stress exposure (Schubert, Schmidt, & 
Rosner, 2016).  Similar to resilience and other positive psychological constructs there is very limited 
research investigating the biological factors underpinning PTG (Schubert et al., 2016). There is a need 
for more research investigating how PTG, resilience and other protective factors interact with HPA-axis 
function that can help inform strategies aimed at improving positive outcomes.  
2.12 Studies in particular disorders 
2.12.1 Examining the role of stress in HIV-NPD comorbidity 
South Africa has the highest rates of HIV globally, with an estimated 7.7 million people living with HIV in 
2018 (UNAIDS, 2018). Due to decreased mortality rates and increased longevity the prevalence has 
continued to rise despite a decrease in new infections. As the nature of HIV is changing into a chronic 
medical condition the burden of illness has shifted to non-AIDS related conditions, such as 
neuropsychiatric disorders (NPDs), including HIV associated neurocognitive disorders (HAND) (van 
den Heuvel, Seedat, & Fennema-Notestine, 2016). Individuals with HIV frequently demonstrate higher 
rates of NPDs than observed in the general population, including common mental disorders, such as 
depression and anxiety, and neurocognitive impairments (Bernard, Dabis, & De Rekeneire, 2017; 
Chaponda et al., 2018; Freeman, Nkomo, Kafaar, & Kelly, 2008; Habib et al., 2013; Joska, Fincham, 
Stein, Paul, & Seedat, 2010; Joska et al., 2011; Kagee & Martin, 2010; Myer et al., 2008; Niu, Luo, Liu, 




In HIV different markers of stress, including psychosocial and biological measures, and specifically 
cortisol levels have been associated with lower CD4 cell counts, higher viral loads and rapider disease 
progression as well as poorer adherence to treatment (Weinstein & Li, 2016). Altered HPA-axis 
function may be one of the pathways contributing to NPD-HIV comorbidity and through which NPDs 
contribute to HIV disease progression (Arseniou, Arvaniti, & Samakouri, 2014; Weinstein & Li, 2016). 
The HPA-axis regulates immune and inflammatory pathways and this is one mechanism whereby a 
dysregulated HPA-axis can influence HIV related outcomes (Arseniou et al., 2014). For instance, stress 
and elevated cortisol levels can influence cytokine production by T lymphocytes contributing to CD4 
lymphocyte destruction and viral replication (Leserman et al., 2000). Furthermore, one South African 
study demonstrated that neurocognitive impairment in HIV positive females was associated with single-
nucleotide polymorphisms (SNPs) of two HPA axis genes, namely corticotrophin-releasing hormone 
receptor 1 (CRHR1) and corticotrophin-releasing hormone-binding protein (CRHBP) (Jacobs et al., 
2018). A dysregulated HPA-axis may therefore play a role in the comorbidity of NPDs in HIV, as well as 
increased adverse effects associated with NPD-HIV comorbidity, such as HIV disease progression.  
There are a limited number of studies that have examined HCC in individuals with HIV. A study in 
Chinese people living with HIV demonstrated that HCC were higher in those with higher stress levels 
and were correlated with anxiety (Qiao et al., 2017). Another study from the Netherlands found that 
though HCC were not associated with HIV status, that in those with HIV HCC were inversely 
associated with MetS, suggesting altered HPA-axis function is associated with multiple morbidity 
(Langerak et al., 2015). No studies utilising HCC have however been conducted in South Africa, the 
country with the highest prevalence of HIV. HCC as a marker of long-term HPA-axis function can 
provide insights into the role chronic stress plays in HIV-NPD comorbidity and HIV disease 
progression. 
A better understanding of the role of stress and HPA-axis dysfunction in HIV-NPD comorbidity can help 
inform treatment strategies. For instance, stress management interventions have been associated with 
reductions in cortisol levels in HIV positive individuals (Antoni, 2003; Jones, Owens, Kumar, Cook, & 




treatment response in intervention studies aimed at treating NPDs in HIV positive individuals. A 
randomised control trial (RCT) in China is utilising HCC as a stress-related outcome marker for an 
mobile-health intervention aimed at increasing physical activity in HIV positive individuals (Guo et al., 
2018). More research regarding the role of stress, and HPA-axis dysfunction in HIV-NPD comorbidity is 
needed, especially in populations experiencing the highest burden of the disease, such as South Africa 
and insights gained need to be utilised in the formulation and implementation of treatment approaches, 
particularly those addressing stress reduction. 
2.12.2 Investigating and addressing physician burnout 
Burnout, a stress related syndrome that is directly linked to stress experienced within the context of 
work, is very prevalent among physicians, with some studies reporting rates as high as 50% (Dewa, 
Loong, Bonato, & Trojanowski, 2017; Rothenberger, 2017). Burnout is generally considered to involve 
three dimensions, emotional exhaustion, depersonalisation and low personal accomplishment 
(Maslach & Jackson, 1981). Burnout is linked to increased health problems, depression and suicidal 
ideation among physicians (Azam, Khan, & Alam, 2017; Kuhn & Flanagan, 2017) and can also have 
adverse impacts beyond the individual by affecting productivity and the quality of healthcare provided 
(Dewa, Loong, Bonato, Thanh, & Jacobs, 2014; Dewa et al., 2017). Risk factors include both individual 
features and organizational factors and although both individual and organisational interventions can 
improve burnout in physicians, the effects are significantly larger for organisational than individually 
focused interventions (Azam et al., 2017; Panagioti et al., 2017; West, Dyrbye, Erwin, & Shanafelt, 
2016). Considering the significant adverse consequences to both physicians and healthcare structures 
further studies are required that investigate the risk factors for burnout and that evaluate the efficacy of 
interventions. HCC as a marker of chronic stress and associated neuroendocrine dysfunction can help 
identify risk factors for burnout and inform the development of strategies to address modifiable factors, 
and to design preventative approaches as well as interventions for physician burnout. The few studies 
that have been conducted utilising HCC have already provided evidence of HPA-axis dysregulation, 
with elevated HCC, in individuals with burnout (Penz et al., 2018; Wang, Dai, & Li, 2019). A Chinese 




these mediated the association between burnout and insomnia (Wang et al., 2019). Furthermore, a 
prospective burnout study also demonstrated that effort-reward imbalance contributed to a blunted 
HPA-axis with reduced HCC over time (Penz et al., 2019). HCC can also be incorporated into 
intervention studies to investigate whether successful interventions are associated with normalisation of 
the HPA-axis and how this relates to clinical outcomes. HCC studies demonstrating that burnout is a 
stress related condition can help set the agenda towards improving working conditions, individual well-
being, as well as patient care.  
2.13 Improving representation and resource allocation in health research and healthcare 
provision  
Some of the results obtained in our study were contrary to what has generally been found e.g. lower 
HCC in patients with schizophrenia, higher HCC in patients with PTSD, inverse associations between 
HCC and age. Although we cannot distinguish to what extent the composition of our sample may have 
influenced these outcomes our results still highlight why research needs to be conducted in more 
diverse populations and settings. Our understanding of HPA-axis function in relation to most outcomes 
is largely driven by research conducted in developed regions, underscoring the need for more studies 
to be conducted in different geographic, ethnic and cultural contexts to both increase equity in 
healthcare research but to also broaden current understanding and thereby advance science and 
improve health and well-being for all.  
There is also a particular need in South Africa to investigate how stress is linked to adverse health 
outcomes. Much of the poor health (and mental health) in South Africa can be ascribed to social 
determinants including poverty, unemployment, and socioeconomic-, racial- and gender- inequality 
(Lund, Breen, Flisher, & Kakuma, 2010; Lund et al., 2018; Mayosi et al., 2012). Chronic stress, and 
associated HPA-axis dysfunction, may be one of the routes through which these larger societal factors 
influence health outcomes. The mechanisms through which these social determinants influence health 
and mental health warrant further investigation and studies that both address these aims and 




Mental disorders are very prevalent and are a major cause of disability globally, as well as in South 
Africa (Herman et al., 2009; Suliman, Stein, Myer, Williams, & Seedat, 2010; Whiteford et al., 2013). 
Despite the high burden of NPDs, funding allocation for research is disproportionately low (Collins et al., 
2011). Mental disorders frequently also remain undiagnosed and under-treated and appropriate mental 
health services are frequently lacking (Patel et al., 2018; Seedat et al., 2008; Suliman et al., 2010). 
Furthermore, despite higher rates of CVD and increased mortality risk, individuals with mental disorders 
are less likely to receive appropriate medical care (Laursen, Nordentoft, & Mortensen, 2014; Penninx & 
Lange, 2018; Walker, McGee, & Drus, 2015). Increased research efforts are required to better 
understand neuroendocrine and related biological pathways leading to mental disorders, as well as co-
occurring somatic conditions, and to investigate preventive and treatment strategies to address these 
problems. Mental health needs to be prioritised in both research and healthcare provision and resource 
allocation ought to be more equitable. 
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Abstract
Background: Posttraumatic stress disorder (PTSD) is a disorder that develops following exposure to severely
stressful events. Altered cortisol secretion has been reported in PTSD; however, results have been inconsistent.
Previous meta-analyses of cortisol levels in PTSD have combined results of studies that have used different tissue
samples (blood, saliva, urine) for cortisol measurement and have not included newer methods of determining
cortisol levels (e.g. hair samples). In this systematic review, we will synthesise evidence from studies evaluating basal
cortisol levels in PTSD patients versus controls and stratify studies according to tissue type used for cortisol
measurement. We will also determine whether results from different tissue types can be pooled and if any specific
tissue samples have better utility in research studies on PTSD.
Methods: We will perform a systematic review of the scientific literature including all studies that have evaluated
basal or baseline cortisol levels in adults with current PTSD versus controls, with and without trauma exposure.
Independent reviewers will conduct searches in electronic databases (Medline, CINAHL, PTSDpubs, Web of Science,
Scopus, ProQuest Dissertations & Theses A&I, ClinicalTrials.gov, and ICTRP), and additional studies will be obtained
by searching the reference lists of articles. Two reviewers (LLvdH and SW) will independently conduct standardised
screening, eligibility assessments, data extraction, and quality assessments before qualitative and, if appropriate,
quantitative (meta-analysis and meta-regression) synthesis. Disagreements that arise at any stage will be resolved by
a third reviewer (ShS).
Discussion: In line with previous reviews, we expect that cortisol levels will be lower in PTSD patients than in
controls, but that patterns may vary somewhat according to the tissue sample in which cortisol is measured. This
systematic review will assist in developing a better understanding of the acute and chronic patterns of basal
cortisol secretion in PTSD and will inform future research.
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Posttraumatic stress disorder (PTSD) develops following
exposure to an extreme stressor(s) or traumatic event(s),
such as being confronted with actual or threatened
death, serious injury, or sexual violence [1]. Symptoms,
causing significant distress or impairment of functioning,
persist for at least a month and involve repeated
re-experiencing of the traumatic event, avoidance of
trauma-related cues, negative changes in thinking and
mood, and increased arousal. In the World Health
Organization (WHO) World Mental Health (WMH)
surveys, the 12-month prevalence of PTSD in the total
sample was 1.1% [2] and the estimated lifetime preva-
lence of PTSD was 2.9% [3]. Of those with PTSD, 42% re-
ported severe role impairment in at least one domain
(work, social life, close relationships, or home maintenance)
[2] and PTSD was one of the three most disabling disorders
[4]. PTSD and other trauma- and stressor-related disorders
are distinguished from other psychiatric disorders in their
requirement of exposure to stressful events to make a diag-
nosis [1]. For PTSD, the stressful event(s) must be of a se-
vere or life-threatening nature; PTSD is, therefore, unique
in that severe stress plays a central aetiological role in the
development of a set of characteristic and persisting
symptoms.
The glucocorticoid, cortisol, is generally viewed as the
body’s chief stress hormone. Cortisol is synthesised and
released from the adrenal cortex which is a component
of the neuro-endocrine hypothalamic–pituitary–adrenal
(HPA) axis. Cortisol influences processes such as metab-
olism, immune function, digestion, and behaviour [5].
Cortisol has a baseline diurnal secretion pattern but is
also released following exposure to a stressor. It has thus
emerged as an objective biological marker of the stress
response [5–7]. A negative feedback loop in the HPA
axis regulates cortisol secretion and allows for the main-
tenance of homeostasis. Prolonged or severe stress can
lead to dysfunction of the HPA axis with resultant dys-
regulation of cortisol secretion and associated adverse
health outcomes [8, 9]. Cortisol levels can be measured
in various tissue samples reflecting cortisol secretion
over different time periods. Traditional sampling
methods, such as blood (serum and plasma), saliva, and
urine are useful for assessing acute cortisol secretion
(less than 24 h); however, newer approaches utilising hair
and nail samples can provide retrospective and chronic
patterns (weeks to months) of cortisol secretion [10–12].
The nature of PTSD as a disorder involving a chronic
maladaptive behavioural response to an extreme
stressor(s) suggests that it likely has a relationship with a
dysregulated endocrine-mediated stress response. In-
deed, HPA axis dysregulation has been reported in
PTSD; however, results have been inconsistent. A previ-
ous systematic review and meta-analysis of basal cortisol
levels in PTSD and controls reported no difference in
cortisol levels between PTSD patients and controls [13].
The authors pooled results from different tissue samples
for their primary analysis and documented significant
heterogeneity. In subgroup analysis, they found that
plasma and serum cortisol levels were significantly lower
in PTSD patients versus trauma unexposed controls
(TUC), suggesting that cortisol findings may vary ac-
cording to tissue type sampled. Furthermore, a recent
meta-analysis that only included salivary cortisol levels
reported lower cortisol levels in PTSD patients than in
controls [14]. Trauma exposure in controls may be an-
other confounding factor, as another meta-analysis that ex-
amined the association between trauma exposure in
adulthood and cortisol levels found no difference in basal
cortisol levels between PTSD patients and trauma-exposed
controls (TEC) [15]. Contrary to these findings, a meta-
analysis that separately evaluated PTSD patients and PTSD
patients with comorbid depression reported lower daily
cortisol output for both groups compared to TUC [16]. In-
consistent findings in meta-analyses could also be ascribed
to variations in tissue sample type in the included studies
and methods used in aggregating results in meta-analysis.
Systematic reviews evaluating cortisol levels in PTSD have
also not included newer tissue sampling methods, such as
hair and nail cortisol measurements. A recent meta-analysis
of hair cortisol studies reported lower hair cortisol levels in
patients with anxiety disorders (PTSD and generalised anx-
iety disorder [GAD]) [17], suggesting that adding newer tis-
sue sampling methods could enhance the understanding of
HPA axis function in PTSD.
In this systematic review, we aim to bring together all
studies that have evaluated basal cortisol levels in PTSD
patients versus controls according to the type of tissue
sampled. By analysing tissue type, we seek to develop a
better understanding of measurement of acute and
chronic patterns of basal cortisol secretion in PTSD pa-
tients versus controls. We will also seek to establish
whether data from different tissue types can be com-
bined and whether sampling a specific tissue for cortisol
measurement has greater utility in PTSD studies.
Objectives
Our objectives are as follows:
1. Our primary objective is to evaluate whether PTSD
is associated with altered basal cortisol levels by
synthesising the available evidence from primary
studies. A previous study that addressed this aim
was published more than 10 years ago [13]. Our
study involves important differences in terms of
methodological approach. In both qualitative and
quantitative synthesis (meta-analyses), we will
group studies according to the tissue type sampled.
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See ‘Additional file 1: Table summarising published
systematic reviews examining basal cortisol levels in
posttraumatic stress disorder’ for a summary of the
results of existing systematic reviews and
explanation of main differences as compared to this
protocol.
2. To evaluate whether pooling results from different
tissue samples is meaningful as this may inform
future approaches to sampling cortisol.
3. To determine the factors that influence the
relationship between basal cortisol levels and PTSD
by performing meta-regression where feasible.
4. To perform a critical evaluation of the available
literature with a view to identifying areas that
require further research.
See Table 1 for research question in PICOTS format.
Methods
This protocol was designed in accordance with the
guidelines set forth by The Cochrane Collaboration [18]
and the Preferred Reporting Items for Systematic Re-
views and Meta-Analyses (PRISMA) [19] Statement. The
systematic review protocol has been registered with the
PROSPERO International prospective register of system-
atic reviews database (PROSPERO registration number:
CRD42018091874) [20]. A PROSPERO search identified
two other systematic reviews registered evaluating corti-
sol levels in PTSD. The first aims to evaluate broader HPA
axis function in PTSD, including factors such as dehydro-
epiandrosterone (DHEA) levels and changes due to psycho-
therapeutic treatment [21], and the second is focused on
evaluating 24-h urinary cortisol levels in PTSD patients and
was registered more recently than our systematic review
protocol [22]. Two reviewers (LLvdH and SW) will in-
dependently conduct standardised screening, eligibility
assessments, data extraction, and quality assessments
prior to qualitative and quantitative (meta-analyses
and meta-regression) synthesis.
Search strategy
Two independent reviewers (LLvdH and SW) will per-
form searches in electronic databases (PubMed/MED-
LINE, Cumulative Index to Nursing and Allied Health
Literature (CINAHL), PTSDpubs, Web of Science, Sco-
pus, and ProQuest Dissertations & Theses A&I) and trial
registries (ClinicalTrials.gov and International Clinical
Trials Registry Platform [ICTRP]) for published and un-
published studies. Additional studies will be identified by
searching the reference lists of relevant reviews and in-
cluded studies. No limits will be placed on publication
date or language; however, articles will only be translated
into English and/or authors contacted for information if
a study is likely to meet our inclusion criteria condi-
tional upon the title and abstract being available in Eng-
lish. Search terms based on ‘PTSD’ and ‘cortisol’ and
applicable synonyms and controlled vocabulary (MeSH
terms) will be used where available. The primary search
terms will first be formulated in MEDLINE (PubMed)
and will then be translated to the other databases. In the
databases, all fields will be searched, excluding SCOPUS
where title, abstract, and keywords will be searched. We
will not place any limitations, such as age group and
study design, on searches, but will manually exclude
studies according to inclusion and exclusion criteria. We
obtained independent peer review from an information
specialist who utilised the PRESS methodology [23] and
made changes to our search strategy and terms accord-
ing to their recommendations. The full search terms for
each of the databases are included in ‘Additional file 2:
Search terms’. Searches in databases will be rerun just
prior to analysis to identify any new studies qualifying
Table 1 Research question in PICOTS format
PICOTS Inclusion and exclusion criteria
Patients or
populations
Adults aged 18 years or older
Patients with current PTSD based on DSM/ICD criteria
Exposures Trauma exposure fulfilling DSM/ICD criteria occurring at least a month prior to assessment in PTSD patients and TEC
Comparison group(s) PTSD patients versus all controls
Subgroup analysis:
PTSD patients versus TEC
PTSD patients versus TUC
Outcomes Basal or baseline cortisol levels (mean levels and standard deviation) measured in different tissue types
Timing At least 1 month since trauma exposure in PTSD patients and TEC
Setting Any setting (inpatient, outpatient, community settings)
Study design Any study design where cortisol levels are compared in patients versus controls (e.g. cross-sectional, case-control and
cohort)
DSM, Diagnostic and Statistical Manual of Mental Disorders; ICD, International Statistical Classification of Diseases and Related Health Problems; PICOTS, Population,
Intervention, Comparison, Outcomes, Timing, Setting; PTSD, posttraumatic stress disorder; TEC, trauma-exposed controls; TUC, trauma-unexposed controls
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for inclusion. Searches will be saved and managed utilising
the reference manager ‘Mendeley’ where duplicates will be
identified and removed. Results from published and un-
published or ‘grey’ literature will be included, provided
studies fulfil the inclusion and exclusion criteria and suffi-
cient information is available to assess study quality.
Search results will be presented in a PRISMA flowchart
according to PRISMA guidelines (Additional file 3: Figure
S1 PRISMA flow diagram).
Selection criteria
Study design
Any study design that compares cortisol levels between
PTSD patients and controls will be included. The most
common designs will be cross-sectional and case–con-
trol studies, but cohort and other study designs will also
be included, as long as the studies address the main
question of this review and fulfil the inclusion/exclusion
criteria. If multiple papers related to a single study have
been published, the data from the study results will ei-
ther be combined or the article with the largest sample
size will be included.
Participants
We will include studies with adults aged 18 years and
older that compare cortisol levels between PTSD pa-
tients and controls. We will only include patients with
current, and not lifetime, PTSD according to DSM/ICD
criteria. Controls, with and without, trauma exposure
and without a history of prior PTSD will be included.
For each tissue type, we will compare cortisol levels in
PTSD patients versus all controls (AC). We will also per-
form subgroup analyses comparing PTSD patients ver-
sus TEC and versus TUC. In both patients and TEC,
trauma exposure should fulfil DSM/ICD criteria of
trauma exposure and should have occurred at least a
month prior to assessment. We will include studies
where trauma exposure is not clearly defined in our AC
group, but not in the subgroup analysis. Including a
group of AC, alongside trauma-specified controls, will
increase the number of qualifying studies and subgroup
analysis will help elucidate the importance of accounting
for trauma exposure in controls. We will include studies
with medical or psychiatric comorbidity provided the de-
tails of comorbidity are well described and comorbidity
is not expected to have a substantial impact on out-
comes. If possible, psychiatric comorbidity will be in-
cluded as a factor in meta-regression.
Outcomes
To be included in the review, sufficient data to compute
effect sizes (mean cortisol levels and standard devia-
tions) must be included in the articles or be made avail-
able from the authors on request. Baseline or basal
cortisol measurement in any tissue sample type (plasma,
serum, whole blood, saliva, urine, hair, nails, and any
others) will be included. Different time periods of sam-
pling will be included, such as morning, evening, 24-h
output, and different lengths of hair/nail samples. Mean
cortisol levels from repeated cortisol measures (e.g. over
24 h) will be included as daily cortisol output. We will
exclude studies evaluating cortisol levels in response to
psychological or pharmacological stress tests. We will
only include studies where the methods to obtain sam-
ples (e.g. time of day for acute measures, area on body
hair samples obtained from) and to determine cortisol
levels (e.g. storage conditions and assay methods used)
are clearly described. We will highlight and report separ-
ately on studies that utilised more than one tissue sam-
ple to determine cortisol levels as these studies may
assist in directly evaluating the utility of specific sam-
pling methods in PTSD studies. In our meta-analysis, we
will include each study only once and we will prioritise
the results according to the largest sample size, the sam-
ple with the most complete data, and the sample with
the newer tissue sample type (e.g. hair or nails), as the
more established sampling approaches have been evalu-
ated in prior meta-analyses.
Study selection
We will first screen the titles and abstracts of articles
and exclude articles based on inclusion/exclusion cri-
teria. We will then screen the full text of the remaining
articles and further sort the articles based on inclusion/
exclusion criteria. We will utilise an eligibility form to
capture and note reasons for including or excluding arti-
cles at this stage (Additional file 4: Eligibility form). The
eligibility form will be piloted on a subset of studies, and
if necessary, modifications will be made. Titles, abstracts,
and full texts will be independently reviewed by re-
viewers 1 and 2 (LLvdH and SW). Any disagreements
will be discussed, and if not resolved, eligibility will be
determined with the assistance of a third reviewer (ShS).
For each stage of review, we will calculate inter-rater
agreement utilising the kappa statistic.
Corresponding authors of manuscripts will be con-
tacted via email in the following cases: to obtain a copy
of the manuscript if one cannot be obtained; if a manu-
script in a foreign language appears eligible for inclusion,
the authors will be contacted to enquire whether the de-
tails of the study including the results are available in
English; if additional information is required to deter-
mine study eligibility; to ask for clarification of methods
and specific results if these were not included in the
manuscript; authors on trial databases will be contacted
to enquire whether study details and results are avail-
able. If no response is received within 2 weeks, a
follow-up email will be sent. If no response is received
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within another 2 weeks, non-response will be noted and
the study excluded. Studies may still be included if au-
thors respond prior to final data analysis.
Data extraction
Data will be abstracted by two independent reviewers
(LLvdH and SW). Data will be entered and managed uti-
lising the Research Electronic Data Capture (REDCap)
database application [24]. REDCap is a system for struc-
tured, clinical study data capture and is designed to
comply with HIPAA regulations. Access control will be
password-protected and role-based. The data extraction
form will be piloted prior to formal data abstraction, and
if necessary, modifications will be made (Additional file 5:
Data extraction form). Data extracted will include study
characteristics such as study design, setting, and sample
size; basic descriptive data (e.g. age, gender, ethnicity) of
patients and controls; trauma-related data such as
trauma type, trauma load, and duration since trauma;
PTSD-related data such as method to determine diagno-
sis, PTSD severity, duration of illness; physical data such
as BMI and blood pressure and any medical or psychi-
atric comorbidity; cortisol-related data such as tissue
type, date and time of sampling, method used to sample
and analyse cortisol, mean cortisol levels and standard
deviations, and the unit of measurement for patients and
controls. If cortisol is measured at multiple time points,
we will extract data for each time point and the mean
total cortisol over a set period (e.g. 24 h) if available.
Quality (risk of bias) assessment
Two reviewers (LLvdH and SW) will perform independent
quality or risk of bias (ROB) assessments, and any dis-
agreements will be resolved by a third reviewer (ShS).
Inter-rater reliability will be determined (kappa statistic).
We will perform ROB assessments with a modified ver-
sion of the Newcastle–Ottawa scale (NOS) [25] adapted
for use in observational studies [26] (Additional file 6:
Modified Newcastle Ottawa Scale). The scale assesses for
four types of bias (selection bias, performance bias, detec-
tion bias, and information bias) with seven questions rated
from 0 to 3 with higher scores reflecting lower ROB. In
addition, we will pilot a tool for ROB assessment designed
for specific use in our review (Additional file 7: Risk of
bias (ROB) assessment), based on the guidelines provided
by the Agency for Healthcare Research and Quality
(AHRQ) [27]. We utilised the approach and applicable
components (blinding of outcome, incomplete outcome
data, selective reporting) from the Cochrane Risk Of Bias
Tool [28] as well as modified components from the NOS.
The ROB assessment contains 11 items assessing for se-
lection bias, performance bias, detection bias, attrition
bias, reporting bias, and funding or conflict of interest
bias. Each item will be rated as ‘low risk of bias’, ‘high risk
of bias’, or ‘unclear risk of bias’, and the results for each
study will be presented graphically (Additional file 8: Ex-
ample risk of bias (ROB) figure). The ROB assessment
tool will be piloted on a subset of studies, and if required,
revisions will be made. We will report on and compare
ROB bias assessments obtained with both tools as the
modified NOS will allow for comparability with existing
studies, whereas the ROB assessment tool designed for
our study utilises examples and explanations specific to
PTSD and cortisol studies, such as specific methods to de-
termine TE and patient status and includes assessments
for additional types of bias not assessed with the modified
NOS. We will utilise the Grading of Recommendations,
Assessment and Evaluation (GRADE) approach to report
the quality of evidence and strength of recommendations
[29]. The influence of bias on quantitative outcomes will
be assessed by performing sensitivity analysis.
Data synthesis
Qualitative synthesis Individual studies will be sum-
marised utilising evidence tables. At a minimum, we will
include the authors, year of publication, setting, study
design, sample sizes, age, sex, ethnicity, trauma type,
time since trauma, trauma and PTSD measures, PTSD
severity, PTSD duration, comorbidity, medication use,
time or time period of cortisol assessment, cortisol
levels, measurement of cortisol levels, and confounders
(see ‘Additional file 9: List of potential moderators’ for a
full list of moderators that will be included). Data will be
organised according to patient and control groups for
each study. We will perform a qualitative evaluation of
heterogeneity by examining factors such as study design,
trauma exposure, settings, populations, and outcome
measurements.
Quantitative synthesis Where appropriate, we will per-
form a meta-analysis for each tissue type sampled.
Meta-analysis will only be performed where there are at
least two comparable studies with sufficient data avail-
able. In articles where results are not reported as means
and standard deviations, study authors will be contacted
to obtain these summary statistics. If these summary sta-
tistics cannot be obtained, we will transform available
summary statistics (e.g. median and interquartile range)
utilising available formulas [30]. We will compare stan-
dardised mean difference (SMD) in cortisol levels be-
tween PTSD cases and all controls, and if possible, we
will perform a subgroup analysis based on trauma ex-
posure status of controls (TEC and TUC). We will util-
ise the SMD to allow for pooling of data from studies
utilising different methods to determine cortisol (e.g.
ELISA versus LC-MS and different tissue samples).
Hedge’s g will be used for studies with smaller sample
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sizes. As we expect there to be heterogeneity in study
design, we will utilise a random-effects model (DerSimo-
nian and Laird) [31]. Results will be graphically repre-
sented utilising forest plots. Heterogeneity will be
assessed utilising the Cochrane’s Q (chi-squared test)
and I2 statistics and by visually inspecting the forest
plots. If significant heterogeneity exists, we will evaluate
whether any specific studies significantly influenced the
results by excluding each individual study and examining
its impact on the pooled SMD and between-study het-
erogeneity. If there are a sufficient number of studies per
tissue type (e.g. ten), we will perform meta-regression, in
addition to the subgroup analysis according to trauma
exposure status of controls. Potential moderators that
will be included in the meta-regression will be year of
publication, age, sex, trauma type, time since index
trauma, developmental stage of trauma exposure, PTSD
severity, psychiatric comorbidity, time period of sam-
pling (e.g. time of day for acute measures and length of
hair sample representing retrospective window for hair
sampling), and method used to determine cortisol level
(ELISA or LC-MS). Moderators will first be entered indi-
vidually and those with a significance level of 0.1 will be
entered in a multivariate meta-regression. The meta-re-
gression will be conducted using a restricted maximum
likelihood (REML) model. To address the issue of statis-
tically dependent effect sizes that may arise from mul-
tiple methods of cortisol assessment within a study or
from either repeated measures within a study that may
have a longitudinal design, robust variance estimation
procedures in meta-regression will be used. We will
evaluate for effect of studies at high ROB and for the ef-
fect of study design type by entering the total score and
domain sub-scores obtained on the modified NOS and
study design type into separate regression models. Fur-
ther sensitivity analyses will be performed to assess the
influence of studies assessed as having a high ROB, by
excluding studies with a high ROB and evaluating the
impact on main outcomes. We will assess for small
study effects with funnel plots (for analyses with 10 or
more studies), and statistical tests for asymmetry (Egger
test) will be performed where appropriate. If asymmetry
is present, we will perform the trim-and-fill procedure
[32]. Data will be analysed with STATA IC version 15.
We will present the results for each tissue type sampled
in a summary of findings table. As a final step, we will pool
the results of studies utilising different tissue types together
utilising a cumulative approach to demonstrate trends ac-
cording to tissue type sampled. We anticipate that we may
have to make certain modifications to our meta-analysis ap-
proach based on the data collected (e.g. certain important
variations may only be evident once the data have been col-
lated). We will stipulate the rationale for any modifications
and clearly specify post-hoc analyses.
Dissemination of results
The manuscript will be submitted for publication to an
appropriate peer-reviewed journal, with preference for
an open-access journal to enhance both accessibility and
visibility. The results will also be presented at relevant
conferences and meetings.
Discussion
In line with previous reviews, we expect that cortisol
levels will generally be lower in PTSD patients than in
controls, with larger difference observed when compared
to TUC than TEC. We expect that patterns (i.e. the dir-
ectionality of cortisol levels in PTSD cases compared
with controls) will be similar across tissue type but
case–control differences may not be statistically signifi-
cant for all tissue types sampled. Some of the variability
may be the result of the time window of cortisol meas-
urement, as reflected by the tissue type sampled. Sys-
tematically identifying this variability may assist in better
delineating acute and chronic patterns of basal cortisol
secretion in PTSD. We will utilise outcomes of this re-
view to identify aspects requiring additional investigation
as well as provide suggestions as to which tissue sample
types may have better utility for PTSD studies.
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